ticker,rpa_date_utc,rpa_time_utc,rp_entity_id,entity_name,relevance,event_sentiment_score,group,sub_type,event_text,news_type,source_name,headline
INCY,2024-01-03,21:09:31,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 7,365 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 7,365 Of Incyte Corp >INCY"
INCY,2024-01-04,18:06:06,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Iyengar Sells 657 Of Incyte Corp,FULL-ARTICLE,Dow Jones Newswires,VP Iyengar Sells 657 Of Incyte Corp >INCY
INCY,2024-01-05,17:28:07,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 7,365 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Sells 7,365 Of Incyte Corp >INCY"
INCY,2024-01-08,13:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Phase 2 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Highlights Growth Opportunities and Provides Business Updates at the 42(nd) Annual J.P. Morgan Healthcare Conference
INCY,2024-01-08,13:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Highlights Growth Opportunities and Provides Business Updates at the 42(nd) Annual J.P. Morgan Healthcare Conference
INCY,2024-01-08,13:30:10,6CC55E,Incyte Corp.,99,0.0,products-services,,Phase 2 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
INCY,2024-01-08,13:30:10,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
INCY,2024-01-08,13:31:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 Study Evaluating the Safety and Efficacy of Ruxolitinib,NEWS-FLASH,Dow Jones Newswires,"Incyte: Primary Endpoint Was Met in Its Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Ruxolitinib Cream in Adults With Mild/Moderate Hidradenitis Suppurative >INCY"
INCY,2024-01-18,19:24:35,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 202 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Morrissey Surrenders 202 Of Incyte Corp >INCY
INCY,2024-01-18,19:27:50,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 202 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 202 Of Incyte Corp >INCY
INCY,2024-01-19,22:33:26,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 3,675 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Surrenders 3,675 Of Incyte Corp >INCY"
INCY,2024-01-19,22:34:21,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Officer Tray Surrenders 1,021 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Surrenders 1,021 Of Incyte Corp >INCY"
INCY,2024-01-22,18:04:58,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 122 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 122 Of Incyte Corp >INCY
INCY,2024-01-22,18:05:39,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 122 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Morrissey Surrenders 122 Of Incyte Corp >INCY
INCY,2024-01-23,13:03:42,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:03:42,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:03:42,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:03:42,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:08:28,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:08:28,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2023 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:08:28,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-23,13:08:28,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
INCY,2024-01-24,19:15:49,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 108 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 108 Of Incyte Corp >INCY
INCY,2024-01-24,19:16:25,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 108 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Morrissey Surrenders 108 Of Incyte Corp >INCY
INCY,2024-01-30,13:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,Agilent Announces Collaboration with Incyte to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
INCY,2024-01-30,13:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,Agilent Announces Collaboration with Incyte to,PRESS-RELEASE,Business Wire,Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
INCY,2024-01-30,13:00:46,6CC55E,Incyte Corp.,100,0.49,partnerships,,Agilent Announces Collaboration With Incyte to,NEWS-FLASH,Dow Jones Newswires,Agilent Announces Collaboration With Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology
INCY,2024-02-05,21:46:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte Corp.: This new agreement with MorphoSys,PRESS-RELEASE,Business Wire,Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi(R) )
INCY,2024-02-05,21:46:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi(R) )
INCY,2024-02-05,21:46:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte Corp.: This new agreement with MorphoSys,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi(R))
INCY,2024-02-05,21:46:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi(R))
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Morphosys entered into a Purchase Agreement with Incyte Corporation,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.49,partnerships,,Morphosys partners with Incyte on the development and commercialization of tafasitamab,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.39,products-services,,Morphosys' Purchase Agreement with Incyte,PRESS-RELEASE,Dow Jones Newswires,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Morphosys entered into a Purchase Agreement with Incyte Corporation,PRESS-RELEASE,DGAP News,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.49,partnerships,,Morphosys partners with Incyte on the development and commercialization of tafasitamab,PRESS-RELEASE,DGAP News,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-05,21:46:09,6CC55E,Incyte Corp.,99,0.39,products-services,,Morphosys' Purchase Agreement with Incyte,PRESS-RELEASE,DGAP News,EQS-Adhoc: Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for EUR 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,4Q EPS 89c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q EPS 89c >INCY
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Adj EPS $1.06,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Adj EPS $1.06 >INCY
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Net $201.1M,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Net $201.1M >INCY
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Rev $1.01B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Rev $1.01B >INCY
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2023 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2023 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: total FY'23 net product revenues of $3.2 billion (+15%,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Fourth quarter 2023 net product revenues grew 7%,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte entered into an asset purchase agreement with MorphoSys AG,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: In December 2023, in collaboration with Syndax Pharmaceuticals",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte anticipates initiating a Phase 3 study for BETi in the second half of 2024,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Other key highlights included additional data from the Phase 1/2 Study of zilurgisertib (INCB000928),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 2 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,013,341 $926,700",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,revenues,,Incyte Corp.: Opzelura net product revenues for the quarter were $109 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Net income $ 201,079 $ 28,461 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.90 $ 0.13 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 6,782,107 $ 5,840,984",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $201,079 $ 28,461",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $239,124 $139,661",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.07 $ 0.63 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Fourth Quarter -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2023 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2023 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: total FY'23 net product revenues of $3.2 billion (+15%,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Fourth quarter 2023 net product revenues grew 7%,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte entered into an asset purchase agreement with MorphoSys AG,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: In December 2023, in collaboration with Syndax Pharmaceuticals",PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte anticipates initiating a Phase 3 study for BETi in the second half of 2024,PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Other key highlights included additional data from the Phase 1/2 Study of zilurgisertib (INCB000928),PRESS-RELEASE,Business Wire,"Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities"
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 2 studies,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -2-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,013,341 $926,700",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: GAAP net income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,revenues,,Incyte Corp.: Opzelura net product revenues for the quarter were $109 million,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,95,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -3-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -4-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Net income $ 201,079 $ 28,461 $",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.90 $ 0.13 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 6,782,107 $ 5,840,984",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -5-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $201,079 $ 28,461",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $239,124 $139,661",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.07 $ 0.63 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -6-
INCY,2024-02-13,12:00:01,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Fourth Quarter and Year-End -6-
INCY,2024-02-13,12:06:05,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees FY24 Jakafi Net Pdt Rev $2.69B - $2.75B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees FY24 Jakafi Net Pdt Rev $2.69B - $2.75B >INCY
INCY,2024-02-14,13:31:30,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Truist Securities
INCY,2024-02-14,13:31:30,6CC55E,Incyte Corp.,100,-0.7,price-targets,downgrade,Incyte Price Target Cut to $84.00/Share From $91.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $84.00/Share From $91.00 by Truist Securities
INCY,2024-02-14,14:07:10,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Stifel
INCY,2024-02-14,14:07:10,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $68.00/Share From $67.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $68.00/Share From $67.00 by Stifel
INCY,2024-02-14,15:35:11,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-02-14,15:35:11,6CC55E,Incyte Corp.,100,0.46,price-targets,upgrade,Incyte Price Target Raised to $65.00/Share From $63.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $65.00/Share From $63.00 by RBC Capital
INCY,2024-02-14,15:51:41,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Citigroup
INCY,2024-02-14,15:51:41,6CC55E,Incyte Corp.,100,-0.24,price-targets,downgrade,Incyte Price Target Cut to $81.00/Share From $82.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $81.00/Share From $82.00 by Citigroup
INCY,2024-02-14,16:46:31,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Market Perform by BMO Capital
INCY,2024-02-14,16:46:31,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $64.00/Share From $58.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $64.00/Share From $58.00 by BMO Capital
INCY,2024-02-14,17:34:54,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Cfo Stamoulis Surrenders 387 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,CFO Stamoulis Surrenders 387 Of Incyte Corp >INCY
INCY,2024-02-14,18:22:31,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Market Perform From Market Outperform by JMP Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Market Perform From Market Outperform by JMP Securities
INCY,2024-02-15,13:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2024-02-15,13:01:10,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2024-02-23,08:05:39,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 4Q 2023 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 4Q 2023 (INCY)"
INCY,2024-02-23,11:04:01,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Buy by Jefferies,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Buy by Jefferies
INCY,2024-02-23,11:04:01,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $81.00/Share by Jefferies,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $81.00/Share by Jefferies
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Announces U.S. Food And Drug Administration Grants Priority Review For Axatilimab,NEWS-FLASH,Dow Jones Newswires,Incyte Announces U.S. Food And Drug Administration Grants Priority Review For Axatilimab For The Treatment Of Chronic Graft-Versus-Host Disease >INCY
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab,PRESS-RELEASE,Business Wire,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.44,products-services,,Incyte Corp.: Despite recent advancements in the treatment,PRESS-RELEASE,Business Wire,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: FDA and our partners at Syndax on the review of our application for,PRESS-RELEASE,Business Wire,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review designation,PRESS-RELEASE,Business Wire,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:08:00,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Business Wire,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:11:01,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:11:01,6CC55E,Incyte Corp.,100,0.44,products-services,,Incyte Corp.: Despite recent advancements in the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:11:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: FDA and our partners at Syndax on the review of our application for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:11:01,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:11:01,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
INCY,2024-02-27,21:13:21,6CC55E,Incyte Corp.,100,0.65,products-services,,Fda Grants Priority Review for Axatilimab,NEWS-FLASH,Dow Jones Newswires,Incyte : FDA Grants Priority Review for Axatilimab for Treatment of Chronic Graft-Versus-Host Disease>INCY
INCY,2024-02-29,12:30:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Knight Therapeutics Announces Launch of Minjuvi(R) in Brazil,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) in Brazil
INCY,2024-02-29,12:30:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Agência Nacional de Vigilância Sanitária) granted Market Authorization for Minjuvi(R) under,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) in Brazil
INCY,2024-02-29,12:30:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) in Brazil
INCY,2024-02-29,12:30:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Knight Therapeutics Inc.: Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208),PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) in Brazil
INCY,2024-02-29,12:30:32,6CC55E,Incyte Corp.,100,0.52,products-services,,Knight Therapeutics Announces Launch of Minjuvi in Brazil,NEWS-FLASH,Dow Jones Newswires,Knight Therapeutics Announces Launch of Minjuvi in Brazil
INCY,2024-03-04,13:00:03,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
INCY,2024-03-04,13:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
INCY,2024-03-04,13:02:40,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
INCY,2024-03-04,13:02:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Presents New Late-Breaking Data from Phase 2 Study,PRESS-RELEASE,Business Wire,Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707),PRESS-RELEASE,Business Wire,Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R) ) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study,PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R) ) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R) ) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Data from Phase 2 Study,PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study -2-
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Data from Phase 2 Study,PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study -3-
INCY,2024-03-10,20:05:00,6CC55E,Incyte Corp.,100,0.0,earnings,,"Incyte Corp.: our quarterly report on Form 10-Q for the quarter ended December 31, 2023",PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 2 Study -3-
INCY,2024-03-10,20:05:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Presents New Late-Breaking Data from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
INCY,2024-03-10,20:05:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
INCY,2024-03-11,09:37:41,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R)) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-11,09:37:41,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R)) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-11,09:37:41,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Ruxolitinib, is approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(R)) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY,2024-03-11,09:37:41,6CC55E,Incyte Corp.,95,0.0,earnings,,"Incyte Corp.: our quarterly report on Form 10-Q for the quarter ended December 31, 2023",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from -3-
INCY,2024-03-13,12:14:45,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by B of A Securities
INCY,2024-03-13,12:14:45,6CC55E,Incyte Corp.,100,-0.44,price-targets,downgrade,Incyte Price Target Cut to $67.00/Share From $69.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $67.00/Share From $69.00 by B of A Securities
INCY,2024-03-29,20:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-03-29,20:30:10,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-04-01,12:30:00,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,Business Wire,"Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia"
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Cms and Incyte Announce Collaboration,PRESS-RELEASE,GlobeNewswire,CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,GlobeNewswire,CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Cms and Incyte Announce Collaboration,PRESS-RELEASE,GlobeNewswire,CMS and Incyte Announce Collaboration and License -2-
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Cms and Incyte Announce Collaboration,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,Hugin GlobeNewswire,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Cms and Incyte Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Cms and Incyte Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
INCY,2024-04-01,12:30:10,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Relying on its strong clinical development,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia"
INCY,2024-04-01,12:31:41,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte, China Medical System Holdings Enter Collaboration",NEWS-FLASH,Dow Jones Newswires,"Incyte, China Medical System Holdings Enter Collaboration and License Agreement for Development and Commercialization of Povorcitinib >INCY"
INCY,2024-04-01,12:32:27,6CC55E,Incyte Corp.,100,0.39,products-services,,"Incyte, China Medical System In Collaboration",NEWS-FLASH,Dow Jones Newswires,"Incyte, China Medical System In Collaboration, License Pact for Povorcitinib >INCY"
INCY,2024-04-01,12:32:34,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte and China Medical System Agreement,NEWS-FLASH,Dow Jones Newswires,"Incyte and China Medical System Agreement is to Research, Develop, Register and Commercialize the Pdt in Mainland China, Hong Kong, Macao, Taiwan Region and Eleven Southeast Asian Countries >INCY"
INCY,2024-04-11,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2024-04-11,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2024 Conference Call: April 30, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2024-04-11,12:04:38,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2024-04-11,12:04:38,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2024 Conference Call: April 30, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2024-04-23,11:00:01,6CC55E,Incyte Corp.,99,0.55,acquisitions-mergers,,Incyte will acquire Escient and its assets for $750 million,PRESS-RELEASE,Business Wire,Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Preclinical data,PRESS-RELEASE,Business Wire,Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:02:50,6CC55E,Incyte Corp.,99,0.55,acquisitions-mergers,,Incyte will acquire Escient and its assets for $750 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:02:50,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:02:50,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Preclinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
INCY,2024-04-23,11:05:51,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte to Acquire Escient for $750 Million,NEWS-FLASH,Dow Jones Newswires,Incyte to Acquire Escient for $750 Million Plus Net Cash Remaining at Close >INCY
INCY,2024-04-23,11:17:35,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte to Buy Escient Pharmaceuticals for $750 Million,FULL-ARTICLE,Dow Jones Newswires,Incyte to Buy Escient Pharmaceuticals for $750 Million
INCY,2024-04-23,12:10:57,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte Initiated at Neutral by Cantor Fitzgerald,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Neutral by Cantor Fitzgerald
INCY,2024-04-24,11:33:19,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by Oppenheimer
INCY,2024-04-24,11:33:19,6CC55E,Incyte Corp.,100,-0.74,price-targets,downgrade,Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues of $881 million in the first quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: reiterating full year 2024 guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 study for,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: In the first quarter of 2024, total revenues grew 9% year-over-year",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte will acquire Escient and its assets for $750 million,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte and China Medical System Holdings Limited announced the Companies entered into a Collaboration and License Agreement,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenues growth in the first quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 880,889 $808,673",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -2-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -3-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -4-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -4-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -4-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -4-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.61,earnings,positive,1Q EPS 75c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q EPS 75c >INCY
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 145,269 $ 84,577",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.76 $ 0.10,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.0,assets,,"Incyte Corp.: Total assets $7,135,605 $ 6,782,107",PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.65 $ 0.38,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,97,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2024 First Quarter Financial -5-
INCY,2024-04-30,11:00:02,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Adj EPS 64c,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Adj EPS 64c >INCY
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 first quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues of $881 million in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: reiterating full year 2024 guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 study for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: In the first quarter of 2024, total revenues grew 9% year-over-year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.65,products-services,,The U.S. Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte will acquire Escient and its assets for $750 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte and China Medical System Holdings Limited announced the Companies entered into a Collaboration and License Agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenues growth in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: In a Phase 1 study of INCB123667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 880,889 $808,673",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -2-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -3-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -4-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -4-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -4-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -4-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 145,269 $ 84,577",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.76 $ 0.10,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.0,assets,,"Incyte Corp.: Total assets $7,135,605 $ 6,782,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.65 $ 0.38,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:01:50,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 First Quarter -5-
INCY,2024-04-30,11:03:30,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 1Q Rev $880.9M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Rev $880.9M >INCY
INCY,2024-05-01,12:12:25,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Market Perform by BMO Capital
INCY,2024-05-01,12:12:25,6CC55E,Incyte Corp.,100,-0.68,price-targets,downgrade,Incyte Price Target Cut to $52.00/Share From $56.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $52.00/Share From $56.00 by BMO Capital
INCY,2024-05-01,12:57:45,6CC55E,Incyte Corp.,100,-0.24,price-targets,downgrade,Incyte Price Target Cut to $83.00/Share From $84.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $83.00/Share From $84.00 by Truist Securities
INCY,2024-05-01,18:06:35,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by TD Cowen
INCY,2024-05-01,18:06:35,6CC55E,Incyte Corp.,100,-0.76,price-targets,downgrade,Incyte Price Target Cut to $80.00/Share From $88.00 by TD Cowen,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $80.00/Share From $88.00 by TD Cowen
INCY,2024-05-02,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT)",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2024-05-02,12:01:10,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2024-05-09,22:28:24,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Acquires 30,000 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"Holder Baker Bros Advisors LP Acquires 30,000 Of Incyte Corp >INCY"
INCY,2024-05-13,11:00:01,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Announces Intention To Buy Back Up To $2.0 Billion,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Intention To Buy Back Up To $2.0 Billion Of Its Common Stock >INCY
INCY,2024-05-13,11:00:02,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Announces Intention to Buy Back up to $2.0,PRESS-RELEASE,Business Wire,Incyte Announces Intention to Buy Back up to $2.0 -2-
INCY,2024-05-13,11:01:30,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Launches Dutch Auction Tender Offer,NEWS-FLASH,Dow Jones Newswires,Incyte Launches Dutch Auction Tender Offer for $1.67 Billion in Stock >INCY
INCY,2024-05-13,11:01:50,6CC55E,Incyte Corp.,100,0.59,equity-actions,approved,"Incyte Corp.: the ""Company"") today announced that its Board of Directors approved a share repurchase authorization",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
INCY,2024-05-13,11:01:50,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte commences Dutch Auction tender offer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
INCY,2024-05-13,11:01:50,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte entered into a separate stock purchase agreement with Julian C. Baker (a member of Incyte's Board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
INCY,2024-05-13,11:01:50,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,interest,Incyte Announces Intention to Buy -2,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Intention to Buy -2-
INCY,2024-05-13,11:02:14,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte To Buy Back Up to $328 Million in Stock,NEWS-FLASH,Dow Jones Newswires,Incyte To Buy Back Up to $328 Million in Stock From Baker Entities >INCY
INCY,2024-05-13,11:24:11,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Sets $2 Billion Stock Buyback,FULL-ARTICLE,Dow Jones Newswires,Incyte Sets $2 Billion Stock Buyback
INCY,2024-05-13,11:30:38,6CC55E,Incyte Corp.,100,0.59,equity-actions,approved,Incyte to buy back $1.67 billion of its own stock,FULL-ARTICLE,MarketWatch,MW Incyte to buy back $1.67 billion of its own stock in Dutch auction tender
INCY,2024-05-13,13:14:53,6CC55E,Incyte Corp.,100,0.59,equity-actions,approved,Incyte Corp.: the company has agreed to repurchase up to $328 million,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Jumps on 'Dutch Auction' Buyback Plan. How It Works. -- Barrons.com
INCY,2024-05-13,14:16:22,6CC55E,Incyte Corp.,100,0.59,equity-actions,approved,Incyte Corp. said Monday its board has approved a share buyback,FULL-ARTICLE,MarketWatch,MW Incyte's stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tender
INCY,2024-05-13,19:06:12,6CC55E,Incyte Corp.,93,0.59,equity-actions,,Incyte announced a $2 billion stock repurchase program,FULL-ARTICLE,Dow Jones Newswires,Incyte Buyback Seen Luring Value Investors -- Market Talk
INCY,2024-05-13,19:06:12,6CC55E,Incyte Corp.,93,0.59,equity-actions,,Incyte announced a $2 billion stock repurchase program,FULL-ARTICLE,Dow Jones Newswires,Incyte Buyback Seen Luring Value Investors -- Market Talk
INCY,2024-05-14,21:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 study of,PRESS-RELEASE,Business Wire,Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Business Wire,Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:00,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-14,21:00:01,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
INCY,2024-05-21,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45(th) Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2024-05-21,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45(th) Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT)",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2024-05-21,17:15:00,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings,PRESS-RELEASE,Business Wire,Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:15:00,6CC55E,Incyte Corp.,100,0.06,assets,,Incyte's decision to move their headquarters to downtown Wilmington,PRESS-RELEASE,Business Wire,Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:15:00,6CC55E,Incyte Corp.,100,0.41,assets,open,"Incyte Corp.: The new building on King Street, expected to open in 2026, will",PRESS-RELEASE,Business Wire,Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:15:01,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:15:01,6CC55E,Incyte Corp.,100,0.06,assets,,Incyte's decision to move their headquarters to downtown Wilmington,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:15:01,6CC55E,Incyte Corp.,100,0.41,assets,open,"Incyte Corp.: The new building on King Street, expected to open in 2026, will",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-21,17:16:28,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte Expands Presence in Delaware Through Acquisition of Two Downtown Wilmington Office Buildings,NEWS-FLASH,Dow Jones Newswires,Incyte Expands Presence in Delaware Through Acquisition of Two Downtown Wilmington Office Buildings
INCY,2024-05-23,07:04:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 1Q 2024 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 1Q 2024 (INCY)"
INCY,2024-05-23,11:15:43,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte Initiated at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Hold by Deutsche Bank
INCY,2024-05-23,11:15:43,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $55.00/Share by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $55.00/Share by Deutsche Bank
INCY,2024-05-30,20:05:01,6CC55E,Incyte Corp.,100,0.57,acquisitions-mergers,completed,Incyte Completes Acquisition Of Escient Pharmaceuticals >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Completes Acquisition Of Escient Pharmaceuticals >INCY
INCY,2024-05-30,20:05:01,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte has acquired Escient and its assets for $750 million,PRESS-RELEASE,Business Wire,Incyte Completes Acquisition of Escient Pharmaceuticals
INCY,2024-05-30,20:05:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Preclinical data,PRESS-RELEASE,Business Wire,Incyte Completes Acquisition of Escient Pharmaceuticals
INCY,2024-05-30,20:05:02,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,Incyte has acquired Escient and its assets for $750 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Completes Acquisition of Escient Pharmaceuticals
INCY,2024-05-30,20:05:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Preclinical data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Completes Acquisition of Escient Pharmaceuticals
INCY,2024-06-06,20:42:38,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Officer Tray Registers 1,093 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"Officer Tray Registers 1,093 Of Incyte Corp >INCY"
INCY,2024-06-07,20:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-06-07,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-06-10,16:26:19,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,093 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Sells 1,093 Of Incyte Corp >INCY"
INCY,2024-06-11,12:00:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte entered into a separate stock purchase agreement with Julian C. Baker (a member of Incyte's Board,PRESS-RELEASE,Business Wire,Incyte Announces Preliminary Results of Tender Offer
INCY,2024-06-11,12:00:03,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte entered into a separate stock purchase agreement with Julian C. Baker (a member of Incyte's Board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Preliminary Results of Tender Offer
INCY,2024-06-12,21:00:45,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 19,164 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 19,164 Of Incyte Corp >INCY"
INCY,2024-06-13,12:00:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte entered into a separate stock purchase agreement with Julian C. Baker (a member of Incyte's Board,PRESS-RELEASE,Business Wire,Incyte Announces Final Results of Tender Offer
INCY,2024-06-13,12:00:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte entered into a separate stock purchase agreement with Julian C. Baker (a member of Incyte's Board,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Final Results of Tender Offer
INCY,2024-06-14,16:18:16,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Dir Schaffert Surrenders 752 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,Dir Schaffert Surrenders 752 Of Incyte Corp >INCY
INCY,2024-06-14,16:18:39,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 19,164 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 19,164 Of Incyte Corp >INCY"
INCY,2024-07-02,09:26:09,6CC55E,Incyte Corp.,100,-0.82,analyst-ratings,negative,Incyte Cut to Underperform From Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Underperform From Market Perform by BMO Capital
INCY,2024-07-02,09:26:09,6CC55E,Incyte Corp.,100,-0.7,price-targets,downgrade,Incyte Price Target Cut to $48.00/Share From $52.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $48.00/Share From $52.00 by BMO Capital
INCY,2024-07-03,16:18:16,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Tray Surrenders 844 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,Officer Tray Surrenders 844 Of Incyte Corp >INCY
INCY,2024-07-03,16:18:40,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 5,560 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Swain Surrenders 5,560 Of Incyte Corp >INCY"
INCY,2024-07-03,16:18:58,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 8,316 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Surrenders 8,316 Of Incyte Corp >INCY"
INCY,2024-07-03,16:19:09,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 6,870 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"CFO Stamoulis Surrenders 6,870 Of Incyte Corp >INCY"
INCY,2024-07-03,16:20:11,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Iyengar Surrenders 5,706 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Surrenders 5,706 Of Incyte Corp >INCY"
INCY,2024-07-03,16:21:17,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 7,695 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Surrenders 7,695 Of Incyte Corp >INCY"
INCY,2024-07-03,16:21:28,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 41,723 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Hoppenot Surrenders 41,723 Of Incyte Corp >INCY"
INCY,2024-07-03,20:06:43,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Entry Into Definitive Agreement >INCY
INCY,2024-07-08,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-07-08,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-07-09,12:00:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2024-07-09,12:00:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2024-07-09,12:12:23,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2024-07-09,12:12:23,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2024-07-09,20:36:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 8,148 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 8,148 Of Incyte Corp >INCY"
INCY,2024-07-11,16:36:07,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 8,148 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 8,148 Of Incyte Corp >INCY"
INCY,2024-07-16,20:45:29,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 1,306 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 1,306 Of Incyte Corp >INCY"
INCY,2024-07-17,16:26:30,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 1,306 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 1,306 Of Incyte Corp >INCY"
INCY,2024-07-17,16:26:41,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Cfo Stamoulis Surrenders 948 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,CFO Stamoulis Surrenders 948 Of Incyte Corp >INCY
INCY,2024-07-17,16:27:34,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Iyengar Surrenders 549 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Iyengar Surrenders 549 Of Incyte Corp >INCY
INCY,2024-07-17,16:28:36,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 4,961 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Hoppenot Surrenders 4,961 Of Incyte Corp >INCY"
INCY,2024-07-17,16:29:21,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Cagnoni Surrenders 749 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,Officer Cagnoni Surrenders 749 Of Incyte Corp >INCY
INCY,2024-07-17,16:31:02,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Swain Surrenders 549 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Swain Surrenders 549 Of Incyte Corp >INCY
INCY,2024-07-17,16:31:24,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Tray Surrenders 466 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,Officer Tray Surrenders 466 Of Incyte Corp >INCY
INCY,2024-07-17,16:32:03,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 1,555 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Surrenders 1,555 Of Incyte Corp >INCY"
INCY,2024-07-25,20:12:32,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 15,571 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 15,571 Of Incyte Corp >INCY"
INCY,2024-07-26,17:09:19,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by Oppenheimer
INCY,2024-07-26,17:09:19,6CC55E,Incyte Corp.,100,-0.48,price-targets,downgrade,Incyte Price Target Cut to $81.00/Share From $84.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $81.00/Share From $84.00 by Oppenheimer
INCY,2024-07-29,19:51:27,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 15,571 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Sells 15,571 Of Incyte Corp >INCY"
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 second quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,044 million in the second quarter",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte Corp.: acquisition of Escient Pharmaceuticals,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Corp.: 2.0 billion share repurchase,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 study for,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: In the second quarter of 2024, total revenues grew 9% year-over-year",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte announces positive topline results from two Phase 3 clinical studies evaluating retifanlimab (Zynyz(R)),PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.57,acquisitions-mergers,completed,"In May 2024, Incyte announced it completed the acquisition of Escient Pharmaceuticals",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.7,products-services,increase,Incyte Corp.: Paid demand increased 9% in the second quarter of 2024 versus the same quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenues growth in the second quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,043,759 $954,610",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,-0.63,earnings,negative,Incyte Corp.: Total GAAP operating (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -2-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakafi net product revenue increased 3%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.62,revenues,up,Incyte Corp.: Opzelura net product revenue increased 52%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Minjuvi/Monjuvi net product,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakavi royalty revenues increased 10%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.59,equity-actions,,Incyte Corp.: Share Repurchase,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.59,equity-actions,completed,"June 2024, Incyte completed a $2.0 billion share repurchase",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -3-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -4-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -5-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Loss) income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -5-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -5-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $4,661,803 $ 6,782,107",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -5-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP net (loss) income per share,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -6-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -6-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: The Non-GAAP net income for the three months ended March 31, 2024",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Second Quarter Financial -6-
INCY,2024-07-30,11:00:01,6CC55E,Incyte Corp.,100,-0.65,earnings,negative,Incyte 2Q Loss/Shr $2.04,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Loss/Shr $2.04 >INCY
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,-0.65,earnings,negative,Incyte 2Q Adj Loss/Shr $1.82,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Adj Loss/Shr $1.82 >INCY
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,-0.65,earnings,negative,Incyte 2Q Loss $444.6M,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Loss $444.6M >INCY
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 2Q Rev $1.04B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Rev $1.04B >INCY
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 second quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,044 million in the second quarter",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.62,acquisitions-mergers,,Incyte Corp.: acquisition of Escient Pharmaceuticals,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.59,equity-actions,,Incyte Corp.: 2.0 billion share repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 study for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: In the second quarter of 2024, total revenues grew 9% year-over-year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte announces positive topline results from two Phase 3 clinical studies evaluating retifanlimab (Zynyz(R)),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.57,acquisitions-mergers,completed,"In May 2024, Incyte announced it completed the acquisition of Escient Pharmaceuticals",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.7,products-services,increase,Incyte Corp.: Paid demand increased 9% in the second quarter of 2024 versus the same quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenues growth in the second quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: Approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,043,759 $954,610",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,-0.63,earnings,negative,Incyte Corp.: Total GAAP operating (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -2-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakafi net product revenue increased 3%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.62,revenues,up,Incyte Corp.: Opzelura net product revenue increased 52%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Minjuvi/Monjuvi net product,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakavi royalty revenues increased 10%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.59,equity-actions,,Incyte Corp.: Share Repurchase,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.59,equity-actions,completed,"June 2024, Incyte completed a $2.0 billion share repurchase",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -3-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -4-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -5-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Loss) income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -5-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -5-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $4,661,803 $ 6,782,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -5-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP net (loss) income per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -6-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -6-
INCY,2024-07-30,11:00:02,6CC55E,Incyte Corp.,98,0.0,earnings,,"Incyte Corp.: The Non-GAAP net income for the three months ended March 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Second Quarter -6-
INCY,2024-07-30,11:04:12,6CC55E,Incyte Corp.,100,0.72,revenues,up,Incyte Raising Low End of FY24 Jakafi Rev Guidance,NEWS-FLASH,Dow Jones Newswires,Incyte Raising Low End of FY24 Jakafi Rev Guidance >INCY
INCY,2024-07-30,11:08:03,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees FY24 Jakafi Revenue $2.71B-$2.75B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees FY24 Jakafi Revenue $2.71B-$2.75B >INCY
INCY,2024-07-30,11:16:09,6CC55E,Incyte Corp.,93,0.0,earnings,,"Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2024",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2024-07-30,20:01:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration with Incyte,PRESS-RELEASE,GlobeNewswire,MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
INCY,2024-07-30,20:01:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration with Incyte,PRESS-RELEASE,DJ Global Press Release Wire,MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
INCY,2024-07-30,20:01:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration with Incyte,FULL-ARTICLE,Dow Jones Newswires,MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
INCY,2024-07-30,20:01:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration with Incyte,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
INCY,2024-07-30,20:01:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration with Incyte,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
INCY,2024-07-30,20:01:13,6CC55E,Incyte Corp.,100,0.49,partnerships,,Retifanlimab Collaboration With Incyte,NEWS-FLASH,Dow Jones Newswires,MacroGenics Announces Achievement of $100 M in Milestones Related to Retifanlimab Collaboration With Incyte
INCY,2024-07-31,11:24:09,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by B of A Securities
INCY,2024-07-31,11:24:09,6CC55E,Incyte Corp.,100,0.64,price-targets,upgrade,Incyte Price Target Raised to $66.00/Share From $62.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $66.00/Share From $62.00 by B of A Securities
INCY,2024-07-31,15:00:30,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-07-31,15:00:30,6CC55E,Incyte Corp.,100,0.7,price-targets,upgrade,Incyte Price Target Raised to $66.00/Share From $61.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $66.00/Share From $61.00 by RBC Capital
INCY,2024-07-31,16:58:00,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2024-07-31,16:58:00,6CC55E,Incyte Corp.,100,0.48,price-targets,upgrade,Incyte Price Target Raised to $61.00/Share From $59.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $61.00/Share From $59.00 by JP Morgan
INCY,2024-07-31,19:44:20,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Citigroup
INCY,2024-07-31,19:44:20,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $88.00/Share From $80.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $88.00/Share From $80.00 by Citigroup
INCY,2024-08-01,18:10:02,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Deutsche Bank
INCY,2024-08-01,18:10:02,6CC55E,Incyte Corp.,100,0.74,price-targets,upgrade,Incyte Price Target Raised to $60.00/Share From $55.00 by Deutsche Bank,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $60.00/Share From $55.00 by Deutsche Bank
INCY,2024-08-07,21:00:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-08-07,21:00:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-08-12,20:46:03,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 11,608 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 11,608 Of Incyte Corp >INCY"
INCY,2024-08-13,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2024-08-13,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2024-08-13,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2024-08-13,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT)",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2024-08-14,19:38:15,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 11,608 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Sells 11,608 Of Incyte Corp >INCY"
INCY,2024-08-14,21:34:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval Of Niktimvo(TM) (axatilimab-csfr) For The Treatment Of Chronic Graft-Versus,NEWS-FLASH,Dow Jones Newswires,Incyte And Syndax Announce U.S. FDA Approval Of Niktimvo(TM) (axatilimab-csfr) For The Treatment Of Chronic Graft-Versus-Host Disease (GVHD) >INCY
INCY,2024-08-14,21:34:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved Niktimvo(TM) (axatilimab-csfr), an anti-CSF-1R antibody, for",PRESS-RELEASE,Business Wire,Incyte and Syndax Announce U.S. FDA Approval of Niktimvo(TM) (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2024-08-14,21:34:00,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Business Wire,Incyte and Syndax Announce U.S. FDA Approval of Niktimvo(TM) (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2024-08-14,21:35:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved Niktimvo(TM) (axatilimab-csfr), an anti-CSF-1R antibody, for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Announce U.S. FDA Approval of Niktimvo(TM) (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2024-08-14,21:35:02,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Announce U.S. FDA Approval of Niktimvo(TM) (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2024-08-15,14:12:55,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-08-15,14:12:55,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $67.00/Share From $66.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $67.00/Share From $66.00 by RBC Capital
INCY,2024-08-15,17:02:34,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval of Axatilimab-Csfr for the Treatment of Chronic Graft-Versus,PRESS-RELEASE,DJ Global Press Release Wire,ASTCT Applauds FDA Approval of Axatilimab-Csfr for the Treatment of Chronic Graft-Versus-Host Disease (cGVHD)
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R),PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R) ) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R) ) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R) ) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R) ) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R) ) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R)) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte (Nasdaq: INCY) today announces positive topline results from the pivotal Phase 3 inMIND trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R)) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R)) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R)) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:30:01,6CC55E,Incyte Corp.,100,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(R)) in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-15,20:33:18,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte: Positive Topline Results From Phase 3 Study of Tafasitamab,NEWS-FLASH,Dow Jones Newswires,Incyte: Positive Topline Results From Phase 3 Study of Tafasitamab in Relapsed or Refractory Follicular Lymphoma
INCY,2024-08-21,15:40:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R),PRESS-RELEASE,Business Wire,Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R) ) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
INCY,2024-08-21,15:40:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R) ) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
INCY,2024-08-21,15:40:51,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R)),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R)) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
INCY,2024-08-21,15:40:51,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz(R)) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
INCY,2024-08-23,07:02:14,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 2Q 2024 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 2Q 2024 (INCY)"
INCY,2024-09-09,20:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-09-09,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-09-12,20:21:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Dickinson Registers 8,450 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Dickinson Registers 8,450 Of Incyte Corp >INCY"
INCY,2024-09-13,20:10:03,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Officer Tray Registers 382 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,Officer Tray Registers 382 Of Incyte Corp >INCY
INCY,2024-09-14,14:30:00,6CC55E,Incyte Corp.,97,0.0,products-services,,Incyte Corp.: In an interim analysis for,PRESS-RELEASE,Business Wire,Incyte's Retifanlimab (Zynyz(R) ) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
INCY,2024-09-14,14:30:01,6CC55E,Incyte Corp.,98,0.0,products-services,,Incyte Corp.: In an interim analysis for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte's Retifanlimab (Zynyz(R)) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
INCY,2024-09-14,16:45:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call and Webcast Information,PRESS-RELEASE,Business Wire,"Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer"
INCY,2024-09-14,16:45:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call and Webcast Information,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer"
INCY,2024-09-16,12:30:06,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by B of A Securities
INCY,2024-09-16,12:30:06,6CC55E,Incyte Corp.,100,0.44,price-targets,upgrade,Incyte Price Target Raised to $68.00/Share From $66.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $68.00/Share From $66.00 by B of A Securities
INCY,2024-09-16,16:55:26,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Guggenheim
INCY,2024-09-16,16:55:26,6CC55E,Incyte Corp.,100,0.66,price-targets,upgrade,Incyte Price Target Raised to $92.00/Share From $86.00 by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $92.00/Share From $86.00 by Guggenheim
INCY,2024-09-16,17:25:13,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Dickinson Sells 8,450 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Dickinson Sells 8,450 Of Incyte Corp >INCY"
INCY,2024-09-16,17:26:50,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Officer Tray Sells 954 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,Officer Tray Sells 954 Of Incyte Corp >INCY
INCY,2024-09-18,12:07:21,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Hold From Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Hold From Buy by Truist Securities
INCY,2024-09-18,12:07:21,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $74.00/Share From $83.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $74.00/Share From $83.00 by Truist Securities
INCY,2024-09-18,21:16:02,6CC55E,Incyte Corp.,99,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,PR Newswire,Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo(TM) (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
INCY,2024-09-25,11:00:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
INCY,2024-09-25,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
INCY,2024-10-01,10:16:17,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Outperform by Wolfe Research,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Outperform by Wolfe Research
INCY,2024-10-03,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-10-03,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-10-04,16:41:13,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Denton Surrenders 2,136 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Denton Surrenders 2,136 Of Incyte Corp >INCY"
INCY,2024-10-08,03:08:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-10-08,03:08:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-10-08,12:00:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2024-10-08,12:00:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2024-10-08,12:04:20,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2024-10-08,12:04:20,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2024-10-10,13:15:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,Lee partners with Incyte on,PRESS-RELEASE,Business Wire,Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
INCY,2024-10-10,13:15:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
INCY,2024-10-10,13:15:23,6CC55E,Incyte Corp.,99,0.49,partnerships,,Lee partners with Incyte on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
INCY,2024-10-10,13:15:23,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
INCY,2024-10-10,15:32:29,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2024-10-10,15:32:29,6CC55E,Incyte Corp.,100,-0.32,price-targets,downgrade,Incyte Price Target Cut to $62.00/Share From $63.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $62.00/Share From $63.00 by Wells Fargo
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated Minjuvi(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated Minjuvi(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-15,12:30:00,6CC55E,Incyte Corp.,100,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval of Minjuvi(R) (tafasitamab) in Mexico
INCY,2024-10-16,20:24:24,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces Health Canada Approval of OPZELURA(R) (ruxolitinib),PRESS-RELEASE,Canadian News Wire,Incyte Announces Health Canada Approval of OPZELURA(R) (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental Vitiligo
INCY,2024-10-16,20:24:24,6CC55E,Incyte Corp.,100,0.0,products-services,,Clinical trial program evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Canadian News Wire,Incyte Announces Health Canada Approval of OPZELURA(R) (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) and Nonsegmental Vitiligo
INCY,2024-10-23,17:22:18,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2024-10-23,17:22:18,6CC55E,Incyte Corp.,100,0.64,price-targets,upgrade,Incyte Price Target Raised to $65.00/Share From $61.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $65.00/Share From $61.00 by JP Morgan
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,3Q EPS 54c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q EPS 54c >INCY
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Adj EPS $1.07,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Adj EPS $1.07 >INCY
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 third quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,138 million in the third quarter",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Following the announcement of the positive topline results from the Phase 3 study,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz(R)),PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 1 data of INCB123667,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"In August, Incyte announced positive topline results from the Phase 3 clinical study evaluating tafasitamab",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 trial evaluating the safety and efficacy of axatilimab in combination with ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 trial evaluating the safety and efficacy of axatilimab in combination with ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 trial for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 studies of povorcitinib in patients,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,137,871 $919,025",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Net $106.5M,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Net $106.5M >INCY
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 3Q Rev $1.14B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Rev $1.14B >INCY
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Jakafi net product revenue increased 16%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,revenues,up,Opzelura net product revenue increased 52%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.84,revenues,up,Monjuvi net product revenue increased 277% and 208%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: For the quarter ended September 30, 2024, total royalty revenues grew by 20%",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: For the nine months ended September 30, 2024, total royalty revenues grew by 12%",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2024,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,012,434 $ 6,782,107",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -6-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -6-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Third Quarter Financial -6-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2024 third quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,138 million in the third quarter",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Following the announcement of the positive topline results from the Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz(R)),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 1 data of INCB123667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"In August, Incyte announced positive topline results from the Phase 3 clinical study evaluating tafasitamab",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 trial evaluating the safety and efficacy of axatilimab in combination with ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2 trial evaluating the safety and efficacy of axatilimab in combination with ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 trial for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 studies of povorcitinib in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,137,871 $919,025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -2-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Jakafi net product revenue increased 16%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,revenues,up,Opzelura net product revenue increased 52%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.84,revenues,up,Monjuvi net product revenue increased 277% and 208%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: For the quarter ended September 30, 2024, total royalty revenues grew by 20%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: For the nine months ended September 30, 2024, total royalty revenues grew by 12%",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -3-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -4-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2024,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,012,434 $ 6,782,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -5-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -6-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -6-
INCY,2024-10-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Third Quarter -6-
INCY,2024-10-29,11:04:35,6CC55E,Incyte Corp.,100,0.0,equity-actions,,Incyte Sees FY24 GAAP Research and Development Expenses of $2.55B - $2.59B,NEWS-FLASH,Dow Jones Newswires,Incyte Sees FY24 GAAP Research and Development Expenses of $2.55B - $2.59B > INCY
INCY,2024-10-29,11:05:02,6CC55E,Incyte Corp.,100,0.0,equity-actions,,Incyte Sees FY24 Adjusted Research and Development Expenses of $2.40B - $2.44B,NEWS-FLASH,Dow Jones Newswires,Incyte Sees FY24 Adjusted Research and Development Expenses of $2.40B - $2.44B > INCY
INCY,2024-10-29,11:06:21,6CC55E,Incyte Corp.,93,0.0,earnings,,"Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2024",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2024-10-29,14:40:39,6CC55E,Incyte Corp.,100,0.72,revenues,above-expectations,Incyte Corp.: the company reported third-quarter revenue that beat analysts' expectations,FULL-ARTICLE,Dow Jones Newswires,"Incyte Shares Hit 52-Week High After 3Q Revenue Beat, Higher Jakafi Guidance"
INCY,2024-10-29,14:40:39,6CC55E,Incyte Corp.,100,0.74,products-services,increase,"Jakafi product revenue was primarily driven by patient demand, which increased 10% in the quarter",FULL-ARTICLE,Dow Jones Newswires,"Incyte Shares Hit 52-Week High After 3Q Revenue Beat, Higher Jakafi Guidance"
INCY,2024-10-30,11:24:14,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Buy From Neutral by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Buy From Neutral by B of A Securities
INCY,2024-10-30,11:24:14,6CC55E,Incyte Corp.,100,0.8,price-targets,upgrade,Incyte Price Target Raised to $90.00/Share From $68.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $90.00/Share From $68.00 by B of A Securities
INCY,2024-10-30,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2024-10-30,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2024-10-30,14:12:34,6CC55E,Incyte Corp.,100,0.72,price-targets,upgrade,Incyte Price Target Raised to $52.00/Share From $48.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $52.00/Share From $48.00 by BMO Capital
INCY,2024-10-30,16:01:44,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2024-10-30,16:01:44,6CC55E,Incyte Corp.,100,0.74,price-targets,upgrade,Incyte Price Target Raised to $71.00/Share From $65.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $71.00/Share From $65.00 by JP Morgan
INCY,2024-10-30,16:09:34,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by Oppenheimer
INCY,2024-10-30,16:09:34,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $82.00/Share From $81.00 by Oppenheimer,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $82.00/Share From $81.00 by Oppenheimer
INCY,2024-10-30,16:40:34,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-10-30,16:40:34,6CC55E,Incyte Corp.,100,0.68,price-targets,upgrade,Incyte Price Target Raised to $72.00/Share From $67.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $72.00/Share From $67.00 by RBC Capital
INCY,2024-10-30,17:14:34,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by Goldman Sachs
INCY,2024-10-30,17:14:34,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $70.00/Share From $63.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $70.00/Share From $63.00 by Goldman Sachs
INCY,2024-10-30,17:43:14,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2024-10-30,17:43:14,6CC55E,Incyte Corp.,100,0.7,price-targets,upgrade,Incyte Price Target Raised to $69.00/Share From $64.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $69.00/Share From $64.00 by Morgan Stanley
INCY,2024-10-30,18:45:55,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Citigroup
INCY,2024-10-30,18:45:55,6CC55E,Incyte Corp.,100,0.6,price-targets,upgrade,Incyte Price Target Raised to $97.00/Share From $92.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $97.00/Share From $92.00 by Citigroup
INCY,2024-10-30,19:43:55,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2024-10-30,19:43:55,6CC55E,Incyte Corp.,100,0.76,price-targets,upgrade,Incyte Price Target Raised to $68.00/Share From $62.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $68.00/Share From $62.00 by Wells Fargo
INCY,2024-11-06,21:22:04,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 3,680 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 3,680 Of Incyte Corp >INCY"
INCY,2024-11-07,21:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-11-07,21:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-11-08,17:50:10,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 3,680 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 3,680 Of Incyte Corp >INCY"
INCY,2024-11-14,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2024-11-14,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2024-11-14,17:17:04,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-11-14,17:17:04,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $80.00/Share From $72.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $80.00/Share From $72.00 by RBC Capital
INCY,2024-11-18,21:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: In addition, data from the Phase 2 study",PRESS-RELEASE,Business Wire,Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
INCY,2024-11-18,21:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: In addition, data from the Phase 2 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
INCY,2024-11-19,14:23:37,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. -- IBD
INCY,2024-11-19,15:52:05,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2024-11-19,15:52:05,6CC55E,Incyte Corp.,100,-0.7,price-targets,downgrade,Incyte Price Target Cut to $74.00/Share From $80.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $74.00/Share From $80.00 by RBC Capital
INCY,2024-11-19,17:21:23,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The company said that two Phase 2 studies,FULL-ARTICLE,Dow Jones Newswires,Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock. -- Barrons.com
INCY,2024-11-19,17:21:23,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock. -- Barrons.com
INCY,2024-11-19,18:35:38,6CC55E,Incyte Corp.,100,-0.65,equity-actions,halt,Incyte Corp. (INCY) Paused due to volatility,NEWS-FLASH,Dow Jones Newswires,Incyte Corp. (INCY) Paused due to volatility
INCY,2024-11-19,18:40:38,6CC55E,Incyte Corp.,100,0.48,equity-actions,resumed,Incyte Corp. (INCY) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Incyte Corp. (INCY) Resumed Trading
INCY,2024-11-19,21:03:08,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,FULL-ARTICLE,Dow Jones Newswires,Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. -- IBD
INCY,2024-11-19,21:30:53,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
INCY,2024-11-21,12:31:13,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment
INCY,2024-11-23,08:00:58,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 3Q 2024 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 3Q 2024 (INCY)"
INCY,2024-11-25,12:33:18,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
INCY,2024-11-25,15:09:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,"Incyte will hold a conference call and webcast on Thursday, December 12, 2024",PRESS-RELEASE,Business Wire,"Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting"
INCY,2024-11-25,15:09:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,"Incyte to Spotlight New Data, Including a Late -2-"
INCY,2024-11-25,15:09:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,"Incyte to Spotlight New Data, Including a Late -2-"
INCY,2024-11-25,15:09:00,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,"Incyte to Spotlight New Data, Including a Late -2-"
INCY,2024-11-26,12:25:55,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment
INCY,2024-11-29,13:01:30,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
INCY,2024-11-29,18:30:44,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 6,043 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 6,043 Of Incyte Corp >INCY"
INCY,2024-12-02,12:25:59,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
INCY,2024-12-03,12:30:38,6CC55E,Incyte Corp.,97,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY)
INCY,2024-12-03,17:54:14,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 6,043 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Sells 6,043 Of Incyte Corp >INCY"
INCY,2024-12-04,12:30:55,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Incyte Corporation Being Investigated on Behalf of Incyte Corporation Investors. Contact Levi & Korsinsky For Details.
INCY,2024-12-05,12:30:41,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation
INCY,2024-12-06,12:25:25,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
INCY,2024-12-06,21:30:02,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-12-06,21:30:02,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2024-12-07,12:30:00,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz(R)),PRESS-RELEASE,Business Wire,Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz(R)) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
INCY,2024-12-09,10:31:37,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz(R)),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz(R)) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
INCY,2024-12-09,12:28:29,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
INCY,2024-12-10,12:28:37,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,INCY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Incyte Corporation
INCY,2024-12-10,15:30:00,6CC55E,Incyte Corp.,98,0.0,products-services,,Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial,PRESS-RELEASE,Business Wire,Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:00,6CC55E,Incyte Corp.,98,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:00,6CC55E,Incyte Corp.,98,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:00,6CC55E,Incyte Corp.,98,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:01,6CC55E,Incyte Corp.,98,0.0,products-services,,Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:01,6CC55E,Incyte Corp.,98,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:01,6CC55E,Incyte Corp.,98,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-10,15:30:01,6CC55E,Incyte Corp.,98,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Late-Breaking Tafasitamab (Monjuvi(R)) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2024-12-11,12:27:01,6CC55E,Incyte Corp.,97,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY)
INCY,2024-12-11,18:21:13,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 1,510 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Surrenders 1,510 Of Incyte Corp >INCY"
INCY,2024-12-11,18:21:26,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Swain Surrenders 873 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Swain Surrenders 873 Of Incyte Corp >INCY
INCY,2024-12-12,12:25:52,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,An Investigation Has Commenced on Behalf of Incyte Corporation Shareholders. Contact Levi & Korsinsky to Discuss your INCY Losses
INCY,2024-12-13,12:30:20,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
INCY,2024-12-16,12:28:41,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
INCY,2024-12-16,21:10:14,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Officer Tray Registers 650 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,Officer Tray Registers 650 Of Incyte Corp >INCY
INCY,2024-12-17,12:25:48,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
INCY,2024-12-17,13:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2024-12-17,13:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2024-12-17,17:38:35,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,300 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Officer Tray Sells 1,300 Of Incyte Corp >INCY"
INCY,2024-12-17,19:52:14,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte Coverage Assumed by UBS at Neutral,NEWS-FLASH,Dow Jones Newswires,Incyte Coverage Assumed by UBS at Neutral
INCY,2024-12-17,19:52:14,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $77.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $77.00/Share by UBS
INCY,2024-12-18,12:32:57,6CC55E,Incyte Corp.,99,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
INCY,2024-12-19,12:26:31,6CC55E,Incyte Corp.,98,0.65,acquisitions-mergers,,Incyte's $750 million acquisition of Escient Pharmaceuticals,PRESS-RELEASE,DJ Global Press Release Wire,Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY
INCY,2024-12-19,15:01:11,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2024-12-19,15:01:11,6CC55E,Incyte Corp.,100,0.44,price-targets,upgrade,Incyte Price Target Raised to $70.00/Share From $68.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $70.00/Share From $68.00 by Wells Fargo
INCY,2021-01-05,07:00:13,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
INCY,2021-01-05,07:00:13,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
INCY,2021-01-05,07:00:13,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
INCY,2021-01-05,07:00:13,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab
INCY,2021-01-06,21:27:59,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 136 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 136 Of Incyte Corp >INCY
INCY,2021-01-06,21:35:16,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 136 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 136 Of Incyte Corp >INCY
INCY,2021-01-07,14:32:50,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Buy,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Buy by Truist Securities
INCY,2021-01-07,14:32:50,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $120.00,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $120.00/Share by Truist Securities
INCY,2021-01-07,16:09:40,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte initiated at buy,NEWS-FLASH,MarketWatch,MW Incyte initiated at buy with $120 price target at Truist Securities
INCY,2021-01-12,21:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,PRESS-RELEASE,Canadian News Wire,Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-12,21:00:05,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-12,21:00:46,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,NEWS-FLASH,Dow Jones Newswires,Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-12,21:01:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Morphosys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-12,21:01:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Morphosys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-12,21:30:18,6CC55E,Incyte Corp.,100,0.0,products-services,,Morphosys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
INCY,2021-01-13,21:18:52,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 127 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 127 Of Incyte Corp >INCY
INCY,2021-01-19,13:00:38,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:00:38,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:00:38,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:00:38,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:04:33,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:04:33,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2020 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:04:33,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-19,13:04:33,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
INCY,2021-01-20,21:46:11,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 174 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 174 Of Incyte Corp >INCY
INCY,2021-01-20,22:03:03,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 174 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 174 Of Incyte Corp >INCY
INCY,2021-01-21,08:34:41,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 4Q 2020 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 4Q 2020 (INCY)"
INCY,2021-01-21,21:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The BLA submission,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:01,6CC55E,Incyte Corp.,99,0.4,products-services,start,Incyte Corp.: The trial enrolled 94 patients,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:01,6CC55E,Incyte Corp.,99,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:02,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The BLA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:02,6CC55E,Incyte Corp.,99,0.4,products-services,start,Incyte Corp.: The trial enrolled 94 patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:02,6CC55E,Incyte Corp.,99,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-21,21:30:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-01-26,19:53:45,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Yao Registers 21,545 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Yao Registers 21,545 Of Incyte Corp >INCY"
INCY,2021-01-26,20:26:55,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 2,744 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 2,744 Of Incyte Corp >INCY"
INCY,2021-01-26,20:29:26,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 3,795 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 3,795 Of Incyte Corp >INCY"
INCY,2021-01-26,20:29:46,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 5,116 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 5,116 Of Incyte Corp >INCY"
INCY,2021-01-27,21:44:42,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 78 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 78 Of Incyte Corp >INCY
INCY,2021-01-27,21:47:44,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 78 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 78 Of Incyte Corp >INCY
INCY,2021-01-27,21:53:03,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 2,744 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Sells 2,744 Of Incyte Corp >INCY"
INCY,2021-01-27,22:04:15,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 5,116 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Sells 5,116 Of Incyte Corp >INCY"
INCY,2021-01-27,22:10:12,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 3,795 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Sells 3,795 Of Incyte Corp >INCY"
INCY,2021-01-27,22:33:49,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Yao Sells 21,545 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Yao Sells 21,545 Of Incyte Corp >INCY"
INCY,2021-01-29,18:36:00,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Pemigatinib,PRESS-RELEASE,Business Wire,"Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement"
INCY,2021-01-29,18:36:00,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Pemigatinib is now being reviewed by the European Commission,PRESS-RELEASE,Business Wire,"Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement"
INCY,2021-01-29,18:36:01,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Pemigatinib,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement"
INCY,2021-01-29,18:36:01,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Pemigatinib is now being reviewed by the European Commission,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement"
INCY,2021-01-29,18:36:20,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Pemigatinib,NEWS-FLASH,Dow Jones Newswires,"Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement"
INCY,2021-01-29,19:06:38,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Gets Positive CHMP Opinion for Pemigatinib,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets Positive CHMP Opinion for Pemigatinib
INCY,2021-02-02,22:53:33,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Dhanak Registers 1,356 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Dhanak Registers 1,356 Of Incyte Corp >INCY"
INCY,2021-02-03,21:29:20,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Dhanak Sells 1,356 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dhanak Sells 1,356 Of Incyte Corp >INCY"
INCY,2021-02-09,12:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,4Q EPS 68c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q EPS 68c >INCY
INCY,2021-02-09,12:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Net $149.9M,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Net $149.9M >INCY
INCY,2021-02-09,12:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Rev $789.5M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Rev $789.5M >INCY
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2020 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2020 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 789,509 $579,389",PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 36,323 $ 32,215",PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte Corp.: our collaboration with MorphoSys and expense related to the PRV, partially offset by",PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: The 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. EDT,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -4-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -4-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,0.0,assets,,"Incyte Corp.: Total assets $ 3,560,918 $ 3,426,750",PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2020 Fourth Quarter and Year-End -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2020 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2020 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 789,509 $579,389",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 36,323 $ 32,215",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -2-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte Corp.: our collaboration with MorphoSys and expense related to the PRV, partially offset by",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: The 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -3-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -4-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -4-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,0.0,assets,,"Incyte Corp.: Total assets $ 3,560,918 $ 3,426,750",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -5-
INCY,2021-02-09,12:00:02,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2020 Fourth Quarter -5-
INCY,2021-02-09,12:00:53,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Adj EPS 93c,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Adj EPS 93c >INCY
INCY,2021-02-09,12:18:30,6CC55E,Incyte Corp.,100,0.64,earnings,up,"Incyte 4Q Profit, Revenue Rise",FULL-ARTICLE,Dow Jones Newswires,"Incyte 4Q Profit, Revenue Rise >INCY"
INCY,2021-02-09,19:44:39,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corporation's CEO HervÃ© Hoppenot on Q4 2020 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q4 2020 Results -- Earnings Call Transcript >INCY
INCY,2021-02-09,19:44:39,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte-corporations-incy-ceo-herv-hoppenot-on-q4-2020-results-earnings,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q4 2020 Results -- Earnings Call Transcript >INCY
INCY,2021-02-10,12:13:44,6CC55E,Incyte Corp.,100,-0.98,analyst-ratings,negative,Incyte Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Underperform From Market Perform by SVB Leerink
INCY,2021-02-10,12:13:44,6CC55E,Incyte Corp.,100,-0.82,price-targets,downgrade,Incyte Price Target Cut to $70.00/Share From $89.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $70.00/Share From $89.00 by SVB Leerink
INCY,2021-02-10,13:21:24,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2021-02-10,13:21:24,6CC55E,Incyte Corp.,100,-0.52,price-targets,downgrade,Incyte Price Target Cut to $93.00/Share From $97.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $93.00/Share From $97.00 by Morgan Stanley
INCY,2021-02-11,12:30:01,6CC55E,Incyte Corp.,98,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has accepted for Priority Review Incyte's Biologics License Application,PRESS-RELEASE,GlobeNewswire,MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
INCY,2021-02-11,12:30:01,6CC55E,Incyte Corp.,98,0.41,products-services,start,Incyte initiated two Phase 3 studies,PRESS-RELEASE,GlobeNewswire,MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
INCY,2021-02-11,12:30:02,6CC55E,Incyte Corp.,98,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has accepted for Priority Review Incyte's Biologics License Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
INCY,2021-02-11,12:30:02,6CC55E,Incyte Corp.,98,0.41,products-services,start,Incyte initiated two Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
INCY,2021-02-11,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2021-02-11,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2021-02-16,21:58:38,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 1,210 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 1,210 Of Incyte Corp >INCY"
INCY,2021-02-18,21:41:02,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 127 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 127 Of Incyte Corp >INCY
INCY,2021-02-22,13:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The sNDA submission,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,13:00:02,6CC55E,Incyte Corp.,99,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,13:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Jakafi was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,13:00:03,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The sNDA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,13:00:03,6CC55E,Incyte Corp.,99,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,13:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Jakafi was approved by the U.S. Food and Drug Administration for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of sNDA for Jakafi(R) (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
INCY,2021-02-22,14:00:26,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Gets FDA Priority Review of Jakafi,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Priority Review of Jakafi in Chronic Graft-Vs-Host Disease >INCY
INCY,2021-02-22,14:00:26,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp. on Monday said the U.S. Food and Drug Administration granted priority review,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Priority Review of Jakafi in Chronic Graft-Vs-Host Disease >INCY
INCY,2021-02-23,22:02:18,6CC55E,Incyte Corp.,100,0.52,insider-trading,,"Chmn Hoppenot Buys 12,925 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Hoppenot Buys 12,925 Of Incyte Corp >INCY"
INCY,2021-02-26,08:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 trial in,PRESS-RELEASE,Business Wire,Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,08:00:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Business Wire,Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,08:00:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Business Wire,Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,08:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 trial in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,08:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,08:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
INCY,2021-02-26,15:07:35,6CC55E,Incyte Corp.,95,0.57,products-services,granted,Incyte Corp.: European Medicines Agency validated the company's marketing authorization application,FULL-ARTICLE,Dow Jones Newswires,Incyte: EMA Validates Application for Retifanlimab in Squamous Cell Anal Carcinoma
INCY,2021-03-03,00:48:00,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 395 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 395 Of Incyte Corp >INCY
INCY,2021-03-03,11:58:57,6CC55E,Incyte Corp.,93,0.39,products-services,,Eli Lilly signed an exclusive worldwide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte, Eli Lilly: Baricitinib Meets Main Endpoint in Alopecia Areata Study"
INCY,2021-03-03,12:13:57,6CC55E,Incyte Corp.,93,0.39,products-services,,Eli Lilly signed an exclusive worldwide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte, Eli Lilly: Baricitinib Meets Main Endpoint in Alopecia Areata Study"
INCY,2021-03-03,21:31:42,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 395 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 395 Of Incyte Corp >INCY
INCY,2021-03-16,20:22:53,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 128 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 128 Of Incyte Corp >INCY
INCY,2021-03-18,20:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Expanded Access Program to,PRESS-RELEASE,Business Wire,Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi(R) ) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
INCY,2021-03-18,20:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: the Company's ongoing clinical development program,PRESS-RELEASE,Business Wire,Incyte Announces Results from the Phase 3 DEVENT -2-
INCY,2021-03-18,20:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Announces Results from the Phase 3 DEVENT Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi(R)) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
INCY,2021-03-18,20:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: the Company's ongoing clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results from the -2-
INCY,2021-03-23,09:13:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Mhlw) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Business Wire,"Incyte Announces Approval of Pemazyre(R) (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy"
INCY,2021-03-23,09:13:00,6CC55E,Incyte Corp.,99,0.63,products-services,,"Incyte Corp.: Previously, the MHLW granted Orphan Drug Designation for",PRESS-RELEASE,Business Wire,"Incyte Announces Approval of Pemazyre(R) (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy"
INCY,2021-03-23,09:13:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Mhlw) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Approval of Pemazyre(R) (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy"
INCY,2021-03-23,09:13:01,6CC55E,Incyte Corp.,99,0.63,products-services,,"Incyte Corp.: Previously, the MHLW granted Orphan Drug Designation for",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Approval of Pemazyre(R) (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy"
INCY,2021-03-23,09:25:59,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Pemazyre (pemigatinib) Approved in Japan for Treatment,NEWS-FLASH,Dow Jones Newswires,"Incyte: Pemazyre (pemigatinib) Approved in Japan for Treatment of Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 Fusion Gene, Worsening After Cancer Chemotherapy"
INCY,2021-03-29,16:04:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Ec) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Business Wire,Incyte Announces the European Commission Approval of Pemazyre(R) (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
INCY,2021-03-29,16:04:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Ec) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the European Commission Approval of Pemazyre(R) (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
INCY,2021-03-29,17:26:20,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets European OK of Pemazyre,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets European OK of Pemazyre in Rare Bile-Duct Cancer >INCY
INCY,2021-03-29,17:26:20,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. on Monday said the European Commission approved Pemazyre for the treatment of certain adults with cholangiocarcinoma,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets European OK of Pemazyre in Rare Bile-Duct Cancer >INCY
INCY,2021-03-30,19:50:32,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Morrissey Registers 20,000 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Morrissey Registers 20,000 Of Incyte Corp >INCY"
INCY,2021-03-31,20:11:33,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Morrissey Sells 20,000 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Morrissey Sells 20,000 Of Incyte Corp >INCY"
INCY,2021-04-02,18:35:47,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 396 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 396 Of Incyte Corp >INCY
INCY,2021-04-05,12:16:38,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2021-04-05,12:16:38,6CC55E,Incyte Corp.,100,-0.7,price-targets,downgrade,Incyte Price Target Cut to $86.00/Share From $93.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $86.00/Share From $93.00 by Morgan Stanley
INCY,2021-04-05,20:26:33,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 396 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 396 Of Incyte Corp >INCY
INCY,2021-04-06,20:30:04,6CC55E,Incyte Corp.,93,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
INCY,2021-04-06,20:30:04,6CC55E,Incyte Corp.,94,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
INCY,2021-04-08,10:45:03,6CC55E,Incyte Corp.,92,0.0,products-services,,"Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study",PRESS-RELEASE,PR Newswire,Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
INCY,2021-04-08,10:45:03,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,Lilly and Incyte announce results from the Phase -2-
INCY,2021-04-08,10:45:03,6CC55E,Incyte Corp.,93,0.0,products-services,,"Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
INCY,2021-04-08,10:45:03,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte announce results -2-
INCY,2021-04-08,11:01:22,6CC55E,Incyte Corp.,100,0.0,products-services,,Eli Lilly and Incyte say Phase 3 study,FULL-ARTICLE,MarketWatch,MW Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal
INCY,2021-04-08,11:01:22,6CC55E,Incyte Corp.,100,0.0,products-services,,Eli Lilly And Incyte Say Phase 3 Study,FULL-ARTICLE,Dow Jones Newswires,Eli Lilly And Incyte Say Phase 3 Study Of Baricitinib In Hospitalized COVID-19 Patients Failed To Meet Main Goal -- MarketWatch
INCY,2021-04-08,11:14:56,6CC55E,Incyte Corp.,100,-0.65,products-services,negative,"Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint",FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint"
INCY,2021-04-08,11:29:56,6CC55E,Incyte Corp.,100,-0.65,products-services,negative,"Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint",FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint"
INCY,2021-04-13,12:00:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2021-04-13,12:00:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2021 Conference Call: May 4, 2021 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2021-04-13,12:01:44,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2021-04-13,12:01:44,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2021 Conference Call: May 4, 2021 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2021-04-13,20:15:29,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Pasquale Surrenders 517 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Surrenders 517 Of Incyte Corp >INCY
INCY,2021-04-16,20:34:32,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Canadian News Wire,Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
INCY,2021-04-19,20:01:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-19,20:01:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-19,20:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte's ongoing clinical development program,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce First Patient Dosed -2-
INCY,2021-04-19,20:01:22,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-19,20:01:22,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-19,20:01:22,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte's ongoing clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce -2-
INCY,2021-04-19,20:16:46,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-19,20:16:46,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma
INCY,2021-04-20,10:45:04,6CC55E,Incyte Corp.,92,0.0,earnings,,Incyte (NASDAQ: INCY) announced today results from a second,PRESS-RELEASE,PR Newswire,Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
INCY,2021-04-20,10:45:04,6CC55E,Incyte Corp.,92,0.7,products-services,,"In Q1 2020, baricitinib received Breakthrough Therapy designation from the FDA",PRESS-RELEASE,PR Newswire,Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
INCY,2021-04-20,10:45:04,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,Lilly and Incyte's Baricitinib Improved Hair -2-
INCY,2021-04-20,10:46:03,6CC55E,Incyte Corp.,93,0.0,earnings,,Incyte (NASDAQ: INCY) announced today results from a second,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
INCY,2021-04-20,10:46:03,6CC55E,Incyte Corp.,93,0.7,products-services,,"In Q1 2020, baricitinib received Breakthrough Therapy designation from the FDA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
INCY,2021-04-20,10:46:03,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte's Baricitinib -2-
INCY,2021-04-20,11:17:57,6CC55E,Incyte Corp.,93,0.39,products-services,,Eli Lilly signed an exclusive worldwide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Eli Lilly, Incyte: Baricitinib Improves Hair Regrowth in Alopecia Areata"
INCY,2021-04-20,11:32:57,6CC55E,Incyte Corp.,93,0.39,products-services,,Eli Lilly signed an exclusive worldwide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Eli Lilly, Incyte: Baricitinib Improves Hair Regrowth in Alopecia Areata"
INCY,2021-04-20,12:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: More than 14 abstracts, including new findings from Incyte's clinical trial programs",PRESS-RELEASE,Business Wire,Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
INCY,2021-04-20,12:00:05,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: More than 14 abstracts, including new findings from Incyte's clinical trial programs",PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
INCY,2021-04-21,07:57:16,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 1Q 2021 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 1Q 2021 (INCY)"
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Findings from a Randomized Phase 2 Study,PRESS-RELEASE,Business Wire,Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Fifty-two-week results,PRESS-RELEASE,Business Wire,Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.64,earnings,up,Incyte Corp.: Updated results at Week 104,PRESS-RELEASE,Business Wire,Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces New Findings from a Randomized Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Fifty-two-week results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,100,0.64,earnings,up,Incyte Corp.: Updated results at Week 104,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-04-23,14:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: the Company's ongoing clinical development program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Findings from -2-
INCY,2021-04-27,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2021-04-27,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2021-04-27,20:58:26,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 127 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 127 Of Incyte Corp >INCY
INCY,2021-05-04,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,1Q EPS 24c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q EPS 24c >INCY
INCY,2021-05-04,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Net $53.5M,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Net $53.5M >INCY
INCY,2021-05-04,11:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 1Q Rev $604.7M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Rev $604.7M >INCY
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: reaffirming full year guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launches of Monjuvi(R) (tafasitamab),PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials of,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: Development collaboration with Cellenkos, Inc.",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemigatinib: In March,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemazyre(R) (pemigatinib) was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 trial in,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte Corp.: Discovery collaboration with Agenus,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte Corp.: MCLA-145 development in collaboration with Merus,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Baricitinib: In April,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib: In March,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenue $ 604,718 $ 568,507",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -2-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 29,220 $ 27,319",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: The 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -3-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: the Company's reaffirmed financial guidance for 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -4-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -4-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -4-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,97,0.0,assets,,"Incyte Corp.: Total assets $3,661,436 $ 3,560,918",PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -5-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,97,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -5-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,97,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -5-
INCY,2021-05-04,11:00:02,6CC55E,Incyte Corp.,97,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2021 First Quarter Financial -5-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: reaffirming full year guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launches of Monjuvi(R) (tafasitamab),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: Development collaboration with Cellenkos, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemigatinib: In March,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemazyre(R) (pemigatinib) was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 trial in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte Corp.: Discovery collaboration with Agenus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte Corp.: MCLA-145 development in collaboration with Merus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Baricitinib: In April,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib: In March,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenue $ 604,718 $ 568,507",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -2-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 29,220 $ 27,319",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: The 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -3-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: the Company's reaffirmed financial guidance for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -4-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -4-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -4-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,96,0.0,assets,,"Incyte Corp.: Total assets $3,661,436 $ 3,560,918",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -5-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,96,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -5-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,96,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -5-
INCY,2021-05-04,11:00:03,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 First Quarter -5-
INCY,2021-05-04,11:01:33,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Adj EPS 67c,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Adj EPS 67c >INCY
INCY,2021-05-04,18:50:57,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corporation's CEO HervÃ© Hoppenot on Q1 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q1 2021 Results -- Earnings Call Transcript >INCY
INCY,2021-05-04,18:50:57,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte-corporations-incy-ceo-herv-hoppenot-on-q1-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q1 2021 Results -- Earnings Call Transcript >INCY
INCY,2021-05-04,20:20:31,6CC55E,Incyte Corp.,100,0.46,legal,,Incyte to Pay $12.6 Million to Resolve False Claims,NEWS-FLASH,Dow Jones Newswires,DOJ: Incyte to Pay $12.6 Million to Resolve False Claims Act Allegations
INCY,2021-05-04,20:20:58,6CC55E,Incyte Corp.,100,0.46,legal,,Doj: Incyte Settlement,NEWS-FLASH,Dow Jones Newswires,DOJ: Incyte Settlement Resolves Allegations About Kickbacks
INCY,2021-05-04,22:42:59,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 396 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 396 Of Incyte Corp >INCY
INCY,2021-05-05,12:28:24,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2021-05-05,12:28:24,6CC55E,Incyte Corp.,100,-0.24,price-targets,downgrade,Incyte Price Target Cut to $85.00/Share From $86.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $85.00/Share From $86.00 by Morgan Stanley
INCY,2021-05-05,20:12:33,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 396 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 396 Of Incyte Corp >INCY
INCY,2021-05-11,20:01:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-11,20:01:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-11,20:01:30,6CC55E,Incyte Corp.,97,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-11,20:01:30,6CC55E,Incyte Corp.,97,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-11,20:39:23,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-11,20:39:23,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
INCY,2021-05-12,20:18:00,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Efficacy and Safety Results from an Open-Label Phase 2 Study,PRESS-RELEASE,Business Wire,Data From Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
INCY,2021-05-12,20:22:20,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Efficacy and Safety Results from an Open-Label Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data From Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
INCY,2021-05-17,11:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Results from Phase 3,PRESS-RELEASE,Business Wire,Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-05-17,11:30:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Results from Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
INCY,2021-05-17,11:30:08,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Results From Phase 3,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Positive Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients With Vitiligo
INCY,2021-05-18,20:29:31,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Acquires 40,000 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Acquires 40,000 Of Incyte Corp >INCY"
INCY,2021-05-19,21:14:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients,PRESS-RELEASE,Business Wire,Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
INCY,2021-05-19,21:14:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 Study to,PRESS-RELEASE,Business Wire,Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
INCY,2021-05-19,21:14:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
INCY,2021-05-19,21:14:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 Study to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
INCY,2021-05-20,10:03:42,6CC55E,Incyte Corp.,100,0.62,products-services,positive,Incyte: Phase 2 Study of Ponatinib Met Primary Endpoint,NEWS-FLASH,Dow Jones Newswires,Incyte: Phase 2 Study of Ponatinib Met Primary Endpoint >INCY
INCY,2021-05-20,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2021-05-20,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2021-06-03,20:46:18,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 395 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 395 Of Incyte Corp >INCY
INCY,2021-06-03,22:54:19,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 395 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 395 Of Incyte Corp >INCY
INCY,2021-06-04,17:33:55,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announce Three-Year Results from Phase 2,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,17:33:55,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announce Three-Year Results from Phase 2,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,17:45:00,6CC55E,Incyte Corp.,97,0.0,products-services,,Incyte Corp.: our ongoing research and development program,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,17:45:00,6CC55E,Incyte Corp.,97,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,17:45:00,6CC55E,Incyte Corp.,97,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announce Three-Year Results from Phase 2,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: our ongoing research and development program,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Three-Year Results,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results -2-
INCY,2021-06-04,18:00:33,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Three-Year Results,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Three-Year Results -3-
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients,PRESS-RELEASE,PR Newswire,Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib),PRESS-RELEASE,PR Newswire,Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,PR Newswire,Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-07,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
INCY,2021-06-08,11:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: our sNDA submission for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi(R) ) in Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-06-08,11:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: our sNDA submission for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi(R)) in Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-06-11,19:56:52,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Dhanak Registers 3,845 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Dhanak Registers 3,845 Of Incyte Corp >INCY"
INCY,2021-06-14,20:29:28,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Dhanak Sells 3,845 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dhanak Sells 3,845 Of Incyte Corp >INCY"
INCY,2021-06-22,20:07:10,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 255 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 255 Of Incyte Corp >INCY
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.63,products-services,,Incyte Corp.: The FDA previously granted retifanlimab Orphan Drug Designation for,PRESS-RELEASE,Business Wire,Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Business Wire,Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Business Wire,Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.63,products-services,,Incyte Corp.: The FDA previously granted retifanlimab Orphan Drug Designation for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-24,19:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-06-25,11:31:13,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2021-06-25,11:31:13,6CC55E,Incyte Corp.,100,-0.54,price-targets,downgrade,Incyte Price Target Cut to $88.00/Share From $92.00 by RBC,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $88.00/Share From $92.00 by RBC Capital
INCY,2021-06-25,11:42:00,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Morphosys Announce Positive CHMP Opinion for Tafasitamab,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:00,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Tafasitamab is now being reviewed by the European Commission,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:14,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Morphosys Announce Positive CHMP Opinion for Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:14,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Tafasitamab is now being reviewed by the European Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:14,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:42:24,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Morphosys Announce Positive CHMP Opinion for Tafasitamab,NEWS-FLASH,Dow Jones Newswires,Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:45:22,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announce Positive CHMP Opinion for Tafasitamab,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,11:45:22,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announce Positive CHMP Opinion for Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,12:11:56,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announce Positive CHMP Opinion for Tafasitamab,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,12:11:56,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Tafasitamab is now being reviewed by the European Commission,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-25,12:11:56,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-06-30,19:36:09,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Yao Registers 27,194 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Yao Registers 27,194 Of Incyte Corp >INCY"
INCY,2021-06-30,20:13:09,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Yao Sells 27,194 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Yao Sells 27,194 Of Incyte Corp >INCY"
INCY,2021-06-30,20:16:03,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 22,079 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 22,079 Of Incyte Corp >INCY"
INCY,2021-07-02,21:45:35,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 396 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 396 Of Incyte Corp >INCY
INCY,2021-07-02,23:17:08,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 396 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 396 Of Incyte Corp >INCY
INCY,2021-07-07,20:10:43,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Dhanak Surrenders 1,573 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dhanak Surrenders 1,573 Of Incyte Corp >INCY"
INCY,2021-07-07,20:16:28,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 2,263 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Surrenders 2,263 Of Incyte Corp >INCY"
INCY,2021-07-07,20:25:21,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 17,651 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Hoppenot Surrenders 17,651 Of Incyte Corp >INCY"
INCY,2021-07-07,20:30:27,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Iyengar Surrenders 2,391 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Surrenders 2,391 Of Incyte Corp >INCY"
INCY,2021-07-07,20:35:11,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Pasquale Surrenders 2,241 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Pasquale Surrenders 2,241 Of Incyte Corp >INCY"
INCY,2021-07-07,20:41:52,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Cfo Stamoulis Surrenders 516 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,CFO Stamoulis Surrenders 516 Of Incyte Corp >INCY
INCY,2021-07-07,20:46:34,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 2,263 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Surrenders 2,263 Of Incyte Corp >INCY"
INCY,2021-07-07,21:46:14,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 3,355 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 3,355 Of Incyte Corp >INCY"
INCY,2021-07-07,21:56:20,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Yao Surrenders 3,358 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Yao Surrenders 3,358 Of Incyte Corp >INCY"
INCY,2021-07-07,22:40:18,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Trower Surrenders 976 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,Officer Trower Surrenders 976 Of Incyte Corp >INCY
INCY,2021-07-14,21:00:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Jakafi(R) (ruxolitinib) was approved by the FDA,PRESS-RELEASE,Business Wire,Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi(R) ) in Chronic Graft-Versus-Host Disease
INCY,2021-07-14,21:00:00,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Positive data from the Phase 3 REACH2 study,PRESS-RELEASE,Business Wire,Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi(R) ) in Chronic Graft-Versus-Host Disease
INCY,2021-07-14,21:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Jakafi(R) (ruxolitinib) was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi(R)) in Chronic Graft-Versus-Host Disease
INCY,2021-07-14,21:00:01,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Positive data from the Phase 3 REACH2 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi(R)) in Chronic Graft-Versus-Host Disease
INCY,2021-07-15,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2021-07-15,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2021 Conference Call: August 3, 2021 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2021-07-16,14:00:04,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,Lilly and Incyte provide update on supplemental -2-
INCY,2021-07-16,14:00:04,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte provide update on -2-
INCY,2021-07-16,14:01:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Lilly and Incyte Update on Supplemental New Drug Application for Baricitinib for Treatment of Moderate to Severe Atopic,NEWS-FLASH,Dow Jones Newswires,Lilly and Incyte Update on Supplemental New Drug Application for Baricitinib for Treatment of Moderate to Severe Atopic Dermatitis
INCY,2021-07-20,10:30:04,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte upgraded to buy from hold,NEWS-FLASH,MarketWatch,MW Incyte upgraded to buy from hold at Benchmark
INCY,2021-07-20,11:52:22,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Buy From Hold by Benchmark,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Buy From Hold by Benchmark
INCY,2021-07-20,11:52:22,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $89.00,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $89.00/Share by Benchmark
INCY,2021-07-21,07:56:20,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 2Q 2021 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 2Q 2021 (INCY)"
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The BLA submission,PRESS-RELEASE,Business Wire,Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Business Wire,Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Business Wire,Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: The BLA submission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-23,20:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Zai Lab announced a collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
INCY,2021-07-29,13:26:09,6CC55E,Incyte Corp.,92,-0.58,products-services,denied,Baricitinib has not been approved by the FDA,PRESS-RELEASE,PR Newswire,FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
INCY,2021-07-29,13:26:10,6CC55E,Incyte Corp.,93,-0.58,products-services,denied,Baricitinib has not been approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
INCY,2021-07-29,13:49:52,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Get Emergency Use Authorization for Covid-19 Treatment,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monotherapy"
INCY,2021-07-29,14:04:52,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Get Emergency Use Authorization for Covid-19 Treatment,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte Get Emergency Use Authorization for Covid-19 Treatment as Monotherapy"
INCY,2021-07-30,18:02:54,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 4,911 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 4,911 Of Incyte Corp >INCY"
INCY,2021-08-02,20:15:25,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 4,911 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Sells 4,911 Of Incyte Corp >INCY"
INCY,2021-08-03,10:00:27,6CC55E,Incyte Corp.,94,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
INCY,2021-08-03,10:00:27,6CC55E,Incyte Corp.,95,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
INCY,2021-08-03,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,2Q EPS 67c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q EPS 67c >INCY
INCY,2021-08-03,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Net $149.5M,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Net $149.5M >INCY
INCY,2021-08-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 2Q Rev $705.7M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Rev $705.7M >INCY
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Corp.: Positive CHMP opinion for tafasitamab,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: 1) Development collaboration with Cellenkos, Inc.",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Tafasitamab: In June,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Pemigatinib: The ongoing launch in the United States,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte Corp.: Ruxolitinib cream: In June, 52",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.41,products-services,start,Incyte plans to initiate a Phase 3 trial,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Baricitinib: In July,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,-0.49,labor-issues,,Incyte Corp.: D. has announced his retirement as Executive Vice President and Head,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 705,709 $688,043",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 38,028 $ 33,364",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -2-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -3-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: the Company's revised financial guidance for 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -4-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -4-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -4-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $3,904,623 $ 3,560,918",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -4-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,95,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -5-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,95,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -5-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -5-
INCY,2021-08-03,11:00:02,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Second Quarter Financial -5-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Corp.: Positive CHMP opinion for tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: 1) Development collaboration with Cellenkos, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Tafasitamab: In June,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,Pemigatinib: The ongoing launch in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte Corp.: Ruxolitinib cream: In June, 52",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.41,products-services,start,Incyte plans to initiate a Phase 3 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Baricitinib: In July,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,-0.49,labor-issues,,Incyte Corp.: D. has announced his retirement as Executive Vice President and Head,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 705,709 $688,043",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 38,028 $ 33,364",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -2-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -3-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: the Company's revised financial guidance for 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -4-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -4-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -4-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $3,904,623 $ 3,560,918",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -4-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,94,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -5-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,94,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -5-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,94,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -5-
INCY,2021-08-03,11:00:03,6CC55E,Incyte Corp.,94,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Second Quarter -5-
INCY,2021-08-03,11:07:23,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte 2Q Jakafi Revenue $529M, Up 12%",NEWS-FLASH,Dow Jones Newswires,"Incyte 2Q Jakafi Revenue $529M, Up 12% >INCY"
INCY,2021-08-03,11:07:54,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Adj EPS 80c,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Adj EPS 80c >INCY
INCY,2021-08-03,17:33:05,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2021 Results -- Earnings Call Transcript >INCY
INCY,2021-08-03,17:33:05,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte-corporations-incy-ceo-herve-hoppenot-on-q2-2021-results-earnings,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2021 Results -- Earnings Call Transcript >INCY
INCY,2021-08-03,21:54:37,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 389 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 389 Of Incyte Corp >INCY
INCY,2021-08-04,08:57:36,6CC55E,Incyte Corp.,100,-0.34,analyst-ratings,neutral,Incyte Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Underperform by SVB Leerink
INCY,2021-08-04,08:57:36,6CC55E,Incyte Corp.,100,-0.54,price-targets,downgrade,Incyte Price Target Cut to $67.00/Share From $70.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $67.00/Share From $70.00 by SVB Leerink
INCY,2021-08-04,20:17:38,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 389 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 389 Of Incyte Corp >INCY
INCY,2021-08-16,23:00:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Business Wire,Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
INCY,2021-08-16,23:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
INCY,2021-08-16,23:00:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
INCY,2021-08-16,23:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
INCY,2021-08-16,23:03:14,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and InnoCare Announce Collaboration,NEWS-FLASH,Dow Jones Newswires,Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.39,products-services,,Partner Incyte Announced Development and Commercialization Agreement with InnoCare,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.39,products-services,,Partner Incyte Announced Development and Commercialization Agreement with InnoCare,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:07:53,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.39,products-services,,Partner Incyte Announced Development and Commercialization Agreement with InnoCare,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.39,products-services,,Partner Incyte Announced Development and Commercialization Agreement with InnoCare,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:08:41,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:30:34,6CC55E,Incyte Corp.,100,0.39,products-services,,Partner Incyte Announced Development and Commercialization Agreement with InnoCare,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:30:34,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,06:30:34,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
INCY,2021-08-17,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2021-08-24,12:30:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Canadian News Wire,Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-08-24,12:30:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-08-26,20:01:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and MorphoSys Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-08-26,20:01:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and MorphoSys Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-08-26,20:01:13,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-08-26,20:01:16,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
INCY,2021-08-26,20:01:16,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
INCY,2021-08-26,20:02:25,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
INCY,2021-08-26,20:02:25,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL
INCY,2021-09-02,21:53:27,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 388 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 388 Of Incyte Corp >INCY
INCY,2021-09-03,11:52:35,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 388 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 388 Of Incyte Corp >INCY
INCY,2021-09-14,13:00:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration,PRESS-RELEASE,Business Wire,Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients,PRESS-RELEASE,PR Newswire,Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib),PRESS-RELEASE,PR Newswire,Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,PR Newswire,Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,00:03:13,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent: Releases Phase 2 Results of Pemigatinib in Chinese Patients,NEWS-FLASH,Dow Jones Newswires,Innovent: Releases Phase 2 Results of Pemigatinib in Chinese Patients With Advanced Cholangiocarcinoma at ESMO Congress 2021
INCY,2021-09-17,20:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Health Canada has granted conditional marketing authorization for Pemazyre,PRESS-RELEASE,Canadian News Wire,"Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma"
INCY,2021-09-17,20:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Health Canada has granted conditional marketing authorization for Pemazyre,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma"
INCY,2021-09-21,19:07:02,6CC55E,Incyte Corp.,100,-0.65,equity-actions,halt,Incyte Corp. (INCY) Halted due to pending news,NEWS-FLASH,Dow Jones Newswires,Incyte Corp. (INCY) Halted due to pending news
INCY,2021-09-21,20:11:45,6CC55E,Incyte Corp.,100,0.52,insider-trading,,"Vp Swain Acquires 1,356 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Acquires 1,356 Of Incyte Corp >INCY"
INCY,2021-09-21,20:13:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Business Wire,"Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)"
INCY,2021-09-21,20:13:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)"
INCY,2021-09-21,20:13:31,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval of Opzelura Cream,NEWS-FLASH,Dow Jones Newswires,Incyte Gets FDA Approval of Opzelura Cream for Atopic Dermatitis >INCY
INCY,2021-09-21,21:25:01,6CC55E,Incyte Corp.,100,0.48,equity-actions,resumed,Incyte Corp. (INCY) Resumed Trading,NEWS-FLASH,Dow Jones Newswires,Incyte Corp. (INCY) Resumed Trading
INCY,2021-09-22,12:59:30,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte gets FDA approval for atopic dermatitis drug,FULL-ARTICLE,MarketWatch,MW Incyte gets FDA approval for atopic dermatitis drug
INCY,2021-09-22,12:59:30,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval For Atopic Dermatitis Drug,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval For Atopic Dermatitis Drug -- MarketWatch
INCY,2021-09-22,16:38:00,6CC55E,Incyte Corp.,98,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) has approved Jakafi(R) (ruxolitinib),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Jakafi(R) (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-09-22,16:38:00,6CC55E,Incyte Corp.,98,0.52,products-services,,Incyte Corp.: Jakafi's supplemental New Drug Application,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Jakafi(R) (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-09-22,16:38:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval of Jakafi(R) -2,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Jakafi(R) -2-
INCY,2021-09-22,16:38:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,U.S. Food and Drug Administration (FDA) has approved Jakafi(R) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Jakafi(R) (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-09-22,16:38:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Jakafi's supplemental New Drug Application,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Jakafi(R) (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
INCY,2021-09-22,17:26:21,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Says FDA Approves Jakafi,FULL-ARTICLE,Dow Jones Newswires,Incyte Says FDA Approves Jakafi in Chronic Graft-Versus-Host Disease
INCY,2021-09-22,17:41:21,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Says FDA Approves Jakafi,FULL-ARTICLE,Dow Jones Newswires,Incyte Says FDA Approves Jakafi in Chronic Graft-Versus-Host Disease
INCY,2021-09-23,10:40:19,6CC55E,Incyte Corp.,100,0.62,analyst-ratings,positive,Incyte Raised to Market Perform From Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Market Perform From Underperform by SVB Leerink
INCY,2021-09-23,10:40:19,6CC55E,Incyte Corp.,100,-0.3,price-targets,downgrade,Incyte Price Target Cut to $66.00/Share From $67.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $66.00/Share From $67.00 by SVB Leerink
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:32:24,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
INCY,2021-09-23,11:37:29,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2021-09-23,11:37:29,6CC55E,Incyte Corp.,100,-0.62,price-targets,downgrade,Incyte Price Target Cut to $86.00/Share From $91.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $86.00/Share From $91.00 by RBC Capital
INCY,2021-09-23,12:52:19,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2021-09-23,12:52:19,6CC55E,Incyte Corp.,100,-0.64,price-targets,downgrade,Incyte Price Target Cut to $80.00/Share From $85.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $80.00/Share From $85.00 by Morgan Stanley
INCY,2021-09-27,10:00:06,6CC55E,Incyte Corp.,100,0.49,partnerships,,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to,PRESS-RELEASE,PR Newswire,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
INCY,2021-09-27,10:00:06,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Conference Call,PRESS-RELEASE,PR Newswire,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
INCY,2021-09-27,10:00:06,6CC55E,Incyte Corp.,100,0.49,partnerships,,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
INCY,2021-09-27,10:00:06,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte to host conference call today at 10:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
INCY,2021-09-27,10:00:11,6CC55E,Incyte Corp.,100,0.49,partnerships,,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to,NEWS-FLASH,Dow Jones Newswires,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
INCY,2021-09-28,12:19:23,6CC55E,Incyte Corp.,100,0.52,insider-trading,,Vp Pasquale Acquires 382 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Acquires 382 Of Incyte Corp >INCY
INCY,2021-09-28,21:00:01,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Board of Directors,PRESS-RELEASE,Business Wire,Incyte Names New Member to Its Board of Directors
INCY,2021-09-28,21:00:01,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Names New Member to Its Board of Directors
INCY,2021-09-28,21:00:17,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Incyte Names New Member to Its Bd of Directors
INCY,2021-09-28,21:00:42,6CC55E,Incyte Corp.,100,0.47,labor-issues,,"Incyte Names Otis Brawley, M.D. to the Board",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Otis Brawley, M.D. to the Board"
INCY,2021-09-30,10:33:55,6CC55E,Incyte Corp.,92,0.49,partnerships,,Eli Lilly & Co. and Incyte Corp. on Thursday said a pair,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks"
INCY,2021-09-30,10:33:55,6CC55E,Incyte Corp.,92,0.39,products-services,,Eli Lilly signed an exclusive world-wide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks"
INCY,2021-09-30,10:48:55,6CC55E,Incyte Corp.,92,0.49,partnerships,,Eli Lilly & Co. and Incyte Corp. on Thursday said a pair,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks"
INCY,2021-09-30,10:48:55,6CC55E,Incyte Corp.,92,0.39,products-services,,Eli Lilly signed an exclusive world-wide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks"
INCY,2021-10-02,09:15:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Incyte Corp.: In September 2021, Opzelura(TM) (ruxolitinib) cream was approved by the FDA",PRESS-RELEASE,Business Wire,Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients With Vitiligo
INCY,2021-10-02,09:15:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Incyte Corp.: In September 2021, Opzelura(TM) (ruxolitinib) cream was approved by the FDA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients With Vitiligo
INCY,2021-10-04,11:15:10,6CC55E,Incyte Corp.,100,-0.82,price-targets,downgrade,Incyte stock price target cut to $95 from $120,NEWS-FLASH,MarketWatch,MW Incyte stock price target cut to $95 from $120 at Truist
INCY,2021-10-04,20:42:15,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Dhanak Sells 389 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Dhanak Sells 389 Of Incyte Corp >INCY
INCY,2021-10-04,22:08:36,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Dhanak Registers 389 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Dhanak Registers 389 Of Incyte Corp >INCY
INCY,2021-10-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2021-10-13,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: The schedule for the press release and conference call,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2021-10-13,12:08:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2021-10-13,12:08:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: The schedule for the press release and conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2021-10-21,08:11:31,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 3Q 2021 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 3Q 2021 (INCY)"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemigatinib is approved in the United States, Europe and Japan",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In January 2020, MorphoSys and Incyte entered into a Collaboration",PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-22,01:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,PR Newswire,"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore"
INCY,2021-10-28,11:47:54,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Ema Validates Application for Ruxolitinib,NEWS-FLASH,Dow Jones Newswires,Incyte: EMA Validates Application for Ruxolitinib Cream in Vitiligo >INCY
INCY,2021-10-28,11:57:12,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration in September approved ruxolitinib,FULL-ARTICLE,Dow Jones Newswires,Incyte: EMA Validates Application for Ruxolitinib Cream in Vitiligo >INCY
INCY,2021-10-28,11:57:12,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: European Medicines Agency validated the company's marketing authorization application,FULL-ARTICLE,Dow Jones Newswires,Incyte: EMA Validates Application for Ruxolitinib Cream in Vitiligo >INCY
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,99,-0.47,regulatory,,Parsaclisib has been granted Priority Review by the FDA,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,99,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The CITADEL (Clinical Investigation of,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: Press Release: Incyte Announces Acceptance of NDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,100,-0.47,regulatory,,Parsaclisib has been granted Priority Review by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The CITADEL (Clinical Investigation of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
INCY,2021-11-01,13:16:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Business Wire,Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-01,13:16:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: as well as results from a Phase 1 study,PRESS-RELEASE,Business Wire,Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-01,13:16:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1 study of INCB086550,PRESS-RELEASE,Business Wire,Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-01,13:16:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-01,13:16:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: as well as results from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-01,13:16:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1 study of INCB086550,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
INCY,2021-11-02,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,3Q EPS 82c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q EPS 82c >INCY
INCY,2021-11-02,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Net $181.7M,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Net $181.7M >INCY
INCY,2021-11-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 3Q Rev $813M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Rev $813M >INCY
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"September, the U.S. Food and Drug Administration (FDA) granted approval of Jakafi",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: Collaboration with Syndax Pharmaceuticals: In September,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: we announced that the FDA accepted a NDA seeking approval of parsaclisib,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 2 trials in,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.69,products-services,,Incyte Corp.: The FDA has granted Fast Track designation,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 812,987 $620,643",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 39,869 $ 34,322",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. EDT,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 4,198,831 $ 3,560,918",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,96,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -5-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,96,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -5-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Third Quarter Financial -5-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"September, the U.S. Food and Drug Administration (FDA) granted approval of Jakafi",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: Collaboration with Syndax Pharmaceuticals: In September,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: we announced that the FDA accepted a NDA seeking approval of parsaclisib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 2 trials in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.69,products-services,,Incyte Corp.: The FDA has granted Fast Track designation,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 812,987 $620,643",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 39,869 $ 34,322",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -2-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2021 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. EDT,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -3-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 4,198,831 $ 3,560,918",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -4-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,95,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -5-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,95,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -5-
INCY,2021-11-02,11:00:02,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Third Quarter -5-
INCY,2021-11-02,11:01:19,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Adj EPS $1.18,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Adj EPS $1.18 >INCY
INCY,2021-11-02,11:01:55,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Backs FY 2021 Guidance,NEWS-FLASH,Dow Jones Newswires,Incyte Backs FY 2021 Guidance >INCY
INCY,2021-11-02,11:32:07,6CC55E,Incyte Corp.,100,0.0,revenues,,Morphosys AG announces Monjuvi(R) Sales,PRESS-RELEASE,DGAP News,"PRESS RELEASE: MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021"
INCY,2021-11-02,11:32:07,6CC55E,Incyte Corp.,100,0.0,revenues,,Morphosys AG announces Monjuvi(R) Sales,PRESS-RELEASE,Dow Jones Newswires,"PRESS RELEASE: MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021"
INCY,2021-11-02,11:33:04,6CC55E,Incyte Corp.,100,0.0,revenues,,Morphosys AG announces Monjuvi(R) Sales,PRESS-RELEASE,Dow Jones Newswires,"PRESS RELEASE: MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021"
INCY,2021-11-02,11:33:04,6CC55E,Incyte Corp.,100,0.0,revenues,,Morphosys AG announces Monjuvi(R) Sales,PRESS-RELEASE,DGAP News,"PRESS RELEASE: MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021"
INCY,2021-11-02,11:57:44,6CC55E,Incyte Corp.,100,0.0,revenues,,Morphosys AG Announces Monjuvi(R) Sales,PRESS-RELEASE,DJ Global Press Release Wire,"MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021"
INCY,2021-11-02,15:15:35,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte-corporation-incy-ceo-herve-hoppenot-on-q3-2021-results-earnings-call,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation CEO Herve Hoppenot on Q3 2021 results -- Earnings Call Transcript >INCY
INCY,2021-11-02,15:15:35,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corporation CEO Herve Hoppenot on Q3 2021 results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation CEO Herve Hoppenot on Q3 2021 results -- Earnings Call Transcript >INCY
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,98,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Business Wire,More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63(rd) Annual ASH Meeting and Exposition
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,98,0.0,products-services,,Incyte Corp.: A Phase 1 Study of INCB057643,PRESS-RELEASE,Business Wire,More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63(rd) Annual ASH Meeting and Exposition
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: inMIND: A Phase 3 Study of Tafasitamab,PRESS-RELEASE,Business Wire,More than 35 Abstracts from Incyte's Oncology -2-
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,More than 35 Abstracts from Incyte's Oncology -2-
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
INCY,2021-11-04,13:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study of INCB057643,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
INCY,2021-11-04,13:44:31,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Market Outperform by JMP Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Market Outperform by JMP Securities
INCY,2021-11-04,13:44:31,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $108.00/Share From $124.00 by JMP Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $108.00/Share From $124.00 by JMP Securities
INCY,2021-11-09,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2021-11-09,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2021-11-19,10:44:46,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte Initiated at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Market Perform by BMO Capital
INCY,2021-11-19,10:44:46,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $75.00/Share by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $75.00/Share by BMO Capital
INCY,2021-11-19,13:50:19,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte started at market perform with $75 stock price target at BMO Capital,NEWS-FLASH,MarketWatch,MW Incyte started at market perform with $75 stock price target at BMO Capital
INCY,2021-12-11,14:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib,PRESS-RELEASE,Business Wire,Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
INCY,2021-12-11,14:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The CITADEL (Clinical Investigation of,PRESS-RELEASE,Business Wire,Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
INCY,2021-12-11,14:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte (Nasdaq:INCY) today announced data from three ongoing Phase 2 studies evaluating parsaclisib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
INCY,2021-12-11,14:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The CITADEL (Clinical Investigation of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
INCY,2021-12-11,17:00:00,6CC55E,Incyte Corp.,96,0.57,products-services,granted,"July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi(R) (tafasitamab-cxix)",PRESS-RELEASE,Business Wire,MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R) ) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-12-11,17:00:00,6CC55E,Incyte Corp.,96,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix),PRESS-RELEASE,Business Wire,MorphoSys and Incyte Announce Additional -2-
INCY,2021-12-11,17:00:28,6CC55E,Incyte Corp.,98,0.57,products-services,granted,"July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi",PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
INCY,2021-12-11,17:00:28,6CC55E,Incyte Corp.,98,0.57,products-services,granted,"July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi",PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
INCY,2021-12-11,17:02:37,6CC55E,Incyte Corp.,96,0.57,products-services,granted,"July 2020, the U.S. Food and Drug Administration (FDA) approved Monjuvi(R) (tafasitamab-cxix)",PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
INCY,2021-12-11,17:02:37,6CC55E,Incyte Corp.,96,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix),PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Additional -2-
INCY,2021-12-14,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Announces Pivotal Phase 2 Results for Parsaclisib,PRESS-RELEASE,PR Newswire,Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3K inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2021-12-14,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,PR Newswire,Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3K inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2021-12-14,00:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Announces Pivotal Phase 2 Results for Parsaclisib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3K inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2021-12-14,00:00:04,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3K inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2021-12-14,00:06:08,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent: Announces Pivotal Phase 2 Results for Parsaclisib,NEWS-FLASH,Dow Jones Newswires,Innovent: Announces Pivotal Phase 2 Results for Parsaclisib Presented at ASH 2021 Show Durable Responses in Patients With Relapsed or Refractory Follicular Lymphoma
INCY,2021-12-14,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2021-12-14,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2021-12-14,21:24:24,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dhanak Surrenders 533 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dhanak Surrenders 533 Of Incyte Corp >INCY
INCY,2021-12-14,21:30:00,6CC55E,Incyte Corp.,97,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(TM)) as a Treatment for Patients with Vitiligo
INCY,2021-12-14,21:30:00,6CC55E,Incyte Corp.,97,0.57,products-services,granted,"Incyte Corp.: In September 2021, Opzelura(TM) (ruxolitinib) cream was approved by the FDA",PRESS-RELEASE,Business Wire,Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(TM)) as a Treatment for Patients with Vitiligo
INCY,2021-12-14,21:30:01,6CC55E,Incyte Corp.,98,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(TM)) as a Treatment for Patients with Vitiligo
INCY,2021-12-14,21:30:01,6CC55E,Incyte Corp.,98,0.57,products-services,granted,"Incyte Corp.: In September 2021, Opzelura(TM) (ruxolitinib) cream was approved by the FDA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(TM)) as a Treatment for Patients with Vitiligo
INCY,2021-12-17,23:32:16,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Buys 1,595,519 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Buys 1,595,519 Of Incyte Corp >INCY"
INCY,2021-12-27,21:13:47,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Dir Dixon Sells 20,000 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Dir Dixon Sells 20,000 Of Incyte Corp >INCY"
INCY,2022-01-04,22:38:26,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Officer Trower Registers 8,214 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"Officer Trower Registers 8,214 Of Incyte Corp >INCY"
INCY,2022-01-05,21:27:40,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Swain Sells 9,319 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Swain Sells 9,319 Of Incyte Corp >INCY"
INCY,2022-01-05,21:42:17,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Trower Sells 8,214 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Officer Trower Sells 8,214 Of Incyte Corp >INCY"
INCY,2022-01-06,21:27:35,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 136 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 136 Of Incyte Corp >INCY
INCY,2022-01-06,21:29:12,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 136 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 136 Of Incyte Corp >INCY
INCY,2022-01-10,18:56:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Swain Registers 10,870 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Swain Registers 10,870 Of Incyte Corp >INCY"
INCY,2022-01-11,21:20:22,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Swain Sells 10,870 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Sells 10,870 Of Incyte Corp >INCY"
INCY,2022-01-18,11:48:14,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Outperform From Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Outperform From Sector Perform by RBC Capital
INCY,2022-01-18,11:48:14,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $90.00/Share From $78.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $90.00/Share From $78.00 by RBC Capital
INCY,2022-01-18,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:09:07,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:09:07,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2021 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:09:07,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-18,13:09:07,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
INCY,2022-01-20,21:19:50,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 202 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 202 Of Incyte Corp >INCY
INCY,2022-01-20,21:22:21,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 202 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 202 Of Incyte Corp >INCY
INCY,2022-01-21,08:48:29,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 4Q 2021 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 4Q 2021 (INCY)"
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong,PRESS-RELEASE,PR Newswire,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Biologics Inc.: Data from previous clinical trials of Pemazyre,PRESS-RELEASE,PR Newswire,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"April 2020, the U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib)",PRESS-RELEASE,PR Newswire,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,PR Newswire,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Innovent Biologics Inc.: Data from previous clinical trials of Pemazyre,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"April 2020, the U.S. Food and Drug Administration (FDA) approved Incyte's Pemazyre(R) (pemigatinib)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-24,07:13:40,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces the Approval of Pemazyre(R) (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
INCY,2022-01-25,21:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte will continue to collaborate with Merus,PRESS-RELEASE,Business Wire,Incyte Provides Update on Parsaclisib and MCLA-145
INCY,2022-01-25,21:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte will continue to collaborate with Merus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Update on Parsaclisib and MCLA-145
INCY,2022-01-25,21:30:56,6CC55E,Incyte Corp.,100,-0.45,products-services,withdrawn,Incyte Withdrawing NDA for Parsaclisib,NEWS-FLASH,Dow Jones Newswires,"Incyte Withdrawing NDA for Parsaclisib in Treatment of Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma and Mantle Cell Lymphoma"
INCY,2022-01-26,21:11:36,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 78 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Dickinson Surrenders 78 Of Incyte Corp >INCY
INCY,2022-01-26,21:13:15,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 78 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 78 Of Incyte Corp >INCY
INCY,2022-02-01,15:50:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Dickinson Registers 7,375 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Dickinson Registers 7,375 Of Incyte Corp >INCY"
INCY,2022-02-02,13:14:35,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2022-02-02,13:14:35,6CC55E,Incyte Corp.,100,-0.26,price-targets,downgrade,Incyte Price Target Cut to $76.00/Share From $77.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $76.00/Share From $77.00 by Morgan Stanley
INCY,2022-02-02,21:26:36,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Dickinson Sells 7,375 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dickinson Sells 7,375 Of Incyte Corp >INCY"
INCY,2022-02-03,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2022-02-03,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2022-02-08,12:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,4Q EPS $2.54 >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q EPS $2.54 >INCY
INCY,2022-02-08,12:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Adj EPS 10c,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Adj EPS 10c >INCY
INCY,2022-02-08,12:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Net $563.9M,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Net $563.9M >INCY
INCY,2022-02-08,12:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Rev $862.9M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Rev $862.9M >INCY
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials of ruxolitinib,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte launched its first dermatology product,PRESS-RELEASE,Business Wire,"Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte presented data from a Phase 1 study,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte will continue to collaborate with Merus,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 862,853 $789,509",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 43,874 $ 36,323",PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -4-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -4-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2021 Fourth Quarter and Year-End -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte launched its first dermatology product,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs"
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte presented data from a Phase 1 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte will continue to collaborate with Merus,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2021 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 862,853 $789,509",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -2-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 43,874 $ 36,323",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -3-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -4-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,98,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -5-
INCY,2022-02-08,12:00:01,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2021 Fourth Quarter -5-
INCY,2022-02-08,12:03:56,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Jakafi Net Product Revenue $592M,NEWS-FLASH,Dow Jones Newswires,"Incyte 4Q Jakafi Net Product Revenue $592M, Up 15% >INCY"
INCY,2022-02-08,12:04:16,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees 2022 Jakafi Revenue $2.3B-$2.4B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2022 Jakafi Revenue $2.3B-$2.4B >INCY
INCY,2022-02-08,12:05:14,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees 2022 Other Hematology/Oncology Net Product Revenue $210M-$240M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2022 Other Hematology/Oncology Net Product Revenue $210M-$240M >INCY
INCY,2022-02-08,12:05:42,6CC55E,Incyte Corp.,100,0.0,equity-actions,,Incyte Sees 2022 Adjusted Research & Development Expenses $1.42B-$1.455B,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2022 Adjusted Research & Development Expenses $1.42B-$1.455B >INCY
INCY,2022-02-08,16:52:36,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte's CEO HervÃ© Hoppenot on Q4 2021 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte's CEO HervÃ© Hoppenot on Q4 2021 Results -- Earnings Call Transcript >INCY
INCY,2022-02-09,11:21:37,6CC55E,Incyte Corp.,100,-0.98,analyst-ratings,negative,Incyte Cut to Underperform From Market Perform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Underperform From Market Perform by SVB Leerink
INCY,2022-02-09,11:21:37,6CC55E,Incyte Corp.,100,-0.66,price-targets,downgrade,Incyte Price Target Cut to $56.00/Share From $60.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $56.00/Share From $60.00 by SVB Leerink
INCY,2022-02-14,23:15:52,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Buys 1,598,374 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Buys 1,598,374 Of Incyte Corp >INCY"
INCY,2022-02-15,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2022-02-15,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2022-02-15,21:25:54,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 1,177 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 1,177 Of Incyte Corp >INCY"
INCY,2022-02-19,01:29:31,6CC55E,Incyte Corp.,94,0.18,acquisitions-mergers,,"Baker Bros. purchased 2,691,041 Incyte shares",FULL-ARTICLE,Dow Jones Newswires,"US Ecology, Incyte See Activist Action -- Barrons.com"
INCY,2022-02-22,22:47:40,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Buys 525,804 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Buys 525,804 Of Incyte Corp >INCY"
INCY,2022-03-10,23:04:29,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Buys 389,080 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Buys 389,080 Of Incyte Corp >INCY"
INCY,2022-03-14,12:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: our sNDA submission for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Vitiligo
INCY,2022-03-14,12:00:03,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte Corp.: our sNDA submission for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Vitiligo
INCY,2022-03-18,13:56:00,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte previously announced positive 24-week results,PRESS-RELEASE,Business Wire,Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
INCY,2022-03-18,13:56:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte previously announced positive 24-week results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
INCY,2022-03-22,20:01:23,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab),PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-22,20:01:23,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,PRESS RELEASE: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-22,20:01:23,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab),PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-22,20:01:23,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,PRESS RELEASE: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-22,20:45:32,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab),PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-22,20:45:32,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DJ Global Press Release Wire,MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R),PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R) ) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Chmp has recommended approval of ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R) ) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Jakafi(R) (ruxolitinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R) ) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R)) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Chmp has recommended approval of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R)) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-25,12:30:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Jakafi(R) (ruxolitinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi(R)) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
INCY,2022-03-26,14:40:00,6CC55E,Incyte Corp.,98,0.0,earnings,,Incyte Corp.: Results at Week 52,PRESS-RELEASE,Business Wire,Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients With Vitiligo
INCY,2022-04-11,15:11:35,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 43,993 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 43,993 Of Incyte Corp >INCY"
INCY,2022-04-12,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2022-04-12,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2022 Conference Call: May 3, 2022 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2022-04-12,12:11:17,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2022-04-12,12:11:17,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2022 Conference Call: May 3, 2022 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2022-04-12,20:11:48,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 43,993 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Sells 43,993 Of Incyte Corp >INCY"
INCY,2022-04-12,20:13:52,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Pasquale Surrenders 517 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Pasquale Surrenders 517 Of Incyte Corp >INCY
INCY,2022-04-18,19:38:50,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 2,000 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 2,000 Of Incyte Corp >INCY"
INCY,2022-04-20,14:46:16,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2022-04-20,14:46:16,6CC55E,Incyte Corp.,100,0.5,price-targets,upgrade,Incyte Price Target Raised to $76.00/Share From $73.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $76.00/Share From $73.00 by Morgan Stanley
INCY,2022-04-21,07:47:39,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 1Q 2022 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 1Q 2022 (INCY)"
INCY,2022-04-21,12:24:16,6CC55E,Incyte Corp.,100,-0.43,labor-issues,,Incyte: Director Wendy Dixon to Retire From Board Effective 2022 Annual,NEWS-FLASH,Dow Jones Newswires,Incyte: Director Wendy Dixon to Retire From Board Effective 2022 Annual Meeting
INCY,2022-04-22,13:40:00,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta(R),PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta(R) ) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
INCY,2022-04-22,13:40:01,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta(R),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta(R)) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
INCY,2022-04-22,13:40:14,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Capmatinib,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Positive CHMP Opinion for Capmatinib for Treatment of METex14 Advanced Non-Small Cell Lung Cancer
INCY,2022-04-28,20:05:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Maruho Announce Strategic Alliance,PRESS-RELEASE,Business Wire,Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
INCY,2022-04-28,20:05:00,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte has successfully launched ruxolitinib cream in the U.S.,PRESS-RELEASE,Business Wire,Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
INCY,2022-04-28,20:05:56,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Maruho Announce Strategic Alliance,NEWS-FLASH,Dow Jones Newswires,Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
INCY,2022-04-28,21:25:43,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Maruho Announce Strategic Alliance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
INCY,2022-04-28,21:25:43,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte has successfully launched ruxolitinib cream in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
INCY,2022-05-03,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,1Q EPS 17c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q EPS 17c >INCY
INCY,2022-05-03,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Adj EPS 55c,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Adj EPS 55c >INCY
INCY,2022-05-03,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Net $38M,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Net $38M >INCY
INCY,2022-05-03,11:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 1Q Rev $733.2M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Rev $733.2M >INCY
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemazyre: The ongoing launches,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Pemazyre was approved in China by the National Medical Products Administration (NMPA),PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Strong U.S. launch of Opzelura,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 733,235 $604,718",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the three months ended March 31, 2022 increased 17% over the prior year",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 42,614 $ 29,220",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2022 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2022 financial guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $ 37,992 $ 53,535",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.17 $ 0.24,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 122,867 $148,756",PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.56 $ 0.68,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2022 First Quarter Financial -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemazyre: The ongoing launches,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Pemazyre was approved in China by the National Medical Products Administration (NMPA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Strong U.S. launch of Opzelura,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenue $ 733,235 $604,718",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the three months ended March 31, 2022 increased 17% over the prior year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 42,614 $ 29,220",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -2-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,unchanged,Incyte Corp.: The Company has reaffirmed its full year 2022 financial guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -3-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $ 37,992 $ 53,535",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.17 $ 0.24,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -4-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,94,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 122,867 $148,756",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,94,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.56 $ 0.68,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,94,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -5-
INCY,2022-05-03,11:00:01,6CC55E,Incyte Corp.,94,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 First Quarter -5-
INCY,2022-05-03,11:01:38,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Backs 2022 Guidance,NEWS-FLASH,Dow Jones Newswires,Incyte Backs 2022 Guidance >INCY
INCY,2022-05-03,15:39:49,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte's CEO HervÃ© Hoppenot on Q1 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte's CEO HervÃ© Hoppenot on Q1 2022 Results -- Earnings Call Transcript >INCY
INCY,2022-05-04,09:23:23,6CC55E,Incyte Corp.,100,-0.34,analyst-ratings,neutral,Incyte Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Underperform by SVB Leerink
INCY,2022-05-04,09:23:23,6CC55E,Incyte Corp.,100,0.48,price-targets,upgrade,Incyte Price Target Raised to $58.00/Share From $56.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $58.00/Share From $56.00 by SVB Leerink
INCY,2022-05-04,12:07:03,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by RBC Capital
INCY,2022-05-04,12:07:03,6CC55E,Incyte Corp.,100,-0.22,price-targets,downgrade,Incyte Price Target Cut to $88.00/Share From $89.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $88.00/Share From $89.00 by RBC Capital
INCY,2022-05-04,20:15:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2022-05-04,20:15:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2022-05-05,05:20:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced the European Commission (EC) has approved Jakavi(R) (ruxolitinib),PRESS-RELEASE,Business Wire,Incyte Announces European Commission Approval of Jakavi(R) (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
INCY,2022-05-05,05:20:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced the European Commission (EC) has approved Jakavi(R) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces European Commission Approval of Jakavi(R) (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
INCY,2022-05-05,05:33:16,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte: Ruxolitinib Gets European Commission Approval,NEWS-FLASH,Dow Jones Newswires,Incyte: Ruxolitinib Gets European Commission Approval as First Post-Steroid Treatment for Acute & Chronic Graft-Versus-Host Disease
INCY,2022-05-05,13:30:10,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2022-05-05,13:30:10,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly And Incyte's OLUMIANT(R) (baricitinib),NEWS-FLASH,Dow Jones Newswires,FDA Approves Lilly And Incyte's OLUMIANT(R) (baricitinib) For The Treatment Of Certain Hospitalized Patients With COVID-19 >LLY
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R) (baricitinib),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -2-
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -2-
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -3-
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R) (baricitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
INCY,2022-05-11,10:45:06,6CC55E,Incyte Corp.,92,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Lilly and Incyte's -2-
INCY,2022-05-11,10:47:38,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Fda Approves Lilly, Incyte's Olumiant",NEWS-FLASH,Dow Jones Newswires,"FDA Approves Lilly, Incyte's Olumiant for Certain Hospitalized Covid-19 Patients"
INCY,2022-05-11,10:57:17,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda approves Eli Lilly and Incyte's Olumiant,NEWS-FLASH,MarketWatch,MW FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
INCY,2022-05-11,11:04:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda approves Eli Lilly and Incyte's Olumiant,FULL-ARTICLE,MarketWatch,MW FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19
INCY,2022-05-11,11:04:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Eli Lilly And Incyte's Olumiant,FULL-ARTICLE,Dow Jones Newswires,FDA Approves Eli Lilly And Incyte's Olumiant For Treatment Of Certain Hospitalized Adults With COVID-19 -- MarketWatch
INCY,2022-05-11,11:13:05,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Fda Approves Lilly, Incyte Drug Olumiant",FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients"
INCY,2022-05-11,11:13:05,6CC55E,Incyte Corp.,100,0.39,products-services,,Eli Lilly signed an exclusive world-wide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients"
INCY,2022-05-11,11:28:05,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Fda Approves Lilly, Incyte Drug Olumiant",FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients"
INCY,2022-05-11,11:28:05,6CC55E,Incyte Corp.,100,0.39,products-services,,Eli Lilly signed an exclusive world-wide license and collaboration agreement with Incyte,FULL-ARTICLE,Dow Jones Newswires,"FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients"
INCY,2022-05-20,12:11:30,6CC55E,Incyte Corp.,93,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,CHMP Recommends Approval of Lilly and Incyte's OLUMIANT(R) (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
INCY,2022-05-20,12:11:30,6CC55E,Incyte Corp.,94,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: CHMP Recommends Approval of Lilly and Incyte's OLUMIANT(R) (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
INCY,2022-05-24,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2022-05-24,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2022-05-26,01:15:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Innocare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab,PRESS-RELEASE,Business Wire,InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,01:15:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte entered into a collaboration and license agreement with InnoCare,PRESS-RELEASE,Business Wire,InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,01:15:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,01:15:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Innocare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,01:15:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte entered into a collaboration and license agreement with InnoCare,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,01:15:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
INCY,2022-05-26,10:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study,PRESS-RELEASE,Business Wire,Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study Evaluating Safety and Efficacy of Parsaclisib,PRESS-RELEASE,Business Wire,Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: inMIND: A Phase 3 Study of Tafasitamab,PRESS-RELEASE,Business Wire,Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study Evaluating Safety and Efficacy of Parsaclisib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: inMIND: A Phase 3 Study of Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-05-26,10:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
INCY,2022-06-13,20:01:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Pfizer Inc.: We are pleased to collaborate with MorphoSys and Incyte,PRESS-RELEASE,Business Wire,"Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,"Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:15,6CC55E,Incyte Corp.,100,0.49,partnerships,,Pfizer Inc.: We are pleased to collaborate with MorphoSys and Incyte,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:15,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:30,6CC55E,Incyte Corp.,100,0.49,partnerships,,Pfizer Inc.: We are pleased to collaborate with MorphoSys and Incyte,PRESS-RELEASE,DGAP News,"PRESS RELEASE: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:30,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,DGAP News,"PRESS RELEASE: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:30,6CC55E,Incyte Corp.,100,0.49,partnerships,,Pfizer Inc.: We are pleased to collaborate with MorphoSys and Incyte,PRESS-RELEASE,Dow Jones Newswires,"PRESS RELEASE: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:01:30,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,"PRESS RELEASE: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-13,20:05:47,6CC55E,Incyte Corp.,100,0.49,partnerships,,Morphosys and Incyte Enter Into Clinical Trial Collaboration,NEWS-FLASH,Dow Jones Newswires,"Pfizer, MorphoSys and Incyte Enter Into Clinical Trial Collaboration for Monjuvi (tafasitamab-Cxix) in Combination With TTI-622, a Fusion Protein Directed Against CD47"
INCY,2022-06-14,01:50:29,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R) (baricitinib),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
INCY,2022-06-14,01:50:29,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -2-
INCY,2022-06-14,01:50:29,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly And Incyte's OLUMIANT(R) (baricitinib),NEWS-FLASH,Dow Jones Newswires,FDA Approves Lilly And Incyte's OLUMIANT(R) (baricitinib) As First And Only Systemic Medicine For Adults With Severe Alopecia Areata >LLY
INCY,2022-06-14,01:50:29,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R),PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -3-
INCY,2022-06-14,01:50:29,6CC55E,Incyte Corp.,100,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,PR Newswire,FDA Approves Lilly and Incyte's OLUMIANT(R) -3-
INCY,2022-06-14,01:50:30,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approves Lilly and Incyte's OLUMIANT(R) (baricitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Lilly and Incyte's OLUMIANT(R) (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
INCY,2022-06-14,01:50:30,6CC55E,Incyte Corp.,99,0.39,products-services,,Lilly and Incyte announced an exclusive worldwide license and collaboration agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: FDA Approves Lilly and Incyte's -3-
INCY,2022-06-30,20:01:39,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 11,488 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 11,488 Of Incyte Corp >INCY"
INCY,2022-07-06,20:07:14,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Dhanak Surrenders 2,181 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dhanak Surrenders 2,181 Of Incyte Corp >INCY"
INCY,2022-07-06,20:08:36,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 3,506 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Surrenders 3,506 Of Incyte Corp >INCY"
INCY,2022-07-06,20:09:18,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 21,174 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Hoppenot Surrenders 21,174 Of Incyte Corp >INCY"
INCY,2022-07-06,20:10:23,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Iyengar Surrenders 2,599 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Surrenders 2,599 Of Incyte Corp >INCY"
INCY,2022-07-06,20:12:00,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Pasquale Surrenders 3,043 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Pasquale Surrenders 3,043 Of Incyte Corp >INCY"
INCY,2022-07-06,20:12:41,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 1,124 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 1,124 Of Incyte Corp >INCY"
INCY,2022-07-06,20:13:01,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 3,856 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 3,856 Of Incyte Corp >INCY"
INCY,2022-07-06,20:13:41,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 2,599 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Surrenders 2,599 Of Incyte Corp >INCY"
INCY,2022-07-06,20:14:36,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Tray Surrenders 987 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,Officer Tray Surrenders 987 Of Incyte Corp >INCY
INCY,2022-07-08,14:33:33,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 2,873 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 2,873 Of Incyte Corp >INCY"
INCY,2022-07-08,14:36:17,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 5,787 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 5,787 Of Incyte Corp >INCY"
INCY,2022-07-11,20:01:11,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 2,873 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 2,873 Of Incyte Corp >INCY"
INCY,2022-07-11,20:01:25,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 5,787 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Sells 5,787 Of Incyte Corp >INCY"
INCY,2022-07-12,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2022-07-12,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2022 Conference Call: August 2, 2022 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2022-07-12,12:08:37,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2022-07-12,12:08:37,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2022 Conference Call: August 2, 2022 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces U.S. FDA Approval Of Opzelura(TM) (ruxolitinib),NEWS-FLASH,Dow Jones Newswires,Incyte Announces U.S. FDA Approval Of Opzelura(TM) (ruxolitinib) Cream For The Treatment Of Vitiligo >INCY
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura(TM) (ruxolitinib),PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 3 data,PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Results at Week 24,PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,01:08:00,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Business Wire,Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,01:13:36,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval Show Treatment With Opzelura,NEWS-FLASH,Dow Jones Newswires,"Incyte: Phase 3 Data Supporting FDA Approval Show Treatment With Opzelura Improved Facial, Total Body Repigmentation >INCY"
INCY,2022-07-19,09:35:54,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura(TM) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,09:35:54,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 3 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,09:35:54,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Investor conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,09:35:54,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Results at Week 24,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,09:35:54,6CC55E,Incyte Corp.,100,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
INCY,2022-07-19,11:14:55,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets Delayed FDA Nod for Vitiligo Treatment,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets Delayed FDA Nod for Vitiligo Treatment -- Market Talk
INCY,2022-07-19,11:14:55,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets Delayed FDA Nod for Vitiligo Treatment,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets Delayed FDA Nod for Vitiligo Treatment -- Market Talk
INCY,2022-07-19,12:33:31,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte gets FDA approval for a new vitiligo treatment,FULL-ARTICLE,MarketWatch,MW Incyte gets FDA approval for a new vitiligo treatment
INCY,2022-07-19,12:33:31,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. (INCY) said Monday that the Food and Drug Administration approved Opzelura,FULL-ARTICLE,MarketWatch,MW Incyte gets FDA approval for a new vitiligo treatment
INCY,2022-07-19,12:33:31,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval For A New Vitiligo Treatment,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval For A New Vitiligo Treatment -- MarketWatch
INCY,2022-07-19,12:33:31,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. (INCY) said Monday that the Food and Drug Administration approved Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval For A New Vitiligo Treatment -- MarketWatch
INCY,2022-07-20,08:42:03,6CC55E,Incyte Corp.,100,-0.34,analyst-ratings,neutral,Incyte Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Underperform by SVB Leerink
INCY,2022-07-20,08:42:03,6CC55E,Incyte Corp.,100,0.72,price-targets,upgrade,Incyte Price Target Raised to $63.00/Share From $58.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $63.00/Share From $58.00 by SVB Leerink
INCY,2022-07-21,07:54:43,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 2Q 2022 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 2Q 2022 (INCY)"
INCY,2022-07-26,20:01:12,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,564 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Officer Tray Sells 1,564 Of Incyte Corp >INCY"
INCY,2022-07-28,11:31:25,6CC55E,Incyte Corp.,100,0.01,analyst-ratings,neutral,Incyte Initiated at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Equal-Weight by Wells Fargo
INCY,2022-07-28,11:31:25,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $76.00/Share by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $76.00/Share by Wells Fargo
INCY,2022-08-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,2Q EPS 72c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q EPS 72c >INCY
INCY,2022-08-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Adj EPS $1.01,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Adj EPS $1.01 >INCY
INCY,2022-08-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Net $161.4M,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Net $161.4M >INCY
INCY,2022-08-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 2Q Rev $911.4M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Rev $911.4M >INCY
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.46,revenues,up,Incyte Corp.: Total revenues increased 29% year-over-year,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: total product revenues of $664 million,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte intends to initiate a Phase 3 study in,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launch of Opzelura,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Opzelura was also approved by the FDA,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 911,397 $705,709",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the quarter ended June 30, 2022 increased 13% over the prior year",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 50,636 $ 38,028",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2022,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 226,353 $ 178,833 $",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.73 $ 0.68 $,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,319,035 $ 4,933,352",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Non-GAAP net income per share,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -5-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Second Quarter Financial -5-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.46,revenues,up,Incyte Corp.: Total revenues increased 29% year-over-year,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: total product revenues of $664 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte intends to initiate a Phase 3 study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launch of Opzelura,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Opzelura was also approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 911,397 $705,709",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the quarter ended June 30, 2022 increased 13% over the prior year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 50,636 $ 38,028",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -2-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -3-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2022,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 226,353 $ 178,833 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.73 $ 0.68 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,319,035 $ 4,933,352",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Non-GAAP net income per share,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -4-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,94,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -5-
INCY,2022-08-02,11:00:02,6CC55E,Incyte Corp.,94,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Second Quarter -5-
INCY,2022-08-02,11:07:31,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees 2022 Jakafi Net Product Revenue $2.36B-$2.4B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2022 Jakafi Net Product Revenue $2.36B-$2.4B >INCY
INCY,2022-08-02,15:53:24,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2022 Results -- Earnings Call Transcript,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2022 Results -- Earnings Call Transcript >INCY
INCY,2022-08-02,15:53:24,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte-corporations-incy-ceo-herve-hoppenot-on-q2-2022-results-earnings,NEWS-FLASH,Dow Jones Newswires,Incyte Corporation's CEO HervÃ© Hoppenot on Q2 2022 Results -- Earnings Call Transcript >INCY
INCY,2022-08-03,10:23:40,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte downgraded to in line from outperform at Evercore ISI,NEWS-FLASH,MarketWatch,MW Incyte downgraded to in line from outperform at Evercore ISI
INCY,2022-08-03,11:23:02,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Neutral From Buy by Guggenheim
INCY,2022-08-03,13:59:23,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2022-08-03,13:59:23,6CC55E,Incyte Corp.,100,-0.26,price-targets,downgrade,Incyte Price Target Cut to $76.00/Share From $77.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $76.00/Share From $77.00 by Morgan Stanley
INCY,2022-08-03,19:30:44,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to In-Line From Outperform by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to In-Line From Outperform by Evercore ISI Group
INCY,2022-08-03,19:30:44,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $78.00/Share From $90.00 by Evercore ISI Group,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $78.00/Share From $90.00 by Evercore ISI Group
INCY,2022-08-23,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2022-08-23,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2022-08-24,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Business Wire,Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Business Wire,Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Inhibitor ruxolitinib approved by the U.S. Food & Drug Administration,PRESS-RELEASE,Business Wire,Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Business Wire,Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:10,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:10,6CC55E,Incyte Corp.,99,0.52,products-services,,"Incyte Corp.: Opzelura, a novel cream formulation",PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:10,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Inhibitor ruxolitinib approved by the U.S. Food & Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-24,12:00:10,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2022-08-26,14:00:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval Of Pemazyre(R) (pemigatinib),NEWS-FLASH,Dow Jones Newswires,Incyte Announces FDA Approval Of Pemazyre(R) (pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement >INCY
INCY,2022-08-26,14:00:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:00,6CC55E,Incyte Corp.,100,0.71,products-services,,"Pemazyre, which received accelerated FDA approval",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:00,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Clinical trials of PEMAZYRE,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre(R) (pemigatinib),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.71,products-services,,"Pemazyre, which received accelerated FDA approval",PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.65,products-services,,Incyte Corp.: The FDA grants Priority Review,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Clinical trials of PEMAZYRE,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval of Pemazyre(R),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) -2-
INCY,2022-08-26,14:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval of Pemazyre(R),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Pemazyre(R) -3-
INCY,2022-08-26,14:26:37,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment
INCY,2022-08-26,14:26:37,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. said Friday that the U.S. Food and Drug Administration has approved its treatment Pemazyre,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment
INCY,2022-08-26,14:41:37,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment
INCY,2022-08-26,14:41:37,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. said Friday that the U.S. Food and Drug Administration has approved its treatment Pemazyre,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte entered into a collaboration and license agreement with InnoCare,PRESS-RELEASE,Business Wire,InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Innocare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-09-08,23:39:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte entered into a collaboration and license agreement with InnoCare,PRESS-RELEASE,Dow Jones Newswires,Press Release: InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
INCY,2022-10-03,10:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,"Incyte Corp.: the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded",PRESS-RELEASE,Business Wire,"Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R<BETA> Monoclonal Antibody"
INCY,2022-10-03,10:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: our successful launch of Opzelura(TM) (ruxolitinib),PRESS-RELEASE,Business Wire,"Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R<BETA> Monoclonal Antibody"
INCY,2022-10-03,10:03:17,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,"Incyte Corp.: the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R<BETA> Monoclonal Antibody"
INCY,2022-10-03,10:03:17,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: our successful launch of Opzelura(TM) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R<BETA> Monoclonal Antibody"
INCY,2022-10-03,10:18:03,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,"Incyte Corp. on Monday said it agreed to buy Villaris Therapeutics, a biopharmaceutical company working to develop",FULL-ARTICLE,Dow Jones Newswires,Incyte Adds to Vitiligo Arsenal With Deal to Buy Villaris Therapeutics >INCY
INCY,2022-10-04,11:33:52,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Corp. Names Susanne Schaffert to Board,RNS-SEC8K,Dow Jones Newswires,Incyte Corp. Names Susanne Schaffert to Board >INCY
INCY,2022-10-04,12:00:01,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Board of Directors,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Names New Member to Its Board of Directors
INCY,2022-10-04,12:00:02,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Board of Directors,PRESS-RELEASE,Business Wire,Incyte Names New Member to Its Board of Directors
INCY,2022-10-04,12:00:04,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names New Member to Its Bd of Directors,NEWS-FLASH,Dow Jones Newswires,Incyte Names New Member to Its Bd of Directors
INCY,2022-10-04,12:00:17,6CC55E,Incyte Corp.,100,0.47,labor-issues,,Incyte Names Susanne Schaffert to the Board,NEWS-FLASH,Dow Jones Newswires,Incyte Names Susanne Schaffert to the Board >INCY
INCY,2022-10-06,22:12:54,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
INCY,2022-10-06,22:12:54,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Knight Therapeutics Inc.: our partner, Incyte, as we work towards regulatory submissions in additional countries in Latin America",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
INCY,2022-10-06,22:31:57,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
INCY,2022-10-06,22:31:57,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Knight Therapeutics Inc.: our partner, Incyte, as we work towards regulatory submissions in additional countries in Latin America",PRESS-RELEASE,Dow Jones Newswires,Press Release: Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
INCY,2022-10-11,12:00:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2022-10-11,12:00:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2022 Conference Call: November 1, 2022 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2022-10-18,11:55:01,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2022-10-18,11:55:01,6CC55E,Incyte Corp.,100,-0.26,price-targets,downgrade,Incyte Price Target Cut to $75.00/Share From $76.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $75.00/Share From $76.00 by Wells Fargo
INCY,2022-10-21,08:07:44,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 3Q 2022 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 3Q 2022 (INCY)"
INCY,2022-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,3Q EPS 50c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q EPS 50c >INCY
INCY,2022-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Adj EPS 60c,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Adj EPS 60c >INCY
INCY,2022-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Net $112.8M,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Net $112.8M >INCY
INCY,2022-11-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 3Q Rev $823.3M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Rev $823.3M >INCY
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.65,revenues,up,Incyte Corp.: Total net product revenues grew,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Our total net product revenues grew 20%,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemigatinib (Pemazyre(R) ): In August,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Pemazyre was approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,"Incyte announced an agreement to acquire Villaris Therapeutics, an asset",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 823,303 $ 812,987",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the quarter ended September 30, 2022 increased 13% over the prior year",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 54,584 $ 39,869",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP (gain) loss,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -2-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -3-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -4-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -4-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Net income $112,775 $181,739",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -4-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.51 $ 0.82 $,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -4-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,0.0,assets,,"Incyte Corp.: Total assets $ 5,510,214 $ 4,933,352",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $112,775 $181,739",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $133,795 $261,824",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.60 $ 1.19 $,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:00:03,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Third Quarter Financial -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.65,revenues,up,Incyte Corp.: Total net product revenues grew,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Our total net product revenues grew 20%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 2) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Pemigatinib (Pemazyre(R) ): In August,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Pemazyre was approved by the U.S. Food and Drug Administration (FDA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,100,0.55,acquisitions-mergers,,"Incyte announced an agreement to acquire Villaris Therapeutics, an asset",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 823,303 $ 812,987",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the quarter ended September 30, 2022 increased 13% over the prior year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 54,584 $ 39,869",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP (gain) loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -2-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP collaboration loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative expenses",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -3-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -4-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -4-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Net income $112,775 $181,739",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -4-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.51 $ 0.82 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -4-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,0.0,assets,,"Incyte Corp.: Total assets $ 5,510,214 $ 4,933,352",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $112,775 $181,739",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $133,795 $261,824",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.60 $ 1.19 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,-0.68,revenues,down,Incyte Corp.: 1) Included within the Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:02:00,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Third Quarter -5-
INCY,2022-11-01,11:04:45,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Now Sees 2022 Jakafi Product Rev,NEWS-FLASH,Dow Jones Newswires,Incyte Now Sees 2022 Jakafi Product Rev $2.38B-$2.4B >INCY
INCY,2022-11-02,12:15:41,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2022-11-02,12:15:41,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley
INCY,2022-11-02,12:46:11,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by RBC Capital
INCY,2022-11-02,12:46:11,6CC55E,Incyte Corp.,100,0.64,price-targets,upgrade,Incyte Price Target Raised to $82.00/Share From $77.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $82.00/Share From $77.00 by RBC Capital
INCY,2022-11-03,14:24:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 study of,PRESS-RELEASE,Business Wire,More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64(th) ASH Annual Meeting
INCY,2022-11-03,14:24:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Ruxolitinib,PRESS-RELEASE,Business Wire,More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64(th) ASH Annual Meeting
INCY,2022-11-03,14:24:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Randomized Study to Assess Safety of Tafasitamab,PRESS-RELEASE,Business Wire,More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64(th) ASH Annual Meeting
INCY,2022-11-03,14:24:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,More than 50 Abstracts from Incyte's Robust -2-
INCY,2022-11-03,14:24:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,More than 50 Abstracts from Incyte's Robust -2-
INCY,2022-11-03,14:24:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
INCY,2022-11-03,14:24:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
INCY,2022-11-03,14:24:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Randomized Study to Assess Safety of Tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
INCY,2022-11-07,13:15:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration,PRESS-RELEASE,Business Wire,Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRAS(G12C) -Mutated Solid Tumors
INCY,2022-11-07,13:15:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients,PRESS-RELEASE,Business Wire,Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRAS(G12C) -Mutated Solid Tumors
INCY,2022-11-07,13:15:00,6CC55E,Incyte Corp.,100,0.34,products-services,,Mirati will supply Incyte with,PRESS-RELEASE,Business Wire,Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRAS(G12C) -Mutated Solid Tumors
INCY,2022-11-07,13:15:25,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Mirati Therapeutics Enter Into Clinical Trial Collaboration,NEWS-FLASH,Dow Jones Newswires,Incyte and Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients With KRASG12C-Mutated Solid Tumors
INCY,2022-11-07,13:18:31,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
INCY,2022-11-07,13:18:31,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
INCY,2022-11-07,13:18:31,6CC55E,Incyte Corp.,100,0.34,products-services,,Mirati will supply Incyte with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
INCY,2022-11-17,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2022-11-17,13:00:10,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2022-12-02,13:30:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and CMS Announce Collaboration,PRESS-RELEASE,Business Wire,Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
INCY,2022-12-02,13:30:00,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: we have successfully launched ruxolitinib cream (Opzelura(TM)) in atopic dermatitis and vitiligo in the United States,PRESS-RELEASE,Business Wire,Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
INCY,2022-12-02,13:30:20,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and CMS Announce Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
INCY,2022-12-02,13:30:20,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: we have successfully launched ruxolitinib cream (Opzelura(TM)) in atopic dermatitis and vitiligo in the United States,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
INCY,2022-12-02,13:30:23,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and CMS Announce Collaboration,NEWS-FLASH,Dow Jones Newswires,Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
INCY,2022-12-05,12:00:06,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq: INCY) today announced that results from the Phase 1/2 trial of axatilimab,PRESS-RELEASE,PR Newswire,Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
INCY,2022-12-05,12:00:06,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,PR Newswire,Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
INCY,2022-12-05,12:00:32,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte (Nasdaq: INCY) today announced that results from the Phase 1/2 trial of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
INCY,2022-12-05,12:00:32,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
INCY,2022-12-06,11:14:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Hk) Joins Hand with Incyte on,PRESS-RELEASE,GlobeNewswire,"CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: This approval was mainly supported by the positive results of two pivotal Phase 3 clinical studies,PRESS-RELEASE,GlobeNewswire,"CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Hk) Joins Hand with Incyte on,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: This approval was mainly supported by the positive results of two pivotal Phase 3 clinical studies,PRESS-RELEASE,Hugin GlobeNewswire,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Hk) Joins Hand with Incyte on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: This approval was mainly supported by the positive results of two pivotal Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,Hk) Joins Hand with Incyte on,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-06,11:14:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: This approval was mainly supported by the positive results of two pivotal Phase 3 clinical studies,PRESS-RELEASE,Dow Jones Newswires,"Press Release: CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient"
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 2 data,PRESS-RELEASE,Business Wire,Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and tolerability of INCB00928,PRESS-RELEASE,Business Wire,Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 Study of,PRESS-RELEASE,Business Wire,Incyte Announces Data from Two LIMBER Studies -2-
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 2 data,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Phase 1/2 study evaluating the safety and tolerability of INCB00928,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
INCY,2022-12-10,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Two -2-
INCY,2022-12-11,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: INCA033989 clinical trials,PRESS-RELEASE,Business Wire,Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
INCY,2022-12-11,20:00:00,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
INCY,2022-12-11,20:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: INCA033989 clinical trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
INCY,2022-12-13,21:01:48,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dhanak Surrenders 533 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dhanak Surrenders 533 Of Incyte Corp >INCY
INCY,2022-12-15,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2022-12-15,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2022-12-21,21:02:14,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,223 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Sells 1,223 Of Incyte Corp >INCY"
INCY,2022-12-27,16:03:36,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 17,324 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 17,324 Of Incyte Corp >INCY"
INCY,2022-12-28,21:02:55,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 17,324 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Sells 17,324 Of Incyte Corp >INCY"
INCY,2023-01-03,14:16:16,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2023-01-03,14:16:16,6CC55E,Incyte Corp.,100,0.5,price-targets,upgrade,Incyte Price Target Raised to $75.00/Share From $72.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $75.00/Share From $72.00 by Wells Fargo
INCY,2023-01-05,20:51:59,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 28,399 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 28,399 Of Incyte Corp >INCY"
INCY,2023-01-06,04:34:17,6CC55E,Incyte Corp.,100,0.65,products-services,,China NMPA Grants Priority Review Designation to New Drug Application for Parsaclisib,NEWS-FLASH,Dow Jones Newswires,Innovent: China NMPA Grants Priority Review Designation to New Drug Application for Parsaclisib to Treat Relapsed or Refractory Follicular Lymphoma
INCY,2023-01-06,21:01:23,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 117 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 117 Of Incyte Corp >INCY
INCY,2023-01-06,21:01:48,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 28,399 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Sells 28,399 Of Incyte Corp >INCY"
INCY,2023-01-06,21:02:06,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 117 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 117 Of Incyte Corp >INCY
INCY,2023-01-17,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:08:25,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:08:25,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2022 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:08:25,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-17,13:08:25,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
INCY,2023-01-18,21:02:08,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 174 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Morrissey Surrenders 174 Of Incyte Corp >INCY
INCY,2023-01-18,21:02:33,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 174 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 174 Of Incyte Corp >INCY
INCY,2023-01-21,08:44:31,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 4Q 2022 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 4Q 2022 (INCY)"
INCY,2023-01-23,21:01:16,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 105 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Morrissey Surrenders 105 Of Incyte Corp >INCY
INCY,2023-01-23,21:01:28,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Dickinson Surrenders 105 Of Incyte Corp >INCY,FULL-ARTICLE,Dow Jones Newswires,VP Dickinson Surrenders 105 Of Incyte Corp >INCY
INCY,2023-01-24,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2023-01-24,13:00:10,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2023-01-30,14:51:37,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 7,000 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 7,000 Of Incyte Corp >INCY"
INCY,2023-01-30,14:57:59,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Dhanak Registers 2,419 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Dhanak Registers 2,419 Of Incyte Corp >INCY"
INCY,2023-01-30,21:01:55,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 7,000 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Sells 7,000 Of Incyte Corp >INCY"
INCY,2023-01-30,21:02:23,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Dhanak Sells 2,419 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Dhanak Sells 2,419 Of Incyte Corp >INCY"
INCY,2023-01-31,09:53:17,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Overweight by Piper Sandler
INCY,2023-01-31,09:53:17,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $100.00/Share by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $100.00/Share by Piper Sandler
INCY,2023-01-31,19:40:00,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Pasquale Registers 60,024 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Pasquale Registers 60,024 Of Incyte Corp >INCY"
INCY,2023-02-01,21:01:58,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Pasquale Sells 60,024 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Pasquale Sells 60,024 Of Incyte Corp >INCY"
INCY,2023-02-01,23:06:37,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Pasquale Registers 802 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Pasquale Registers 802 Of Incyte Corp >INCY
INCY,2023-02-02,21:01:24,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Pasquale Sells 802 Of Incyte Corp,FULL-ARTICLE,Dow Jones Newswires,VP Pasquale Sells 802 Of Incyte Corp >INCY
INCY,2023-02-07,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,4Q EPS 13c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q EPS 13c >INCY
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Total FY'22 net product revenues grew 18% to $2.75 billion,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte announced that results from the Phase 1/2 trial of axatilimab,PRESS-RELEASE,Business Wire,"Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: Additionally, two Phase 2 trials",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $926,700 $ 862,853",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -2-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $926,700 $862,853",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the year ended December 31, 2022 increased 13% over the prior year",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: GAAP cost of product revenues $ 59,163 $ 43,874",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -3-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -4-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -4-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Adj EPS 62c,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Adj EPS 62c >INCY
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $139,661 $ 22,565",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.13 $ 2.55 $,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.0,assets,,"Incyte Corp.: Total assets $ 5,840,984 $ 4,933,352",PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.63 $ 0.10 $,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2022 Fourth Quarter and Year-end -5-
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Net $28.5M,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Net $28.5M >INCY
INCY,2023-02-07,12:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Rev $926.7M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Rev $926.7M >INCY
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Total FY'22 net product revenues grew 18% to $2.75 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Parsaclisib + ruxolitinib in myelofibrosis (MF): Final results from the Phase 2 trial,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte announced that results from the Phase 1/2 trial of axatilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs"
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 2 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2022 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $926,700 $ 862,853",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -2-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $926,700 $862,853",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.41,revenues,up,"Incyte Corp.: Jakafi net product revenues for the year ended December 31, 2022 increased 13% over the prior year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -3-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -4-
INCY,2023-02-07,12:01:20,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2022 Fourth Quarter -4-
INCY,2023-02-07,12:01:43,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees 2023 Jakafi Net Product Revenue $2.53B-$2.63B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2023 Jakafi Net Product Revenue $2.53B-$2.63B >INCY
INCY,2023-02-07,12:02:13,6CC55E,Incyte Corp.,100,0.0,equity-actions,,Incyte Sees 2023 Adjusted Research-and-Development Expenses $1.485B-$1.52B,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2023 Adjusted Research-and-Development Expenses $1.485B-$1.52B >INCY
INCY,2023-02-07,15:50:44,6CC55E,Incyte Corp.,99,0.9,earnings,up,Incyte earnings rocketed 520% to 62 cents,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,15:50:44,6CC55E,Incyte Corp.,99,0.41,revenues,up,Revenue from Incyte's Jakafi climbed 9%,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,15:50:44,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: The company also calls for $215 million to $225 million in sales,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,17:53:55,6CC55E,Incyte Corp.,93,0.57,products-services,granted,Incyte Corp.: The company anticipates receiving approval for Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Sees Skin Treatment Opzelura as Growth Driver in 2023 -- Market Talk
INCY,2023-02-07,17:53:56,6CC55E,Incyte Corp.,93,0.57,products-services,granted,Incyte Corp.: The company anticipates receiving approval for Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Sees Skin Treatment Opzelura as Growth Driver in 2023 -- Market Talk
INCY,2023-02-07,18:04:39,6CC55E,Incyte Corp.,99,0.9,earnings,up,Incyte earnings rocketed 520% to 62 cents,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,18:04:39,6CC55E,Incyte Corp.,99,0.41,revenues,up,Revenue from Incyte's Jakafi climbed 9%,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,18:04:39,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: The company also calls for $215 million to $225 million in sales,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,21:06:16,6CC55E,Incyte Corp.,99,0.9,earnings,up,Incyte earnings rocketed 520% to 62 cents,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,21:06:16,6CC55E,Incyte Corp.,99,0.41,revenues,up,Revenue from Incyte's Jakafi climbed 9%,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-07,21:06:16,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: The company also calls for $215 million to $225 million in sales,FULL-ARTICLE,Dow Jones Newswires,"Top-Notch Medical Stocks Incyte, Haemonetics Beat -- And Shares Crumbled -- IBD"
INCY,2023-02-08,13:23:17,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by Mizuho
INCY,2023-02-08,13:44:07,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2023-02-08,13:44:07,6CC55E,Incyte Corp.,100,-0.4,price-targets,downgrade,Incyte Price Target Cut to $80.00/Share From $82.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $80.00/Share From $82.00 by JP Morgan
INCY,2023-02-08,14:32:07,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Overweight by Piper Sandler,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Overweight by Piper Sandler
INCY,2023-02-08,15:19:07,6CC55E,Incyte Corp.,100,0.2,analyst-ratings,neutral,Incyte Is Maintained at Outperform by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by Cowen & Co.
INCY,2023-02-08,15:19:07,6CC55E,Incyte Corp.,100,0.6,price-targets,upgrade,Incyte Price Target Raised to $100.00/Share From $95.00 by Cowen & Co.,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $100.00/Share From $95.00 by Cowen & Co.
INCY,2023-02-10,13:20:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces 52-Week Results from Phase 2 Study,PRESS-RELEASE,Business Wire,Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
INCY,2023-02-10,13:20:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: New results at Week 52,PRESS-RELEASE,Business Wire,Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
INCY,2023-02-10,13:20:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces 52-Week Results from Phase 2,PRESS-RELEASE,Business Wire,Incyte Announces 52-Week Results from Phase 2 -2-
INCY,2023-02-10,13:20:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces 52-Week Results from Phase 2 Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
INCY,2023-02-10,13:20:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: New results at Week 52,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
INCY,2023-02-10,13:20:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announces 52-Week Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces 52-Week Results -2-
INCY,2023-02-15,21:02:27,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 1,179 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 1,179 Of Incyte Corp >INCY"
INCY,2023-02-16,12:55:30,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Credit Suisse
INCY,2023-02-16,12:55:30,6CC55E,Incyte Corp.,100,0.6,price-targets,upgrade,Incyte Price Target Raised to $100.00/Share From $95.00 by Credit Suisse,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $100.00/Share From $95.00 by Credit Suisse
INCY,2023-02-16,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2023-02-16,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2023-02-21,21:03:22,6CC55E,Incyte Corp.,100,0.52,insider-trading,,"Vp Dhanak Acquires 3,693 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Dhanak Acquires 3,693 Of Incyte Corp >INCY"
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The CHMP opinion recommending the approval of ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Business Wire,Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.82,products-services,positive,Incyte Announces Positive CHMP Opinion for Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The CHMP opinion recommending the approval of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:07:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
INCY,2023-02-24,12:37:42,6CC55E,Incyte Corp.,95,0.57,products-services,granted,"Incyte's blockbuster cancer drug Jakafi, won U.S. Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Incyte Gets CHMP Backing for Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-02-24,12:37:42,6CC55E,Incyte Corp.,95,0.0,revenues,,Incyte reported Opzelua revenue of $129 million in 2022,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets CHMP Backing for Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-03-03,21:35:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Provides Update on Interim Analysis,PRESS-RELEASE,Business Wire,Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
INCY,2023-03-03,21:35:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Provides Update on Interim Analysis,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
INCY,2023-03-03,21:43:23,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte: Provides Update on Interim Analysis,NEWS-FLASH,Dow Jones Newswires,Incyte: Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients With Myelofibrosis
INCY,2023-03-04,00:00:59,6CC55E,Incyte Corp.,100,0.0,stock-picks,,"Stocks to Watch: Incyte, Sallie Mae",FULL-ARTICLE,Dow Jones Newswires,"Stocks to Watch: Incyte, Sallie Mae"
INCY,2023-03-06,17:23:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference call details,PRESS-RELEASE,Business Wire,Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:23:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:23:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Business Wire,Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:23:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Business Wire,Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:49:12,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference call details,PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:49:12,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:49:12,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-06,17:49:12,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Multiple Abstracts from Incyte's Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
INCY,2023-03-07,11:30:08,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: Our partnership with Caris,PRESS-RELEASE,PR Newswire,Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
INCY,2023-03-07,11:30:18,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte Corp.: Our partnership with Caris,PRESS-RELEASE,Dow Jones Newswires,Press Release: Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Session: Novel Clinical Trials,PRESS-RELEASE,Business Wire,Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study of Ruxolitinib in Combination with Abemaciclib,PRESS-RELEASE,Business Wire,Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study of Ruxolitinib in Combination with Abemaciclib,PRESS-RELEASE,Business Wire,Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Session: Novel Clinical Trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study of Ruxolitinib in Combination with Abemaciclib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study of Ruxolitinib in Combination with Abemaciclib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-14,22:30:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
INCY,2023-03-15,20:07:32,6CC55E,Incyte Corp.,100,0.37,equity-actions,increase,"Holder Baker Bros Advisors LP Acquires 40,000 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"Holder Baker Bros Advisors LP Acquires 40,000 Of Incyte Corp >INCY"
INCY,2023-03-18,14:40:00,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Long-Term Extension Data from Phase 3,PRESS-RELEASE,Business Wire,Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-18,14:40:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-18,14:40:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Business Wire,Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-18,19:40:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707),PRESS-RELEASE,Business Wire,Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-03-18,19:40:00,6CC55E,Incyte Corp.,100,0.4,products-services,start,Incyte Corp.: The study enrolled 171 patients,PRESS-RELEASE,Business Wire,Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-03-18,19:40:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Data from Phase 2b Study,PRESS-RELEASE,Business Wire,Incyte Announces Data from Phase 2b Study -2-
INCY,2023-03-20,09:32:11,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Long-Term Extension Data from Phase 3,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-20,09:32:11,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-20,09:32:11,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura(R) (Ruxolitinib) Cream in Vitiligo
INCY,2023-03-20,11:35:42,6CC55E,Incyte Corp.,100,-0.34,analyst-ratings,neutral,Incyte Is Maintained at Underperform by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Underperform by SVB Leerink
INCY,2023-03-20,11:35:42,6CC55E,Incyte Corp.,100,-0.56,price-targets,downgrade,Incyte Price Target Cut to $60.00/Share From $63.00 by SVB Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $60.00/Share From $63.00 by SVB Leerink
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval Of Zynyz(TM) (retifanlimab,NEWS-FLASH,Dow Jones Newswires,Incyte Announces FDA Approval Of Zynyz(TM) (retifanlimab-dlwr) For The Treatment Of Metastatic Or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC) >INCY
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved Zynyz(TM) (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death",PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Regulatory approval for Incyte PD-1 inhibitor,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"The U.S. Food and Drug Administration (FDA) has approved Zynyz(TM) (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Regulatory approval for Incyte PD-1 inhibitor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:14:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
INCY,2023-03-22,17:22:17,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr,PRESS-RELEASE,GlobeNewswire,MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr)
INCY,2023-03-22,17:22:17,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr)
INCY,2023-03-22,17:22:17,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr,PRESS-RELEASE,DJ Global Press Release Wire,MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr)
INCY,2023-03-22,17:22:17,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr,FULL-ARTICLE,Dow Jones Newswires,MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr)
INCY,2023-03-22,17:22:18,6CC55E,Incyte Corp.,100,0.57,products-services,granted,U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr,PRESS-RELEASE,Dow Jones Newswires,Press Release: MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ(TM) (retifanlimab-dlwr)
INCY,2023-03-24,10:09:04,6CC55E,Incyte Corp.,96,0.0,revenues,,"Incyte, which reported Jakafi revenue",FULL-ARTICLE,Dow Jones Newswires,FDA Rejects Incyte's Bid for Once-Daily Jakafi Approval >INCY
INCY,2023-03-24,10:24:04,6CC55E,Incyte Corp.,95,0.0,revenues,,"Incyte, which reported Jakafi revenue",FULL-ARTICLE,Dow Jones Newswires,FDA Rejects Incyte's Bid for Once-Daily Jakafi Approval
INCY,2023-03-24,13:17:32,6CC55E,Incyte Corp.,99,0.57,products-services,granted,The FDA approved Incyte's drug,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Dives On Surprise Rejection For Updated Jakafi -- IBD
INCY,2023-03-24,16:53:10,6CC55E,Incyte Corp.,99,0.65,revenues,up,Help Incyte extend Jakafi sales,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker -- IBD
INCY,2023-03-24,16:53:10,6CC55E,Incyte Corp.,99,0.57,products-services,granted,The FDA approved Incyte's drug,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker -- IBD
INCY,2023-03-24,20:03:13,6CC55E,Incyte Corp.,99,0.65,revenues,up,Help Incyte extend Jakafi sales,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker -- IBD
INCY,2023-03-24,20:03:13,6CC55E,Incyte Corp.,99,0.57,products-services,granted,The FDA approved Incyte's drug,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker -- IBD
INCY,2023-03-27,06:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre(R) (pemigatinib)",PRESS-RELEASE,Business Wire,Incyte Announces Japanese Approval of Pemazyre(R) (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
INCY,2023-03-27,06:00:01,6CC55E,Incyte Corp.,100,0.63,products-services,,"Incyte Corp.: Previously, the MHLW granted Orphan Drug Designation (ODD) for",PRESS-RELEASE,Business Wire,Incyte Announces Japanese Approval of Pemazyre(R) (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
INCY,2023-03-27,06:00:10,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre(R) (pemigatinib)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Japanese Approval of Pemazyre(R) (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
INCY,2023-03-27,06:00:10,6CC55E,Incyte Corp.,100,0.63,products-services,,"Incyte Corp.: Previously, the MHLW granted Orphan Drug Designation (ODD) for",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Japanese Approval of Pemazyre(R) (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
INCY,2023-03-27,06:16:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte: Pemazyre (pemigatinib) Received Japan Approval for Treatment,NEWS-FLASH,Dow Jones Newswires,Incyte: Pemazyre (pemigatinib) Received Japan Approval for Treatment of Myeloid/Lymphoid Neoplasms
INCY,2023-04-05,11:00:06,6CC55E,Incyte Corp.,100,0.49,partnerships,,Biotheryx Announces Research Collaboration and License Agreement with Incyte,PRESS-RELEASE,PR Newswire,Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
INCY,2023-04-10,10:18:29,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Sector Perform From Outperform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Sector Perform From Outperform by RBC Capital
INCY,2023-04-10,10:18:29,6CC55E,Incyte Corp.,100,-0.42,price-targets,downgrade,Incyte Price Target Cut to $79.00/Share From $81.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $79.00/Share From $81.00 by RBC Capital
INCY,2023-04-11,12:00:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2023-04-11,12:00:00,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2023 Conference Call: May 2, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2023-04-11,12:09:43,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2023-04-11,12:09:43,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2023 Conference Call: May 2, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2023-04-12,15:11:01,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2023-04-12,15:11:01,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $77.00/Share From $76.00 by Morgan Stanley
INCY,2023-04-16,19:01:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Five-Year Results,PRESS-RELEASE,Business Wire,"MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-16,19:01:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Business Wire,"MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-16,19:01:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Business Wire,"MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-16,19:01:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Five-Year Results,PRESS-RELEASE,Business Wire,MorphoSys and Incyte Announce Five-Year Results -2-
INCY,2023-04-16,19:01:25,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Five-Year Results,PRESS-RELEASE,DGAP News,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-16,19:01:25,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,DGAP News,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-16,19:01:25,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,DGAP News,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-16,19:01:26,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Five-Year Results,PRESS-RELEASE,Dow Jones Newswires,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-16,19:01:26,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Dow Jones Newswires,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-16,19:01:26,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Dow Jones Newswires,"EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)"
INCY,2023-04-17,09:38:14,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Announce Five-Year Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-17,09:38:14,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Dow Jones Newswires,"Press Release: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-17,09:38:14,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) approved Monjuvi in combination with lenalidomide,PRESS-RELEASE,Dow Jones Newswires,"Press Release: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi(R) (tafasitamab-cxix)"
INCY,2023-04-18,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2023-04-18,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib),PRESS-RELEASE,PR Newswire,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.0,products-services,,Results of the Phase 2 study of pemigatinib,PRESS-RELEASE,PR Newswire,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,PR Newswire,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"2020, the U.S. Food and Drug Administration (FDA) approved Pemazyre(R) (pemigatinib)",PRESS-RELEASE,PR Newswire,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.0,products-services,,Results of the Phase 2 study of pemigatinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,"In December 2018, Innovent and Incyte entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,00:00:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"2020, the U.S. Food and Drug Administration (FDA) approved Pemazyre(R) (pemigatinib)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre(R) (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib),PRESS-RELEASE,Business Wire,Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Results at Week 24,PRESS-RELEASE,Business Wire,Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Business Wire,Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: Results at Week 24,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte entered into a strategic alliance agreement with Maruho Co., Ltd.",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces European Commission Approval of Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:21:41,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces European Commission Approval of Opzelura,NEWS-FLASH,Dow Jones Newswires,Incyte Announces European Commission Approval of Opzelura Cream for Treatment of Non-Segmental Vitiligo With Facial Involvement in Adults and Adolescents
INCY,2023-04-20,14:41:51,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp. on Thursday said the European Commission has approved its Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets European OK of Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-04-20,14:41:51,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Incyte's blockbuster cancer drug Jakafi, won U.S. Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Incyte Gets European OK of Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-04-20,14:41:51,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte reported Opzelura revenue,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets European OK of Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-04-21,08:01:35,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 1Q 2023 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 1Q 2023 (INCY)"
INCY,2023-05-01,19:00:00,6CC55E,Incyte Corp.,96,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura(R) (ruxolitinib) Cream
INCY,2023-05-01,19:00:00,6CC55E,Incyte Corp.,97,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura(R) (ruxolitinib) Cream
INCY,2023-05-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,1Q EPS 10c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q EPS 10c >INCY
INCY,2023-05-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Adj EPS 37c,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Adj EPS 37c >INCY
INCY,2023-05-02,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Net $21.7M,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Net $21.7M >INCY
INCY,2023-05-02,11:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 1Q Rev $808.7M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Rev $808.7M >INCY
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The U.S. Food and Drug Administration (FDA) issued a complete response letter for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Net product revenues of $580 million,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 7%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Regulatory approval for Incyte's PD-1 inhibitor,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Monjuvi(R) (tafasitamab-cxix)/Minjuvi(R) (tafasitamab): Minjuvi,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemazyre was approved in Japan by the Japanese Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launch of Pemazyre,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Opzelura was approved by the European Commission,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 2 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: Additionally, two Phase 3 trials",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Development of the adenosine program,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -2-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -4-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -4-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -4-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -5-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -5-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $ 21,703 $ 37,992",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -5-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.10 $ 0.17,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -5-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,797,623 $ 5,840,984",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -5-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,95,0.0,earnings,,"Incyte Corp.: Non-GAAP Net Income $ 84,577 $122,867",PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -6-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,95,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.38 $ 0.56,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -6-
INCY,2023-05-02,11:00:01,6CC55E,Incyte Corp.,95,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2023 First Quarter Financial -6-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The U.S. Food and Drug Administration (FDA) issued a complete response letter for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Net product revenues of $580 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 7%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Regulatory approval for Incyte's PD-1 inhibitor,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Monjuvi(R) (tafasitamab-cxix)/Minjuvi(R) (tafasitamab): Minjuvi,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Pemazyre was approved in Japan by the Japanese Ministry of Health, Labour and Welfare (MHLW)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: The launch of Pemazyre,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.57,products-services,granted,Opzelura was approved by the European Commission,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.0,products-services,,Incyte Corp.: Phase 2 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.0,products-services,,"Incyte Corp.: Additionally, two Phase 3 trials",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.0,products-services,,Incyte Corp.: Development of the adenosine program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,95,0.0,earnings,,Incyte Corp.: 2023 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -2-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 808,673 $733,235",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP net income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Opzelura net product revenues for the quarter were $57 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -3-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -4-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -4-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -4-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -4-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -4-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -5-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -5-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Net income $ 21,703 $ 37,992",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -5-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.10 $ 0.17,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -5-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,797,623 $ 5,840,984",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -5-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,94,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $ 21,703 $ 37,992",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -6-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,94,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 84,577 $122,867",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -6-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,94,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 0.38 $ 0.56,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -6-
INCY,2023-05-02,11:01:40,6CC55E,Incyte Corp.,94,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 First Quarter -6-
INCY,2023-05-02,11:07:16,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Sees 2023 Jakafi Net Product Revenue $2.55B-$2.63B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Sees 2023 Jakafi Net Product Revenue $2.55B-$2.63B >INCY
INCY,2023-05-02,17:33:17,6CC55E,Incyte Corp.,100,0.86,revenues,up,Opzelura sales skyrocketed 343%,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales -- IBD
INCY,2023-05-02,17:33:17,6CC55E,Incyte Corp.,100,-0.75,revenues,below-expectations,Pemazyre sales missed.,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales -- IBD
INCY,2023-05-02,20:04:56,6CC55E,Incyte Corp.,100,0.86,revenues,up,Opzelura sales skyrocketed 343%,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales -- IBD
INCY,2023-05-02,20:04:56,6CC55E,Incyte Corp.,100,-0.75,revenues,below-expectations,Pemazyre sales missed.,FULL-ARTICLE,Dow Jones Newswires,Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales -- IBD
INCY,2023-05-03,11:24:43,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by Mizuho
INCY,2023-05-03,11:24:43,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $82.00/Share From $95.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $82.00/Share From $95.00 by Mizuho
INCY,2023-05-03,11:29:43,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Stifel
INCY,2023-05-03,11:29:43,6CC55E,Incyte Corp.,100,-0.76,price-targets,downgrade,Incyte Price Target Cut to $73.00/Share From $80.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $73.00/Share From $80.00 by Stifel
INCY,2023-05-03,14:26:54,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2023-05-03,14:26:54,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $70.00/Share From $79.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $70.00/Share From $79.00 by RBC Capital
INCY,2023-05-03,14:31:04,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by TD,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by TD Cowen
INCY,2023-05-03,14:31:04,6CC55E,Incyte Corp.,100,-0.68,price-targets,downgrade,Incyte Price Target Cut to $93.00/Share From $100.00 by TD,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $93.00/Share From $100.00 by TD Cowen
INCY,2023-05-03,15:21:24,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Market Perform by BMO Capital
INCY,2023-05-03,15:21:24,6CC55E,Incyte Corp.,100,-0.66,price-targets,downgrade,Incyte Price Target Cut to $70.00/Share From $75.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $70.00/Share From $75.00 by BMO Capital
INCY,2023-05-04,11:28:49,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Outperform by JMP Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Outperform by JMP Securities
INCY,2023-05-04,11:28:49,6CC55E,Incyte Corp.,100,-0.82,price-targets,downgrade,Incyte Price Target Cut to $93.00/Share From $113.00 by JMP Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $93.00/Share From $113.00 by JMP Securities
INCY,2023-05-04,15:53:49,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte downgraded to neutral from buy at BofA Securities,FULL-ARTICLE,MarketWatch,MW Incyte downgraded to neutral from buy at BofA Securities
INCY,2023-05-08,12:30:33,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Pablo Cagnoni President, Head of Research & Development >INCY",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Pablo Cagnoni President, Head of Research & Development >INCY"
INCY,2023-05-08,12:47:28,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Pablo Cagnoni President, Head of R&D",FULL-ARTICLE,Dow Jones Newswires,"Incyte Names Pablo Cagnoni President, Head of R&D"
INCY,2023-05-08,12:47:28,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Pablo Cagnoni President, Head of R&D",FULL-ARTICLE,Dow Jones Newswires,"Incyte Names Pablo Cagnoni President, Head of R&D"
INCY,2023-05-23,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2023-05-23,12:00:10,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1/2 Study of,PRESS-RELEASE,Business Wire,Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 Study of Retifanlimab (INCMGA00012,PRESS-RELEASE,Business Wire,Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1/2 Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1/2 Study of Retifanlimab (INCMGA00012,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
INCY,2023-05-25,21:01:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Across Incyte's Oncology -2-
INCY,2023-06-16,20:07:17,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Dir Schaffert Surrenders 488 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,Dir Schaffert Surrenders 488 Of Incyte Corp >INCY
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Mhra Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream,PRESS-RELEASE,Business Wire,MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces European Commission Approval Of Opzelura(R) (Ruxolitinib),PRESS-RELEASE,Business Wire,MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Ruxolitinib cream is also approved in the U.S.,PRESS-RELEASE,Business Wire,MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Mhra Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces European Commission Approval Of Opzelura(R) (Ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Ruxolitinib cream is also approved in the U.S.,PRESS-RELEASE,Dow Jones Newswires,Press Release: MHRA Grants Marketing Authorisation for Opzelura(R) (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
INCY,2023-07-05,10:12:44,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Uk MHRA Grants Marketing Authorization for Opzelura Cream,NEWS-FLASH,Dow Jones Newswires,"Incyte: UK MHRA Grants Marketing Authorization for Opzelura Cream for Non-Segmental Vitiligo With Facial Involvement in Adults, Adolescents >INCY"
INCY,2023-07-05,10:29:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets U.K. Nod for Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets U.K. Nod for Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-07-05,10:29:06,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Incyte's blockbuster cancer drug Jakafi, won U.S. Food and Drug Administration approval",FULL-ARTICLE,Dow Jones Newswires,Incyte Gets U.K. Nod for Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-07-05,10:29:06,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte reported Opzelura revenue of $56.6 million in the first quarter,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets U.K. Nod for Opzelura in Non-Segmental Vitiligo >INCY
INCY,2023-07-06,20:01:21,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Dhanak Surrenders 6,044 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Dhanak Surrenders 6,044 Of Incyte Corp >INCY"
INCY,2023-07-06,20:01:25,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Pasquale Surrenders 8,468 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Pasquale Surrenders 8,468 Of Incyte Corp >INCY"
INCY,2023-07-06,20:01:39,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Iyengar Surrenders 6,215 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Surrenders 6,215 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:09,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 8,442 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Surrenders 8,442 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:19,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 6,304 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Surrenders 6,304 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:19,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 6,073 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"CFO Stamoulis Surrenders 6,073 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:30,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Officer Tray Surrenders 1,136 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Surrenders 1,136 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:30,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 5,783 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"VP Swain Surrenders 5,783 Of Incyte Corp >INCY"
INCY,2023-07-06,20:02:45,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 43,467 Of Incyte Corp >INCY",FULL-ARTICLE,Dow Jones Newswires,"Chmn Hoppenot Surrenders 43,467 Of Incyte Corp >INCY"
INCY,2023-07-11,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2023-07-11,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2023-07-11,12:09:36,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2023-07-11,12:09:36,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2023-07-11,20:05:10,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura(R)) in Children with Atopic Dermatitis
INCY,2023-07-11,20:05:10,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura(R)) in Children with Atopic Dermatitis
INCY,2023-07-11,20:05:16,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results From Phase 3 Trial Evaluating Ruxolitinib,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Positive Topline Results From Phase 3 Trial Evaluating Ruxolitinib Cream in Children With Atopic Dermatitis
INCY,2023-07-24,11:00:08,6CC55E,Incyte Corp.,99,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,PR Newswire,Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
INCY,2023-07-24,11:00:35,6CC55E,Incyte Corp.,99,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
INCY,2023-07-24,11:03:32,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Plan to File for FDA Approval by End of Year,NEWS-FLASH,Dow Jones Newswires,"Syndax, Incyte Plan to File for FDA Approval by End of Year >SNDX INCY"
INCY,2023-07-25,10:09:59,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Buy by Citigroup
INCY,2023-07-25,10:09:59,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $82.00/Share by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $82.00/Share by Citigroup
INCY,2023-07-31,20:01:01,6CC55E,Incyte Corp.,100,0.34,products-services,,Replimune will supply Incyte with,PRESS-RELEASE,Business Wire,Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:01:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,This collaboration with Incyte to,PRESS-RELEASE,Business Wire,Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:01:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte will initiate and sponsor the clinical trial of INCB99280,PRESS-RELEASE,Business Wire,Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:01:06,6CC55E,Incyte Corp.,100,0.39,products-services,,Replimune and Incyte Enter Into Clinical Trial Collaboration and Supply Agreement,NEWS-FLASH,Dow Jones Newswires,Replimune and Incyte Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients With Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:02:27,6CC55E,Incyte Corp.,100,0.34,products-services,,Replimune will supply Incyte with,PRESS-RELEASE,Dow Jones Newswires,Press Release: Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:02:27,6CC55E,Incyte Corp.,100,0.49,partnerships,,This collaboration with Incyte to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:02:27,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte will initiate and sponsor the clinical trial of INCB99280,PRESS-RELEASE,Dow Jones Newswires,Press Release: Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
INCY,2023-07-31,20:05:09,6CC55E,Incyte Corp.,100,0.34,products-services,,Replimune Will Supply Incyte With,NEWS-FLASH,Dow Jones Newswires,Replimune Will Supply Incyte With RP1 for the Study and Shr Equally in Costs of the Study >INCY
INCY,2023-07-31,20:06:04,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte Sees Clinical Trial Initiating in Early 2024,NEWS-FLASH,Dow Jones Newswires,Incyte Sees Clinical Trial Initiating in Early 2024 >INCY
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,2Q EPS 90c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q EPS 90c >INCY
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Adj EPS 99c,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Adj EPS 99c >INCY
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Net $203.5M,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Net $203.5M >INCY
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 2Q Rev $954.6M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Rev $954.6M >INCY
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Net product revenues for the quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 14%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.88,revenues,up,Incyte Corp.: Net product revenues of $80 million grew 384%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: Opzelura was approved in Europe,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: Collaboration with Replimune Group, Inc. In July",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.39,products-services,,"Incyte and Replimune Group, Inc. announced a clinical trial collaboration and supply agreement",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -2-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -2-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 954,610 $ 911,397",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -2-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -2-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -2-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total Opzelura net product revenues for the quarter were $80 million,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.84,revenues,up,Minjuvi net product revenues grew 198%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -3-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -4-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -4-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $223,029 $226,353",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.91 $ 0.73 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.0,assets,,"Incyte Corp.: Total assets $6,208,259 $ 5,840,984",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.00 $ 1.02 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:00:01,6CC55E,Incyte Corp.,97,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Second Quarter Financial -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Net product revenues for the quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 14%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.88,revenues,up,Incyte Corp.: Net product revenues of $80 million grew 384%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: Opzelura was approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: Collaboration with Replimune Group, Inc. In July",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.39,products-services,,"Incyte and Replimune Group, Inc. announced a clinical trial collaboration and supply agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Incyte Corp.: approved as Olumiant in EU,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -2-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -2-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 954,610 $ 911,397",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -2-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -2-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -2-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total Opzelura net product revenues for the quarter were $80 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.84,revenues,up,Minjuvi net product revenues grew 198%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -3-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -4-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -4-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $223,029 $226,353",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.91 $ 0.73 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.0,assets,,"Incyte Corp.: Total assets $6,208,259 $ 5,840,984",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.00 $ 1.02 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:01:40,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Second Quarter -5-
INCY,2023-08-01,11:06:23,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte 2Q Jakafi Net Product Revenue $682M, Up 14%",NEWS-FLASH,Dow Jones Newswires,"Incyte 2Q Jakafi Net Product Revenue $682M, Up 14% >INCY"
INCY,2023-08-01,20:58:02,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 21,511 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 21,511 Of Incyte Corp >INCY"
INCY,2023-08-02,13:10:47,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Truist Securities
INCY,2023-08-02,13:10:47,6CC55E,Incyte Corp.,100,-0.76,price-targets,downgrade,Incyte Price Target Cut to $91.00/Share From $100.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $91.00/Share From $100.00 by Truist Securities
INCY,2023-08-02,13:32:27,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Market Perform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Market Perform by BMO Capital
INCY,2023-08-02,13:32:27,6CC55E,Incyte Corp.,100,-0.44,price-targets,downgrade,Incyte Price Target Cut to $68.00/Share From $70.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $68.00/Share From $70.00 by BMO Capital
INCY,2023-08-02,15:57:28,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Stifel
INCY,2023-08-02,15:57:28,6CC55E,Incyte Corp.,100,0.5,price-targets,upgrade,Incyte Price Target Raised to $76.00/Share From $73.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $76.00/Share From $73.00 by Stifel
INCY,2023-08-02,16:04:38,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2023-08-02,16:04:38,6CC55E,Incyte Corp.,100,0.52,price-targets,upgrade,Incyte Price Target Raised to $73.00/Share From $70.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $73.00/Share From $70.00 by RBC Capital
INCY,2023-08-03,20:01:07,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 21,511 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Stein Sells 21,511 Of Incyte Corp >INCY"
INCY,2023-08-14,21:41:17,6CC55E,Incyte Corp.,100,0.0,equity-actions,,Incyte Corp. Reports 6.9% Stake in Merus N.V.,NEWS-FLASH,Dow Jones Newswires,Incyte Corp. Reports 6.9% Stake in Merus N.V.
INCY,2023-08-19,07:36:40,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 2Q 2023 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 2Q 2023 (INCY)"
INCY,2023-08-22,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2023-08-22,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2023-09-01,21:45:27,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Swain Registers 8,449 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Swain Registers 8,449 Of Incyte Corp >INCY"
INCY,2023-09-06,20:01:18,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Swain Sells 8,449 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Swain Sells 8,449 Of Incyte Corp >INCY"
INCY,2023-09-13,13:00:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Abcellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY),PRESS-RELEASE,Business Wire,AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
INCY,2023-09-13,13:00:30,6CC55E,Incyte Corp.,100,0.49,partnerships,,Abcellera (Nasdaq:ABCL) announced today that it has entered into a strategic collaboration with Incyte (Nasdaq:INCY),PRESS-RELEASE,Dow Jones Newswires,Press Release: AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
INCY,2023-09-13,13:01:09,6CC55E,Incyte Corp.,100,0.49,partnerships,,Abcellera Announces Collaboration With Incyte to,NEWS-FLASH,Dow Jones Newswires,AbCellera Announces Collaboration With Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
INCY,2023-09-18,12:12:06,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Analysts maintained their buy rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,Incyte Shares Drop After FDA Approves GSK's Competing Blood-cancer Treatment -- MarketWatch
INCY,2023-09-18,12:12:06,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Analysts maintained their buy rating on Incyte,FULL-ARTICLE,MarketWatch,MW Incyte shares drop after FDA approves GSK's competing blood-cancer treatment
INCY,2023-09-18,16:03:53,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Gsk Snags Approval For A New Jakafi,FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-18,16:03:53,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte's total sales, at $682 million",FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-18,16:03:53,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Berens maintained his market perform rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-18,20:08:11,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Gsk Snags Approval For A New Jakafi,FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-18,20:08:11,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte's total sales, at $682 million",FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-18,20:08:11,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Berens maintained his market perform rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival -- IBD
INCY,2023-09-27,21:01:05,6CC55E,Incyte Corp.,94,0.57,products-services,granted,Jakafi (ruxolitinib) was authorized by the FDA in May 2019,PRESS-RELEASE,PR Newswire,"Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi"
INCY,2023-09-27,21:01:05,6CC55E,Incyte Corp.,94,0.57,products-services,granted,The US FDA recently approved ruxolitinib,PRESS-RELEASE,PR Newswire,"Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi"
INCY,2023-09-27,21:01:29,6CC55E,Incyte Corp.,94,0.57,products-services,granted,Jakafi (ruxolitinib) was authorized by the FDA in May 2019,PRESS-RELEASE,PR Newswire,"Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi"
INCY,2023-09-27,21:01:29,6CC55E,Incyte Corp.,94,0.57,products-services,granted,The US FDA recently approved ruxolitinib,PRESS-RELEASE,PR Newswire,"Graft Versus Host Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Companies - Glia, Incyte, Novartis, GlaxoSmithKline, Pfizer, BMS, Roche, AstraZeneca, Sanofi"
INCY,2023-09-29,17:43:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 Study of Ruxolitinib,PRESS-RELEASE,Business Wire,Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2023-09-29,17:43:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2023-09-29,17:43:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 Study of Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2023-09-29,17:43:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
INCY,2023-10-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2023-10-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2023-10-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2023-10-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2023-10-10,20:45:08,6CC55E,Incyte Corp.,100,0.0,products-services,,Knight Therapeutics Announces Regulatory Submission of Pemigatinib,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
INCY,2023-10-10,20:45:08,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Anvisa granted regulatory approval in Brazil for Minjuvi(R),PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
INCY,2023-10-10,20:45:08,6CC55E,Incyte Corp.,100,0.52,products-services,,Knight Therapeutics Inc.: The commercial launch of Minjuvi(R),PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
INCY,2023-10-10,20:45:08,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
INCY,2023-10-10,20:45:57,6CC55E,Incyte Corp.,100,0.0,products-services,,Knight Therapeutics Announces Regulatory Submission of Pemigatinib,NEWS-FLASH,Dow Jones Newswires,Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
INCY,2023-10-11,12:15:00,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive 52-Week Data from Phase 2b Study,PRESS-RELEASE,Business Wire,Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-10-11,12:15:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707),PRESS-RELEASE,Business Wire,Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-10-11,12:15:00,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive 52-Week Data from Phase,PRESS-RELEASE,Business Wire,Incyte Announces Positive 52-Week Data from Phase -2-
INCY,2023-10-11,12:15:00,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive 52-Week Data from Phase 2b Study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-10-11,12:15:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
INCY,2023-10-11,12:15:29,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive 52-Week Data From Phase 2b Study,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Positive 52-Week Data From Phase 2b Study Evaluating Povorcitinib in Patients With Extensive Nonsegmental Vitiligo
INCY,2023-10-11,13:15:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte (Nasdaq:INCY) announced today its partnership with actress, singer and songwriter Mandy Moore on Moments",PRESS-RELEASE,Business Wire,Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
INCY,2023-10-11,13:15:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
INCY,2023-10-11,14:30:00,6CC55E,Incyte Corp.,97,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura(R) (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
INCY,2023-10-11,14:30:00,6CC55E,Incyte Corp.,98,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura(R) (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
INCY,2023-10-13,12:00:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Data From Incyte's Povorcitinib Clinical Program,PRESS-RELEASE,Business Wire,Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8(th) Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
INCY,2023-10-13,12:06:44,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Data From Incyte's Povorcitinib Clinical Program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
INCY,2023-10-13,14:30:00,6CC55E,Incyte Corp.,92,0.0,products-services,,Phase 3 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces New Data for Ruxolitinib Cream (Opzelura(R) ) in Children with Atopic Dermatitis
INCY,2023-10-13,14:30:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Announces New Data for Ruxolitinib Cream -2-
INCY,2023-10-13,14:30:00,6CC55E,Incyte Corp.,93,0.0,products-services,,Phase 3 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data for Ruxolitinib Cream (Opzelura(R)) in Children with Atopic Dermatitis
INCY,2023-10-13,14:30:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data for -2-
INCY,2023-10-16,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Updated Results from POD1UM-201: A Phase 2 Study of Retifanlimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
INCY,2023-10-16,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Updated Results from POD1UM-201: A Phase 2 Study of Retifanlimab,PRESS-RELEASE,Business Wire,Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
INCY,2023-10-18,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,3Q EPS 76c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q EPS 76c >INCY
INCY,2023-10-31,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Adj EPS $1.10,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Adj EPS $1.10 >INCY
INCY,2023-10-31,11:00:00,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Net $171.3M,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Net $171.3M >INCY
INCY,2023-10-31,11:00:00,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 3Q Rev $919M >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Rev $919M >INCY
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 third quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues of $919 million in the third quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.34,earnings,,Incyte Corp.: tightening full year 2023 guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 2 study evaluating povorcitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 3%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.82,revenues,up,Incyte Corp.: Net product revenues of $92 million grew 141%,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,filed,Incyte Corp.: we expected to file the IND by year-end 2023,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Corp.: Positive 52-week data from a Phase 2b clinical trial,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: approved in Europe,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -2-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -2-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 919,025 $ 823,303",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -2-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -2-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -2-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $919,025 $ 823,303",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total Opzelura net product revenues for the quarter were $92 million,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP loss,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -3-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -4-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $248,719 $ 133,795 $",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.76 $ 0.51 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.0,assets,,"Incyte Corp.: Total assets $ 6,388,239 $ 5,840,984",PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.11 $ 0.60 $,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:02,6CC55E,Incyte Corp.,97,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2023 Third Quarter Financial -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2023 third quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues of $919 million in the third quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.34,earnings,,Incyte Corp.: tightening full year 2023 guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Phase 2 study evaluating povorcitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Net product revenues grew 3%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.82,revenues,up,Incyte Corp.: Net product revenues of $92 million grew 141%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,products-services,filed,Incyte Corp.: we expected to file the IND by year-end 2023,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Two Phase 3 trials evaluating ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.84,products-services,positive,Incyte Corp.: Positive 52-week data from a Phase 2b clinical trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 3 study in,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Baricitinib (Olumiant(R) )(2) AD: approved in Europe,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $ 919,025 $ 823,303",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -2-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total Opzelura net product revenues for the quarter were $92 million,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2023 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -3-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -4-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -4-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $248,719 $ 133,795 $",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.76 $ 0.51 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.0,assets,,"Incyte Corp.: Total assets $ 6,388,239 $ 5,840,984",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.11 $ 0.60 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:00:40,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2023 Third Quarter -5-
INCY,2023-10-31,11:02:10,6CC55E,Incyte Corp.,100,-0.75,revenues,down,Incyte Narrows 2023 View To Jakafi Rev,NEWS-FLASH,Dow Jones Newswires,Incyte Narrows 2023 View To Jakafi Rev $2.59B-$2.62B >INCY
INCY,2023-10-31,11:14:16,6CC55E,Incyte Corp.,92,0.64,earnings,up,Incyte posted brisk growth in its third-quarter net income,FULL-ARTICLE,Dow Jones Newswires,"Incyte 3Q Net Income, Revenue Rise on Stronger Jakafi, Opzelura Sales"
INCY,2023-10-31,11:18:58,6CC55E,Incyte Corp.,100,0.0,revenues,,Jakafi Revenue Projection for,FULL-ARTICLE,Dow Jones Newswires,Incyte Tightens Jakafi Revenue Projection for 2023
INCY,2023-11-01,12:58:20,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2023-11-01,12:58:20,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $64.00/Share From $74.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $64.00/Share From $74.00 by Morgan Stanley
INCY,2023-11-01,16:45:30,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2023-11-01,16:45:31,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $63.00/Share From $74.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $63.00/Share From $74.00 by RBC Capital
INCY,2023-11-02,13:00:07,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1/2 Study of,PRESS-RELEASE,Business Wire,Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
INCY,2023-11-02,13:00:07,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
INCY,2023-11-02,13:00:07,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference call details,PRESS-RELEASE,Business Wire,Incyte to Spotlight More Than 40 Hematology and -2-
INCY,2023-11-02,13:00:07,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte to Spotlight More Than 40 Hematology and -2-
INCY,2023-11-02,13:01:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Phase 1/2 Study of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
INCY,2023-11-02,13:01:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
INCY,2023-11-02,13:01:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference call details,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Spotlight More Than 40 -2-
INCY,2023-11-02,13:01:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Spotlight More Than 40 -2-
INCY,2023-11-02,13:52:34,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Goldman Sachs
INCY,2023-11-02,13:52:34,6CC55E,Incyte Corp.,100,-0.8,price-targets,downgrade,Incyte Price Target Cut to $98.00/Share From $114.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $98.00/Share From $114.00 by Goldman Sachs
INCY,2023-11-19,08:42:09,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 3Q 2023 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 3Q 2023 (INCY)"
INCY,2023-11-21,11:13:54,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Neutral From Buy by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Neutral From Buy by Goldman Sachs
INCY,2023-11-21,11:13:54,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $65.00/Share by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $65.00/Share by Goldman Sachs
INCY,2023-11-22,14:30:58,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by Goldman Sachs
INCY,2023-11-22,14:30:58,6CC55E,Incyte Corp.,100,-0.84,price-targets,downgrade,Incyte Price Target Cut to $65.00/Share From $98.00 by Goldman Sachs,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $65.00/Share From $98.00 by Goldman Sachs
INCY,2023-12-04,12:32:03,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Buy From Neutral by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Buy From Neutral by Guggenheim
INCY,2023-12-10,22:00:00,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte expect to submit a Biologics License Application (BLA),PRESS-RELEASE,Business Wire,Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-10,22:00:00,6CC55E,Incyte Corp.,99,0.63,products-services,,Axatilimab was granted Orphan Drug Designation by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-10,22:00:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Business Wire,Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-11,10:36:01,6CC55E,Incyte Corp.,99,0.0,products-services,filed,Incyte expect to submit a Biologics License Application (BLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-11,10:36:01,6CC55E,Incyte Corp.,99,0.63,products-services,,Axatilimab was granted Orphan Drug Designation by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-11,10:36:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
INCY,2023-12-12,13:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2023-12-12,13:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2023-12-13,13:26:17,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Outperform From Market Perform by Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Outperform From Market Perform by Leerink Partners
INCY,2023-12-13,13:26:17,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $78.00/Share by Leerink,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $78.00/Share by Leerink Partners
INCY,2023-12-13,21:33:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Officer Tray Registers 1,067 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"Officer Tray Registers 1,067 Of Incyte Corp >INCY"
INCY,2023-12-14,18:06:11,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by Mizuho,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by Mizuho
INCY,2023-12-14,18:06:11,6CC55E,Incyte Corp.,100,-0.64,price-targets,downgrade,Incyte Price Target Cut to $77.00/Share From $82.00 by Mizuho,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $77.00/Share From $82.00 by Mizuho
INCY,2023-12-14,19:12:50,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,277 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Sells 1,277 Of Incyte Corp >INCY"
INCY,2025-01-08,23:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-01-08,23:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-01-13,13:30:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,"Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference"
INCY,2025-01-13,13:30:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,"Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference"
INCY,2025-01-13,13:30:01,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,"Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference"
INCY,2025-01-15,22:34:36,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo(TM) (axatilimab,NEWS-FLASH,Dow Jones Newswires,Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo(TM) (axatilimab-csfr) 9 Mg And 22 Mg Vial Sizes >SNDX
INCY,2025-01-15,22:34:36,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has approved Niktimvo(TM) (axatilimab-csfr) in 9 mg and 22 mg vial,PRESS-RELEASE,PR Newswire,Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo(TM) (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY,2025-01-15,22:34:36,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,PR Newswire,Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo(TM) (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY,2025-01-15,22:34:36,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The U.S. Food and Drug Administration (FDA) has approved Niktimvo(TM) (axatilimab-csfr) in 9 mg and 22 mg vial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo(TM) (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY,2025-01-15,22:34:36,6CC55E,Incyte Corp.,100,0.39,products-services,,Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo(TM) (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY,2025-01-17,20:32:39,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 10,692 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 10,692 Of Incyte Corp >INCY"
INCY,2025-01-17,20:33:49,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 3,672 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 3,672 Of Incyte Corp >INCY"
INCY,2025-01-17,20:34:29,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 908 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 908 Of Incyte Corp >INCY
INCY,2025-01-17,20:35:07,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Flannelly Surrenders 3,158 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Surrenders 3,158 Of Incyte Corp >INCY"
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call,PRESS-RELEASE,Business Wire,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Fourth Quarter and Year-End 2024 Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,13:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY,2025-01-21,21:06:46,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 12,352 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 12,352 Of Incyte Corp >INCY"
INCY,2025-01-22,21:06:47,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 12,352 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Sells 12,352 Of Incyte Corp >INCY"
INCY,2025-01-22,21:07:31,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Morrissey Surrenders 429 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Morrissey Surrenders 429 Of Incyte Corp >INCY
INCY,2025-02-07,21:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-02-07,21:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,4Q EPS $1.02 >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q EPS $1.02 >INCY
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Adj EPS $1.43,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Adj EPS $1.43 >INCY
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 4Q Net $201.2M,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Net $201.2M >INCY
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 4Q Rev $1.18B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 4Q Rev $1.18B >INCY
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,"Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024",PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2024 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Fourth quarter 2024 net product revenues increased 11%,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura net revenues,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.72,revenues,up,Incyte Corp.: we anticipate a year of continued strong revenue growth,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Four new product,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: At least three Phase 3 study,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: 2024 full year net product revenues of $2.79 billion,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 2 trial evaluating the safety and efficacy of axatilimab,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Business Wire,"Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Data from the Phase 3 studies are anticipated in the first half of 2025,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 trial for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Opzelura was granted approval by the Swiss Agency for Therapeutic Products (Swissmedic),PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 studies of povorcitinib in patients,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,178,698 $1,013,341",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: For the quarter and full year ended December 31, 2024, total royalty revenues",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Jakafi net product revenue increased 11%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.6,revenues,up,Opzelura net product revenue increased 48% and 50%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.84,revenues,up,Monjuvi net product revenue increased 265% and 222%,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's guidance for the fiscal year 2025,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2025,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $201,212 $201,079",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 1.04 $ 0.90 $,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,444,322 $ 6,782,107",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.0,earnings,,"Incyte Corp.: Non-GAAP Net Income $281,353 $239,124",PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -6-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.46 $ 1.07 $,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -6-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2024 Fourth Quarter and Year-End -6-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,"Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Reports 2024 Fourth Quarter and Year-End Financial Results,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.41,revenues,up,Incyte Corp.: Fourth quarter 2024 net product revenues increased 11%,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net revenues,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Opzelura net revenues,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.72,revenues,up,Incyte Corp.: we anticipate a year of continued strong revenue growth,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Four new product,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: At least three Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: 2024 full year net product revenues of $2.79 billion,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 2 trial evaluating the safety and efficacy of axatilimab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones"
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 trials,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Data from the Phase 3 studies are anticipated in the first half of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 trial for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Opzelura was granted approval by the Swiss Agency for Therapeutic Products (Swissmedic),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The Phase 3 studies of povorcitinib in patients,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2024 Fourth Quarter and Year-end Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: Total GAAP revenues $1,178,698 $1,013,341",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -2-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,"Incyte Corp.: For the quarter and full year ended December 31, 2024, total royalty revenues",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,Incyte Corp.: Milestone and contract revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.41,revenues,up,Jakafi net product revenue increased 11%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.6,revenues,up,Opzelura net product revenue increased 48% and 50%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.84,revenues,up,Monjuvi net product revenue increased 265% and 222%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -3-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's guidance for the fiscal year 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -4-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte's financial guidance for 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: GAAP Net Income $201,212 $201,079",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 1.04 $ 0.90 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 5,444,322 $ 6,782,107",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -5-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.0,earnings,,"Incyte Corp.: Non-GAAP Net Income $281,353 $239,124",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -6-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.46 $ 1.07 $,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -6-
INCY,2025-02-10,12:00:01,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2024 Fourth Quarter -6-
INCY,2025-02-10,12:02:36,6CC55E,Incyte Corp.,93,0.0,earnings,,Incyte Corporation issued a press release announcing financial results for its fourth fiscal quarter,RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2025-02-11,09:47:53,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Stifel
INCY,2025-02-11,09:47:53,6CC55E,Incyte Corp.,100,0.42,price-targets,upgrade,Incyte Price Target Raised to $77.00/Share From $75.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $77.00/Share From $75.00 by Stifel
INCY,2025-02-11,12:26:33,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Citigroup
INCY,2025-02-11,12:26:33,6CC55E,Incyte Corp.,100,-0.78,price-targets,downgrade,Incyte Price Target Cut to $88.00/Share From $97.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $88.00/Share From $97.00 by Citigroup
INCY,2025-02-11,14:15:13,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2025-02-11,14:15:13,6CC55E,Incyte Corp.,100,-0.44,price-targets,downgrade,Incyte Price Target Cut to $68.00/Share From $70.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $68.00/Share From $70.00 by RBC Capital
INCY,2025-02-18,13:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2025-02-18,13:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2025-02-20,13:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration,PRESS-RELEASE,Business Wire,Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
INCY,2025-02-20,13:03:43,6CC55E,Incyte Corp.,99,0.49,partnerships,,Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
INCY,2025-02-23,08:16:54,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 4Q 2024 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 4Q 2024 (INCY)"
INCY,2025-02-26,21:07:10,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Denton Registers 14,069 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Denton Registers 14,069 Of Incyte Corp >INCY"
INCY,2025-02-28,14:30:00,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
INCY,2025-02-28,14:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
INCY,2025-02-28,23:35:13,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Denton Sells 14,069 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Denton Sells 14,069 Of Incyte Corp >INCY"
INCY,2025-03-04,22:18:58,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 599 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 599 Of Incyte Corp >INCY
INCY,2025-03-06,22:10:42,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 599 Of Incyte Corp,FULL-ARTICLE,Dow Jones Newswires,VP Denton Sells 599 Of Incyte Corp >INCY
INCY,2025-03-07,21:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-03-07,21:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-03-08,14:01:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-08,14:01:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Topline data from a separate Phase 3 study,PRESS-RELEASE,Business Wire,Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-08,14:01:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Opzelura(R) ) was approved by the FDA,PRESS-RELEASE,Business Wire,Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-08,14:01:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-08,14:01:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Topline data from a separate Phase 3 study,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-08,14:01:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Opzelura(R) ) was approved by the FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura(R)) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY,2025-03-14,20:13:45,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 19,807 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 19,807 Of Incyte Corp >INCY"
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte will hold a conference call and webcast today at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte will hold a conference call and webcast today at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:00:07,6CC55E,Incyte Corp.,100,0.84,products-services,positive,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
INCY,2025-03-17,11:21:06,6CC55E,Incyte Corp.,92,0.84,products-services,positive,Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib,FULL-ARTICLE,Dow Jones Newswires,Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa
INCY,2025-03-17,13:16:38,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,He reiterated his neutral rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' -- IBD"
INCY,2025-03-17,13:16:38,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Phipps has an outperform rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' -- IBD"
INCY,2025-03-17,15:21:54,6CC55E,Incyte Corp.,93,0.84,products-services,positive,Incyte Corp.: The company on Monday announced positive top-line results from its Phase 3 clinical trial program,FULL-ARTICLE,Dow Jones Newswires,Incyte Is Today's Worst S&P 500 Stock. Here's Why. -- Barrons.com
INCY,2025-03-17,20:13:09,6CC55E,Incyte Corp.,98,0.0,analyst-ratings,neutral,He reiterated his neutral rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive' -- IBD"
INCY,2025-03-17,20:13:09,6CC55E,Incyte Corp.,98,0.34,analyst-ratings,neutral,Phipps has an outperform rating on Incyte,FULL-ARTICLE,Dow Jones Newswires,"Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive' -- IBD"
INCY,2025-03-18,11:45:13,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Market Perform From Outperform by William Blair,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Market Perform From Outperform by William Blair
INCY,2025-03-18,14:14:04,6CC55E,Incyte Corp.,100,-0.58,analyst-ratings,negative,Incyte Cut to Neutral From Buy by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Cut to Neutral From Buy by Guggenheim
INCY,2025-03-18,14:14:04,6CC55E,Incyte Corp.,100,0.0,price-targets,unchanged,Incyte Price Target Maintained With a $92.00/Share by Guggenheim,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Maintained With a $92.00/Share by Guggenheim
INCY,2025-03-18,14:19:44,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Truist Securities
INCY,2025-03-18,14:19:44,6CC55E,Incyte Corp.,100,-0.42,price-targets,downgrade,Incyte Price Target Cut to $72.00/Share From $74.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $72.00/Share From $74.00 by Truist Securities
INCY,2025-03-18,20:01:52,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 19,807 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Flannelly Sells 19,807 Of Incyte Corp >INCY"
INCY,2025-03-24,11:57:27,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Morgan Stanley
INCY,2025-03-24,11:57:27,6CC55E,Incyte Corp.,100,-0.64,price-targets,downgrade,Incyte Price Target Cut to $65.00/Share From $69.00 by Morgan Stanley,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $65.00/Share From $69.00 by Morgan Stanley
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.52,products-services,,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated Minjuvi(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated Minjuvi(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-26,11:30:00,6CC55E,Incyte Corp.,100,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Launch of Minjuvi(R) (tafasitamab) in Mexico
INCY,2025-03-27,21:05:58,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Trotta Surrenders 537 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Trotta Surrenders 537 Of Incyte Corp >INCY
INCY,2025-04-07,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-04-07,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-04-10,12:00:02,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2025-04-10,12:00:02,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report First Quarter Financial Results
INCY,2025-04-10,12:02:04,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2025-04-10,12:02:04,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report First Quarter Financial Results
INCY,2025-04-21,17:25:30,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2025-04-21,17:25:31,6CC55E,Incyte Corp.,100,-0.44,price-targets,downgrade,Incyte Price Target Cut to $68.00/Share From $70.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $68.00/Share From $70.00 by JP Morgan
INCY,2025-04-23,15:03:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Business Wire,Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-23,15:03:00,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: Final Results of POD1UM-201, a Phase 2 Study",PRESS-RELEASE,Business Wire,Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-23,15:03:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Interim Safety and Antitumor Activity Data from a Phase 1 Study of INCB123667,PRESS-RELEASE,Business Wire,Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-23,15:03:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 2 Study of Pemigatinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-23,15:03:01,6CC55E,Incyte Corp.,99,0.0,products-services,,"Incyte Corp.: Final Results of POD1UM-201, a Phase 2 Study",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-23,15:03:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Interim Safety and Antitumor Activity Data from a Phase 1 Study of INCB123667,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,053 million in the first quarter",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: New, 18-week data from ongoing Phase 3 study of povorcitinib",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"In April 2025, Incyte announced positive topline results from the Phase 2 study evaluating povorcitinib",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: In March 2025, results from two Phase 3 studies",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,revenues,up,Incyte Corp.: Net product revenue growth in the first quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Opzelura(R) (ruxolitinib) cream:,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 trial for ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"Incyte Corp.: In March 2025, positive results from the Phase 3 studies",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 studies,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte and Genesis Therapeutics, Inc. (Genesis) entered into a strategic collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 First Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 1,052,898 $880,889",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.44,revenues,up,"Incyte Corp.: Total net product revenues for the quarter ended March 31, 2025 increased 26% over the prior year",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.42,revenues,up,Incyte Corp.: Jakafi net product revenue increased 24%,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,revenues,up,Incyte Corp.: Opzelura net product revenue increased 38%,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Minjuvi/Monjuvi net product,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.72,revenues,up,Incyte is raising its full year 2025 Jakafi revenue guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -4-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -4-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 229,459 $132,719",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.82 $ 0.76,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,749,365 $ 5,444,322",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.18 $ 0.59,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: The Non-GAAP net income for the three months ended March 31, 2024",PRESS-RELEASE,Business Wire,Incyte Reports 2025 First Quarter Financial -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,1Q EPS 80c >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q EPS 80c >INCY
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Adj EPS $1.16,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Adj EPS $1.16 >INCY
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 1Q Net $158.2M,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Net $158.2M >INCY
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 1Q Rev $1.05B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 1Q Rev $1.05B >INCY
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2025 first quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,053 million in the first quarter",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: New, 18-week data from ongoing Phase 3 study of povorcitinib",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"In April 2025, Incyte announced positive topline results from the Phase 2 study evaluating povorcitinib",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: In March 2025, results from two Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,revenues,up,Incyte Corp.: Net product revenue growth in the first quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Opzelura(R) (ruxolitinib) cream:,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: A Phase 3 trial for ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,100,0.84,products-services,positive,"Incyte Corp.: In March 2025, positive results from the Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Incyte and Genesis Therapeutics, Inc. (Genesis) entered into a strategic collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 First Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $ 1,052,898 $880,889",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP basic EPS,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.44,revenues,up,"Incyte Corp.: Total net product revenues for the quarter ended March 31, 2025 increased 26% over the prior year",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.42,revenues,up,Incyte Corp.: Jakafi net product revenue increased 24%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,revenues,up,Incyte Corp.: Opzelura net product revenue increased 38%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte Corp.: Minjuvi/Monjuvi net product,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -2-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Financial Guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.72,revenues,up,Incyte is raising its full year 2025 Jakafi revenue guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -3-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Minjuvi(R) (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in August 2021,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -4-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -4-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Income from operations,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,"Incyte Corp.: Non-GAAP Net Income $ 229,459 $132,719",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Net income per share: Basic $ 0.82 $ 0.76,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,749,365 $ 5,444,322",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: Non-GAAP net income per share: Basic $ 1.18 $ 0.59,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:00:01,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: The Non-GAAP net income for the three months ended March 31, 2024",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 First Quarter -5-
INCY,2025-04-29,11:04:19,6CC55E,Incyte Corp.,93,0.0,earnings,,"Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March 31, 2025",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2025-04-30,15:50:01,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2025-04-30,15:50:01,6CC55E,Incyte Corp.,100,0.54,price-targets,upgrade,Incyte Price Target Raised to $67.00/Share From $64.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $67.00/Share From $64.00 by RBC Capital
INCY,2025-04-30,16:08:51,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2025-04-30,16:08:51,6CC55E,Incyte Corp.,100,0.32,price-targets,upgrade,Incyte Price Target Raised to $59.00/Share From $58.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $59.00/Share From $58.00 by Wells Fargo
INCY,2025-05-01,12:00:04,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2025-05-01,12:00:04,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conference,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2025-05-07,20:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-05-07,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-05-14,11:54:01,6CC55E,Incyte Corp.,99,0.46,legal,,"Incyte Corp.: the ""Company"") and Novartis Pharma AG (""Novartis"") entered into a settlement agreement",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Other Events >INCY
INCY,2025-05-14,11:54:01,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte Corp.: the Company to Novartis under the Collaboration,RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Other Events >INCY
INCY,2025-05-14,12:05:12,6CC55E,Incyte Corp.,100,0.39,products-services,,"Incyte, Novartis Reach Settlement Agreement on",RNS-SEC8K,Dow Jones Newswires,"Incyte, Novartis Reach Settlement Agreement on Litigation Relating to Royalty Payments >INCY"
INCY,2025-05-14,12:30:49,6CC55E,Incyte Corp.,100,0.46,legal,,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties",FULL-ARTICLE,Dow Jones Newswires,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties"
INCY,2025-05-14,12:30:49,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Novartis entered into a collaboration,FULL-ARTICLE,Dow Jones Newswires,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties"
INCY,2025-05-14,12:45:49,6CC55E,Incyte Corp.,100,0.46,legal,,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties",FULL-ARTICLE,Dow Jones Newswires,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties"
INCY,2025-05-14,12:45:49,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Novartis entered into a collaboration,FULL-ARTICLE,Dow Jones Newswires,"Incyte, Novartis Pharma Reach Settlement Over Jakafi Royalties"
INCY,2025-05-15,18:30:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval Of Zynyz(R) (retifanlimab-dlwr),NEWS-FLASH,Dow Jones Newswires,Incyte Announces FDA Approval Of Zynyz(R) (retifanlimab-dlwr) Making It The First And Only Approved First-Line Treatment For Advanced Anal Cancer Patients In The United States >INCY
INCY,2025-05-15,18:30:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz(R) (retifanlimab-dlwr),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(R) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY,2025-05-15,18:30:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The Priority Review and FDA approval of the supplemental Biologics License Application (sBLA),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(R) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY,2025-05-15,18:30:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval of Zynyz(R),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Zynyz(R) -2-
INCY,2025-05-15,18:33:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz(R) (retifanlimab-dlwr),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Zynyz(R) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY,2025-05-15,18:33:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The Priority Review and FDA approval of the supplemental Biologics License Application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Zynyz(R) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
INCY,2025-05-22,07:15:24,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 1Q 2025 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 1Q 2025 (INCY)"
INCY,2025-05-27,12:00:00,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET)",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conference
INCY,2025-05-27,12:00:01,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conference
INCY,2025-05-27,15:39:48,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Truist Securities
INCY,2025-05-27,15:39:48,6CC55E,Incyte Corp.,100,0.3,price-targets,upgrade,Incyte Price Target Raised to $73.00/Share From $72.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $73.00/Share From $72.00 by Truist Securities
INCY,2025-05-29,21:31:05,6CC55E,Incyte Corp.,95,0.57,products-services,granted,"May, 2025, the FDA approved Zynyz",PRESS-RELEASE,PR Newswire,Anal Cancer Market Heats Up Following Incyte's Zynyz Greenlight | DelveInsight
INCY,2025-05-29,21:31:25,6CC55E,Incyte Corp.,95,0.57,products-services,granted,"May, 2025, the FDA approved Zynyz",PRESS-RELEASE,PR Newswire,Anal Cancer Market Heats Up Following Incyte's Zynyz Greenlight | DelveInsight
INCY,2025-05-30,20:07:00,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Officer Tray Registers 963 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,Officer Tray Registers 963 Of Incyte Corp >INCY
INCY,2025-06-02,20:32:59,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Officer Tray Registers 651 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,Officer Tray Registers 651 Of Incyte Corp >INCY
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,"Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,"Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,"Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Business Wire,"Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,14:30:00,6CC55E,Incyte Corp.,99,0.71,products-services,,Monjuvi(R) (tafasitamab-cxix) received accelerated approval by,PRESS-RELEASE,Dow Jones Newswires,"Press Release: Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025"
INCY,2025-06-03,16:04:47,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by UBS
INCY,2025-06-03,16:04:47,6CC55E,Incyte Corp.,100,0.0,price-targets,unchanged,Incyte Price Target Maintained With a $61.00/Share by UBS,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Maintained With a $61.00/Share by UBS
INCY,2025-06-03,20:01:42,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Officer Tray Sells 1,614 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"Officer Tray Sells 1,614 Of Incyte Corp >INCY"
INCY,2025-06-03,20:09:38,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Denton Registers 1,795 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Denton Registers 1,795 Of Incyte Corp >INCY"
INCY,2025-06-05,20:05:09,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Denton Sells 1,795 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Denton Sells 1,795 Of Incyte Corp >INCY"
INCY,2025-06-06,20:30:00,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-06-06,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-06-12,16:01:03,6CC55E,Incyte Corp.,100,0.49,partnerships,,Expands Partnership with Incyte to,PRESS-RELEASE,PR Newswire,Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
INCY,2025-06-12,16:01:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: FDA approves axatilimab,PRESS-RELEASE,PR Newswire,Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
INCY,2025-06-12,16:01:03,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: FDA approves retifanlimab-dlwr with carboplatin,PRESS-RELEASE,PR Newswire,Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
INCY,2025-06-12,16:01:03,6CC55E,Incyte Corp.,100,0.71,products-services,,Incyte Corp.: FDA grants accelerated approval to retifanlimab,PRESS-RELEASE,PR Newswire,Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
INCY,2025-06-12,21:17:51,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Dir Schaffert Surrenders 849 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,Dir Schaffert Surrenders 849 Of Incyte Corp >INCY
INCY,2025-06-12,22:45:00,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Business Wire,Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-12,22:45:00,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Business Wire,Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-12,22:45:00,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Business Wire,Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-12,22:45:01,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Dow Jones Newswires,Press Release: Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-12,22:45:01,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Dow Jones Newswires,Press Release: Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-12,22:45:01,6CC55E,Incyte Corp.,93,0.57,products-services,granted,"May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz(R) (retifanlimab-dlwr) in combination with carboplatin and paclitaxel",PRESS-RELEASE,Dow Jones Newswires,Press Release: Phase 3 Data for Incyte's Retifanlimab (Zynyz(R)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
INCY,2025-06-15,07:15:00,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: Results as of April 4, 2025",PRESS-RELEASE,Business Wire,Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,07:15:00,6CC55E,Incyte Corp.,99,-0.54,products-services,,Incyte Corp.: No infusion interruptions due to,PRESS-RELEASE,Business Wire,Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,07:15:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The clinical trial program for,PRESS-RELEASE,Business Wire,Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,07:15:01,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: Results as of April 4, 2025",PRESS-RELEASE,Dow Jones Newswires,Press Release: Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,07:15:01,6CC55E,Incyte Corp.,99,-0.54,products-services,,Incyte Corp.: No infusion interruptions due to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,07:15:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The clinical trial program for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
INCY,2025-06-15,08:00:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Qiagen and Incyte Announce Precision Medicine Collaboration,PRESS-RELEASE,Business Wire,QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
INCY,2025-06-16,17:34:17,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Buy From Hold by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Buy From Hold by Stifel
INCY,2025-06-16,17:34:17,6CC55E,Incyte Corp.,100,0.82,price-targets,upgrade,Incyte Price Target Raised to $107.00/Share From $75.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $107.00/Share From $75.00 by Stifel
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval Of Monjuvi(R) (tafasitamab-cxix) In Combination With Rituximab,NEWS-FLASH,Dow Jones Newswires,Incyte Announces FDA Approval Of Monjuvi(R) (tafasitamab-cxix) In Combination With Rituximab And Lenalidomide For Patients With Relapsed Or Refractory Follicular Lymphoma >INCY
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval Of Monjuvi(R) (tafasitamab-cxix) In Combination With Rituximab,NEWS-FLASH,Dow Jones Newswires,Incyte Announces FDA Approval Of Monjuvi(R) (tafasitamab-cxix) In Combination With Rituximab And Lenalidomide For Patients With Relapsed Or Refractory Follicular Lymphoma >INCY
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi(R) (tafasitamab-cxix),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The Priority Review and FDA approval of the supplemental Biologics License Application (sBLA),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,19:39:00,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces FDA Approval of Monjuvi(R),PRESS-RELEASE,Business Wire,Incyte Announces FDA Approval of Monjuvi(R) -2-
INCY,2025-06-18,20:12:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Lymphoma Treatment Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Incyte Lymphoma Treatment Gets FDA Approval
INCY,2025-06-18,20:12:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte said it received approval from the Food and Drug Administration for monjuvi,FULL-ARTICLE,Dow Jones Newswires,Incyte Lymphoma Treatment Gets FDA Approval
INCY,2025-06-18,20:27:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Lymphoma Treatment Gets FDA Approval,FULL-ARTICLE,Dow Jones Newswires,Incyte Lymphoma Treatment Gets FDA Approval
INCY,2025-06-18,20:27:22,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte said it received approval from the Food and Drug Administration for monjuvi,FULL-ARTICLE,Dow Jones Newswires,Incyte Lymphoma Treatment Gets FDA Approval
INCY,2025-06-18,22:39:28,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi(R) (tafasitamab-cxix),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,22:39:28,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Fda Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,22:39:28,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Corp.: The Priority Review and FDA approval of the supplemental Biologics License Application (sBLA),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,22:39:28,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Morphosys and Incyte entered into: (a) in January 2020, a collaboration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-18,22:39:28,6CC55E,Incyte Corp.,100,0.39,products-services,,Incyte obtained exclusive rights to,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces FDA Approval of Monjuvi(R) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
INCY,2025-06-20,20:40:41,6CC55E,Incyte Corp.,100,0.0,products-services,filed,Fda Extended Review for Supplemental New Drug Application for Ruxolitinib,NEWS-FLASH,Dow Jones Newswires,Incyte: FDA Extended Review for Supplemental New Drug Application for Ruxolitinib Cream for Treatment of Children With Mild to Moderate Atopic Dermatitis to Sept 19 >INCY
INCY,2025-06-26,11:30:00,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot To Retire >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot To Retire >INCY
INCY,2025-06-26,11:30:00,6CC55E,Incyte Corp.,99,0.53,labor-issues,,"Meury, joins Incyte as President and CEO",PRESS-RELEASE,Business Wire,Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:00,6CC55E,Incyte Corp.,99,0.53,labor-issues,,"Meury, joins Incyte as President and CEO",PRESS-RELEASE,Business Wire,Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:00,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte launched six novel medicines,PRESS-RELEASE,Business Wire,Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:01,6CC55E,Incyte Corp.,99,0.53,labor-issues,,"Meury, joins Incyte as President and CEO",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:01,6CC55E,Incyte Corp.,99,0.53,labor-issues,,"Meury, joins Incyte as President and CEO",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:01,6CC55E,Incyte Corp.,99,0.52,products-services,,Incyte launched six novel medicines,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
INCY,2025-06-26,11:30:26,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Names Julian Baker Chairman >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte Names Julian Baker Chairman >INCY
INCY,2025-06-26,11:31:05,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Bill Meury President, CEO",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Bill Meury President, CEO, Member of Board >INCY"
INCY,2025-06-26,11:31:05,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Bill Meury President, CEO",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Bill Meury President, CEO, Member of Board >INCY"
INCY,2025-06-26,13:12:05,6CC55E,Incyte Corp.,95,0.53,labor-issues,,"Incyte Corp.: the company's board appointed Bill Meury as its new chief executive officer, replacing Herve Hoppenot, who is retiring after 11 years",FULL-ARTICLE,Dow Jones Newswires,Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes -- IBD
INCY,2025-06-26,20:46:35,6CC55E,Incyte Corp.,99,0.53,labor-issues,,"Incyte Corp.: the company's board appointed Bill Meury as its new chief executive, replacing Herve Hoppenot, who is retiring after 11 years",FULL-ARTICLE,Dow Jones Newswires,Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? -- IBD
INCY,2025-06-26,20:46:35,6CC55E,Incyte Corp.,99,0.65,revenues,up,Jakafi sales growth,FULL-ARTICLE,Dow Jones Newswires,Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? -- IBD
INCY,2025-06-27,20:54:31,6CC55E,Incyte Corp.,99,-0.49,labor-issues,,"Incyte Corp.: Hoppenot retired as President and Chief Executive Officer of the Company effective June 26, 2025",RNS-SEC8K,Dow Jones Newswires,"Incyte Files 8K - Director, Officer or Compensation Filing >INCY"
INCY,2025-06-27,20:54:31,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2025 Incentive Compensation Plan,RNS-SEC8K,Dow Jones Newswires,"Incyte Files 8K - Director, Officer or Compensation Filing >INCY"
INCY,2025-06-27,20:54:31,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's annual Incentive Compensation Plan,RNS-SEC8K,Dow Jones Newswires,"Incyte Files 8K - Director, Officer or Compensation Filing >INCY"
INCY,2025-06-27,20:54:31,6CC55E,Incyte Corp.,99,0.0,earnings,,"Incyte Corp.: the Company's Annual Report on Form 10-K for the year ended December 31, 2024",RNS-SEC8K,Dow Jones Newswires,"Incyte Files 8K - Director, Officer or -2-"
INCY,2025-06-27,20:54:31,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,RNS-SEC8K,Dow Jones Newswires,"Incyte Files 8K - Director, Officer or -2-"
INCY,2025-07-02,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-07-02,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-07-02,20:30:37,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 599 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 599 Of Incyte Corp >INCY
INCY,2025-07-03,18:51:30,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 8,617 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 8,617 Of Incyte Corp >INCY"
INCY,2025-07-03,19:12:32,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 10,903 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 10,903 Of Incyte Corp >INCY"
INCY,2025-07-07,20:43:48,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Chmn Hoppenot Surrenders 42,769 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Chmn Hoppenot Surrenders 42,769 Of Incyte Corp >INCY"
INCY,2025-07-07,20:44:32,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 8,617 Of Incyte Corp",FULL-ARTICLE,Dow Jones Newswires,"VP Iyengar Sells 8,617 Of Incyte Corp >INCY"
INCY,2025-07-07,20:45:56,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 599 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 599 Of Incyte Corp >INCY
INCY,2025-07-07,20:47:00,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 10,903 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Sells 10,903 Of Incyte Corp >INCY"
INCY,2025-07-07,20:48:51,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 11,589 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 11,589 Of Incyte Corp >INCY"
INCY,2025-07-07,20:49:16,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Stein Surrenders 12,714 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Surrenders 12,714 Of Incyte Corp >INCY"
INCY,2025-07-07,20:49:48,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Officer Tray Surrenders 897 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,Officer Tray Surrenders 897 Of Incyte Corp >INCY
INCY,2025-07-07,20:57:39,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 6,285 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Surrenders 6,285 Of Incyte Corp >INCY"
INCY,2025-07-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2025-07-10,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Second Quarter Financial Results
INCY,2025-07-10,12:10:06,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2025-07-10,12:10:06,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Second Quarter Financial Results
INCY,2025-07-14,16:11:22,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2025-07-14,16:11:22,6CC55E,Incyte Corp.,100,-0.3,price-targets,downgrade,Incyte Price Target Cut to $67.00/Share From $68.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Cut to $67.00/Share From $68.00 by JP Morgan
INCY,2025-07-14,20:09:24,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 14,952 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 14,952 Of Incyte Corp >INCY"
INCY,2025-07-15,20:21:51,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Iyengar Registers 1,177 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Iyengar Registers 1,177 Of Incyte Corp >INCY"
INCY,2025-07-15,20:39:28,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Denton Registers 3,330 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Denton Registers 3,330 Of Incyte Corp >INCY"
INCY,2025-07-15,20:45:33,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 1,192 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 1,192 Of Incyte Corp >INCY"
INCY,2025-07-16,20:02:57,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Dir Hoppenot Surrenders 9,674 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Officer/Dir Hoppenot Surrenders 9,674 Of Incyte Corp >INCY"
INCY,2025-07-16,20:03:06,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 1,192 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Sells 1,192 Of Incyte Corp >INCY"
INCY,2025-07-16,20:03:48,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Iyengar Sells 1,177 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Iyengar Sells 1,177 Of Incyte Corp >INCY"
INCY,2025-07-16,20:04:31,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Officer Tray Surrenders 1,275 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Officer Tray Surrenders 1,275 Of Incyte Corp >INCY"
INCY,2025-07-16,20:05:47,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Cfo Stamoulis Surrenders 2,852 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"CFO Stamoulis Surrenders 2,852 Of Incyte Corp >INCY"
INCY,2025-07-16,20:06:06,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 14,952 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Sells 14,952 Of Incyte Corp >INCY"
INCY,2025-07-16,20:06:27,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 785 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 785 Of Incyte Corp >INCY
INCY,2025-07-16,20:07:24,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Officer Cagnoni Surrenders 3,908 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"Officer Cagnoni Surrenders 3,908 Of Incyte Corp >INCY"
INCY,2025-07-16,20:07:35,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Swain Surrenders 1,007 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Swain Surrenders 1,007 Of Incyte Corp >INCY"
INCY,2025-07-16,20:09:29,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 1,340 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 1,340 Of Incyte Corp >INCY"
INCY,2025-07-16,20:09:32,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Iyengar Registers 983 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Iyengar Registers 983 Of Incyte Corp >INCY
INCY,2025-07-17,20:04:46,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Trotta Surrenders 182 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Trotta Surrenders 182 Of Incyte Corp >INCY
INCY,2025-07-17,20:06:29,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Denton Sells 4,115 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Denton Sells 4,115 Of Incyte Corp >INCY"
INCY,2025-07-17,20:07:21,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Flannelly Sells 1,340 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Flannelly Sells 1,340 Of Incyte Corp >INCY"
INCY,2025-07-17,20:07:31,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Iyengar Sells 983 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Iyengar Sells 983 Of Incyte Corp >INCY
INCY,2025-07-21,20:03:53,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Stein Registers 3,706 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Stein Registers 3,706 Of Incyte Corp >INCY"
INCY,2025-07-23,19:57:51,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Stein Sells 3,706 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Stein Sells 3,706 Of Incyte Corp >INCY"
INCY,2025-07-24,21:02:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Preliminary Phase 1 Results Of,PRESS-RELEASE,Business Wire,Incyte To Present Initial Data for its TGF<BETA>R2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
INCY,2025-07-24,21:11:36,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Preliminary Phase 1 Results Of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte To Present Initial Data for its TGF<BETA>R2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.61,earnings,positive,2Q EPS $2.04 >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q EPS $2.04 >INCY
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Adj EPS $1.57,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Adj EPS $1.57 >INCY
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 2Q Net $405M,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Net $405M >INCY
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,216 million in the second quarter",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.7,earnings,up,Incyte Corp.: raising full year 2025 guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Zynyz(R) (retifanlimab-dlwr) and Monjuvi(R) (tafasitamab-cxix) approved by the U.S. FDA,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Zynyz(R) (retifanlimab-dlwr) and Monjuvi(R) (tafasitamab-cxix) approved by the U.S. FDA,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: In June 2025, two Phase 3 studies",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenue growth in the second quarter,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 studies,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Second Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $1,215,529 $1,043,759",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakafi net product revenue increased 8%,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.5,revenues,up,Incyte Corp.: Opzelura net product revenue increased 35%,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.65,revenues,up,Incyte Corp.: Zynyz net product revenue increase,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Total royalty revenues for the quarter increased 10% versus the prior year,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,equity-actions,,"Incyte Corp.: The 2024 Non-GAAP selling, general and administrative expenses",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.46,legal,,Incyte paid Novartis $280.0 million as the settlement,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.39,products-services,,"In May 2025, Incyte and Novartis entered into a settlement agreement",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Financial Guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.72,revenues,up,Incyte is raising its revenue guidance,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -3-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,821,354 $ 5,444,322",PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -6-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -6-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports 2025 Second Quarter Financial -6-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 2Q Rev $1.22B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 2Q Rev $1.22B >INCY
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,revenues,,"Incyte Corp.: Total revenues of $1,216 million in the second quarter",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.7,earnings,up,Incyte Corp.: raising full year 2025 guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Zynyz(R) (retifanlimab-dlwr) and Monjuvi(R) (tafasitamab-cxix) approved by the U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Zynyz(R) (retifanlimab-dlwr) and Monjuvi(R) (tafasitamab-cxix) approved by the U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,"Incyte Corp.: In June 2025, two Phase 3 studies",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: update on the Company's clinical development,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.44,revenues,up,Incyte Corp.: Net product revenue growth in the second quarter,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: 1) Clinical development of axatilimab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.41,products-services,start,Incyte plans to initiate Phase 3 studies for its potentially first,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Ruxolitinib Cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Two Phase 3 studies,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: 2025 Second Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $1,215,529 $1,043,759",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -2-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -4-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $5,821,354 $ 5,444,322",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -5-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -6-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -6-
INCY,2025-07-29,11:00:04,6CC55E,Incyte Corp.,98,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports 2025 Second Quarter -6-
INCY,2025-07-29,11:06:52,6CC55E,Incyte Corp.,93,0.0,earnings,,"Incyte Corporation issued a press release announcing financial results for its second fiscal quarter ended June 30, 2025",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2025-07-29,12:12:47,6CC55E,Incyte Corp.,100,0.64,earnings,up,Incyte 2Q Net Up on,FULL-ARTICLE,Dow Jones Newswires,"Incyte 2Q Net Up on Rev Growth, Boosts 2025 Cancer-Drug Rev Views"
INCY,2025-07-29,12:12:47,6CC55E,Incyte Corp.,100,0.72,revenues,up,Incyte Corp.: the company boosted 2025 sales projections,FULL-ARTICLE,Dow Jones Newswires,"Incyte 2Q Net Up on Rev Growth, Boosts 2025 Cancer-Drug Rev Views"
INCY,2025-07-29,12:12:47,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: The company forecast revenue,FULL-ARTICLE,Dow Jones Newswires,"Incyte 2Q Net Up on Rev Growth, Boosts 2025 Cancer-Drug Rev Views"
INCY,2025-07-29,12:12:47,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte is conducting several clinical trials of,FULL-ARTICLE,Dow Jones Newswires,"Incyte 2Q Net Up on Rev Growth, Boosts 2025 Cancer-Drug Rev Views"
INCY,2025-07-30,14:09:48,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Equal-Weight by Wells Fargo
INCY,2025-07-30,14:09:48,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $67.00/Share From $59.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $67.00/Share From $59.00 by Wells Fargo
INCY,2025-07-30,14:39:28,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2025-07-30,14:39:28,6CC55E,Incyte Corp.,100,0.62,price-targets,upgrade,Incyte Price Target Raised to $72.00/Share From $68.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $72.00/Share From $68.00 by RBC Capital
INCY,2025-07-30,15:01:48,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by UBS,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by UBS
INCY,2025-07-30,15:01:48,6CC55E,Incyte Corp.,100,0.76,price-targets,upgrade,Incyte Price Target Raised to $68.00/Share From $62.00 by UBS,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $68.00/Share From $62.00 by UBS
INCY,2025-07-30,15:55:38,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Hold by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Hold by Truist Securities
INCY,2025-07-30,15:55:38,6CC55E,Incyte Corp.,100,0.7,price-targets,upgrade,Incyte Price Target Raised to $79.00/Share From $73.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $79.00/Share From $73.00 by Truist Securities
INCY,2025-07-30,16:24:58,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Citigroup
INCY,2025-07-30,16:24:58,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $103.00/Share From $88.00 by Citigroup,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $103.00/Share From $88.00 by Citigroup
INCY,2025-07-30,16:28:48,6CC55E,Incyte Corp.,100,-0.2,analyst-ratings,neutral,Incyte Is Maintained at Underperform by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Underperform by BMO Capital
INCY,2025-07-30,16:28:48,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $60.00/Share From $52.00 by BMO Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $60.00/Share From $52.00 by BMO Capital
INCY,2025-08-01,12:51:12,6CC55E,Incyte Corp.,100,0.95,analyst-ratings,positive,Incyte Initiated at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Incyte Initiated at Overweight by Barclays
INCY,2025-08-01,12:51:12,6CC55E,Incyte Corp.,100,0.0,price-targets,set,Incyte Price Target Announced at $90.00/Share by Barclays,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Announced at $90.00/Share by Barclays
INCY,2025-08-04,20:06:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 598 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 598 Of Incyte Corp >INCY
INCY,2025-08-04,20:30:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Fda approved retifanlimab as a single agent,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
INCY,2025-08-04,20:30:02,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Axatilimab received FDA approval in August 2024,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
INCY,2025-08-04,20:30:02,6CC55E,Incyte Corp.,99,0.49,partnerships,,Thrilled to expand our partnership with Incyte,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
INCY,2025-08-05,20:05:03,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,Incyte Announces Departure Of Chief Financial Officer,NEWS-FLASH,Dow Jones Newswires,Incyte Announces Departure Of Chief Financial Officer Christiana Stamoulis >INCY
INCY,2025-08-05,20:05:03,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer,PRESS-RELEASE,Business Wire,Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
INCY,2025-08-05,20:05:03,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
INCY,2025-08-05,20:07:11,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Reaffirms Full Yr Fincl Guidance,NEWS-FLASH,Dow Jones Newswires,Incyte Reaffirms Full Yr Fincl Guidance >INCY
INCY,2025-08-05,20:07:38,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,Incyte : CFO Christiana Stamoulis Will Step Down to,NEWS-FLASH,Dow Jones Newswires,"Incyte : CFO Christiana Stamoulis Will Step Down to Pursue Another Opportunity, Effective Sept 16 >INCY"
INCY,2025-08-05,20:07:46,6CC55E,Incyte Corp.,100,0.49,labor-issues,,Incyte Initiates Search for CFO,NEWS-FLASH,Dow Jones Newswires,Incyte Initiates Search for CFO Successor >INCY
INCY,2025-08-06,12:32:54,6CC55E,Incyte Corp.,100,0.94,analyst-ratings,positive,Incyte Raised to Overweight From Equal-Weight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Raised to Overweight From Equal-Weight by Wells Fargo
INCY,2025-08-06,12:32:54,6CC55E,Incyte Corp.,100,0.8,price-targets,upgrade,Incyte Price Target Raised to $89.00/Share From $67.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $89.00/Share From $67.00 by Wells Fargo
INCY,2025-08-06,12:45:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on,PRESS-RELEASE,GlobeNewswire,Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
INCY,2025-08-06,12:45:00,6CC55E,Incyte Corp.,100,0.41,products-services,start,"Today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte's PD-1 inhibitor, retifanlimab",PRESS-RELEASE,GlobeNewswire,Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
INCY,2025-08-06,12:45:01,6CC55E,Incyte Corp.,100,0.49,partnerships,,Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on,PRESS-RELEASE,Dow Jones Newswires,Press Release: Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
INCY,2025-08-06,12:45:01,6CC55E,Incyte Corp.,100,0.41,products-services,start,"Today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte's PD-1 inhibitor, retifanlimab",PRESS-RELEASE,Dow Jones Newswires,Press Release: Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
INCY,2025-08-06,12:45:17,6CC55E,Incyte Corp.,100,0.49,partnerships,,Actuate Therapeutics to Collaborate With Incyte Corp and the University of Pittsburgh on,NEWS-FLASH,Dow Jones Newswires,Actuate Therapeutics to Collaborate With Incyte Corp and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination With Retifanlimab and mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
INCY,2025-08-06,20:03:40,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 598 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 598 Of Incyte Corp >INCY
INCY,2025-08-07,13:18:39,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,"Incyte Chief Financial Officer Christiana Stamoulis Resigns, Effective Sept. 16",RNS-SEC8K,Dow Jones Newswires,"Incyte Chief Financial Officer Christiana Stamoulis Resigns, Effective Sept. 16 >INCY"
INCY,2025-08-07,13:37:38,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,"Incyte Chief Financial Officer Christiana Stamoulis Resigns, Effective Sept. 16",FULL-ARTICLE,Dow Jones Newswires,"Incyte Chief Financial Officer Christiana Stamoulis Resigns, Effective Sept. 16"
INCY,2025-08-07,13:37:38,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,"Incyte's top finance executive, Christiana Stamoulis, is leaving the biopharmaceutical company",FULL-ARTICLE,Dow Jones Newswires,"Incyte Chief Financial Officer Christiana Stamoulis Resigns, Effective Sept. 16"
INCY,2025-08-12,20:24:41,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 14,037 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 14,037 Of Incyte Corp >INCY"
INCY,2025-08-13,20:22:00,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 75,963 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 75,963 Of Incyte Corp >INCY"
INCY,2025-08-15,20:10:04,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 277 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 277 Of Incyte Corp >INCY
INCY,2025-08-19,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2025-08-19,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT)",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2025-08-19,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2025-08-19,12:00:02,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT)",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2025-08-19,20:14:35,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 277 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 277 Of Incyte Corp >INCY
INCY,2025-08-22,07:15:20,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corporation, Inst Holders, 2Q 2025 (INCY)",RNS-SEC13F,Dow Jones Newswires,"Incyte Corporation, Inst Holders, 2Q 2025 (INCY)"
INCY,2025-08-22,14:27:50,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2025-08-22,14:27:50,6CC55E,Incyte Corp.,100,0.74,price-targets,upgrade,Incyte Price Target Raised to $73.00/Share From $67.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $73.00/Share From $67.00 by JP Morgan
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer,PRESS-RELEASE,Business Wire,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer,PRESS-RELEASE,Business Wire,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,"Incyte's former Executive Vice President and Head of Human Resources, following her retirement",PRESS-RELEASE,Business Wire,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:01,6CC55E,Incyte Corp.,100,-0.57,labor-issues,,"Incyte's former Executive Vice President and Head of Human Resources, following her retirement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
INCY,2025-08-25,12:00:55,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Soni Basi Exec VP, Chief Human Resources Officer",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Soni Basi Exec VP, Chief Human Resources Officer >INCY"
INCY,2025-08-25,12:00:55,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Soni Basi Exec VP, Chief Human Resources Officer",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Soni Basi Exec VP, Chief Human Resources Officer >INCY"
INCY,2025-09-02,20:15:42,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 598 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 598 Of Incyte Corp >INCY
INCY,2025-09-04,18:11:40,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by B of A Securities
INCY,2025-09-04,18:11:40,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $104.00/Share From $90.00 by B of A Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $104.00/Share From $90.00 by B of A Securities
INCY,2025-09-04,20:05:55,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 598 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 598 Of Incyte Corp >INCY
INCY,2025-09-10,11:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The late-breaking data from the STOP-HS clinical trial program,PRESS-RELEASE,Business Wire,Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
INCY,2025-09-10,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
INCY,2025-09-10,11:30:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: The late-breaking data from the STOP-HS clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
INCY,2025-09-10,11:30:01,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
INCY,2025-09-16,20:06:28,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 278 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 278 Of Incyte Corp >INCY
INCY,2025-09-17,05:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Data from the STOP-HS clinical trial program,PRESS-RELEASE,Business Wire,Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
INCY,2025-09-17,05:00:01,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: Data from the STOP-HS clinical trial program,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
INCY,2025-09-18,20:07:41,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 278 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 278 Of Incyte Corp >INCY
INCY,2025-09-18,20:21:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Announces Additional FDA Approval Of Opzelura(R) (Ruxolitinib),NEWS-FLASH,Dow Jones Newswires,Incyte Announces Additional FDA Approval Of Opzelura(R) (Ruxolitinib) Cream In Children Ages 2-11 With Atopic Dermatitis >INCY
INCY,2025-09-18,20:21:01,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura(R) (ruxolitinib),PRESS-RELEASE,Business Wire,Incyte Announces Additional FDA Approval of Opzelura(R) (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
INCY,2025-09-18,20:21:01,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 3 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Business Wire,Incyte Announces Additional FDA Approval of Opzelura(R) (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
INCY,2025-09-18,20:36:39,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval for Dermatitis Cream,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Dermatitis Cream for Young Children
INCY,2025-09-18,20:36:39,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The third U.S. approval for Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Dermatitis Cream for Young Children
INCY,2025-09-18,20:41:32,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura(R) (ruxolitinib),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Additional FDA Approval of Opzelura(R) (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
INCY,2025-09-18,20:41:32,6CC55E,Incyte Corp.,100,0.0,products-services,,Phase 3 study evaluating the safety and efficacy of ruxolitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Additional FDA Approval of Opzelura(R) (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
INCY,2025-09-18,20:51:39,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Incyte Gets FDA Approval for Dermatitis Cream,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Dermatitis Cream for Young Children
INCY,2025-09-18,20:51:39,6CC55E,Incyte Corp.,100,0.57,products-services,granted,The third U.S. approval for Opzelura,FULL-ARTICLE,Dow Jones Newswires,Incyte Gets FDA Approval for Dermatitis Cream for Young Children
INCY,2025-09-18,21:12:37,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 17,447 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 17,447 Of Incyte Corp >INCY"
INCY,2025-09-22,11:30:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer,PRESS-RELEASE,Business Wire,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
INCY,2025-09-22,11:30:01,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer,PRESS-RELEASE,Business Wire,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
INCY,2025-09-22,11:30:02,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
INCY,2025-09-22,11:30:02,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
INCY,2025-09-22,11:30:23,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Dave Gardner Exec VP, Chief Strategy Officer",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Dave Gardner Exec VP, Chief Strategy Officer >INCY"
INCY,2025-09-22,11:30:23,6CC55E,Incyte Corp.,100,0.53,labor-issues,,"Incyte Names Dave Gardner Exec VP, Chief Strategy Officer",NEWS-FLASH,Dow Jones Newswires,"Incyte Names Dave Gardner Exec VP, Chief Strategy Officer >INCY"
INCY,2025-09-22,17:15:52,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Buy by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Buy by Stifel
INCY,2025-09-22,17:15:52,6CC55E,Incyte Corp.,100,0.52,price-targets,upgrade,Incyte Price Target Raised to $115.00/Share From $110.00 by Stifel,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $115.00/Share From $110.00 by Stifel
INCY,2025-09-24,14:08:36,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2025-09-24,14:08:36,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $81.00/Share From $72.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $81.00/Share From $72.00 by RBC Capital
INCY,2025-09-24,20:30:01,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Business Wire,Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-09-24,20:30:09,6CC55E,Incyte Corp.,99,0.0,labor-issues,,Incyte Corp.: the Company's 2024 Inducement Stock Incentive Plan,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY,2025-10-02,20:04:01,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 599 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 599 Of Incyte Corp >INCY
INCY,2025-10-03,20:09:34,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Denton Registers 3,501 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Denton Registers 3,501 Of Incyte Corp >INCY"
INCY,2025-10-03,20:47:20,6CC55E,Incyte Corp.,100,0.0,insider-trading,,Vp Heeson Surrenders 463 Of Incyte Corp >INCY,TABULAR-MATERIAL,Dow Jones Newswires,VP Heeson Surrenders 463 Of Incyte Corp >INCY
INCY,2025-10-03,20:48:54,6CC55E,Incyte Corp.,100,0.0,insider-trading,,"Vp Mayes Surrenders 1,569 Of Incyte Corp >INCY",TABULAR-MATERIAL,Dow Jones Newswires,"VP Mayes Surrenders 1,569 Of Incyte Corp >INCY"
INCY,2025-10-06,20:04:20,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,"Vp Denton Sells 4,100 Of Incyte Corp",TABULAR-MATERIAL,Dow Jones Newswires,"VP Denton Sells 4,100 Of Incyte Corp >INCY"
INCY,2025-10-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2025-10-08,12:00:01,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Business Wire,Incyte to Report Third Quarter Financial Results
INCY,2025-10-08,12:18:46,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte to Report Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2025-10-08,12:18:46,6CC55E,Incyte Corp.,100,0.0,investor-relations,,"Incyte Corp.: Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Report Third Quarter Financial Results
INCY,2025-10-09,13:17:42,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Neutral by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Neutral by JP Morgan
INCY,2025-10-09,13:17:42,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $89.00/Share From $73.00 by JP Morgan,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $89.00/Share From $73.00 by JP Morgan
INCY,2025-10-12,22:05:00,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study Of,PRESS-RELEASE,Business Wire,Data from Incyte's TGF<BETA>R2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
INCY,2025-10-12,22:05:03,6CC55E,Incyte Corp.,99,0.0,products-services,,Incyte Corp.: A Phase 1 Study Of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Data from Incyte's TGF<BETA>R2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
INCY,2025-10-15,11:01:24,6CC55E,Incyte Corp.,100,0.57,products-services,granted,"October 2024, Health Canada approved Opzelura",PRESS-RELEASE,Canadian News Wire,Incyte Canada Announces Health Canada approval of Opzelura(R) (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11
INCY,2025-10-15,11:01:24,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Opzelura's expanded indication to,PRESS-RELEASE,Canadian News Wire,Incyte Canada Announces Health Canada approval of Opzelura(R) (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11
INCY,2025-10-15,20:06:51,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,Vp Denton Registers 277 Of Incyte Corp >INCY,RNS-SEC144,Dow Jones Newswires,VP Denton Registers 277 Of Incyte Corp >INCY
INCY,2025-10-16,20:06:44,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 18,495 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 18,495 Of Incyte Corp >INCY"
INCY,2025-10-17,20:02:41,6CC55E,Incyte Corp.,100,-0.49,insider-trading,,Vp Denton Sells 277 Of Incyte Corp,TABULAR-MATERIAL,Dow Jones Newswires,VP Denton Sells 277 Of Incyte Corp >INCY
INCY,2025-10-19,17:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Phase 1 Results for,PRESS-RELEASE,Business Wire,Incyte Announces Phase 1 Results for its TGF<BETA>R2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
INCY,2025-10-19,17:30:00,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Phase 1 Results for,PRESS-RELEASE,Business Wire,Incyte Announces Phase 1 Results for its -2-
INCY,2025-10-20,09:35:12,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Announces Phase 1 Results for,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces Phase 1 Results for its TGF<BETA>R2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
INCY,2025-10-25,23:55:00,6CC55E,Incyte Corp.,97,0.0,earnings,,Incyte Corp.: Eight-week results,PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura(R) (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
INCY,2025-10-25,23:55:00,6CC55E,Incyte Corp.,97,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Business Wire,Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura(R) (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
INCY,2025-10-25,23:55:03,6CC55E,Incyte Corp.,97,0.0,earnings,,Incyte Corp.: Eight-week results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura(R) (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
INCY,2025-10-25,23:55:03,6CC55E,Incyte Corp.,97,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura(R) (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
INCY,2025-10-27,11:30:00,6CC55E,Incyte Corp.,100,0.49,partnerships,,Incyte and Enable Injections Announce Strategic Partnership,PRESS-RELEASE,Business Wire,Incyte and Enable Injections Announce Strategic Partnership for enFuse(R) On-Body Delivery System
INCY,2025-10-27,11:49:02,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte (NASDAQ:INCY) and Enable Injections, Inc. (""Enable"") today announced a new partnership",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte and Enable Injections Announce Strategic Partnership for enFuse(R) On-Body Delivery System
INCY,2025-10-27,20:24:33,6CC55E,Incyte Corp.,100,-0.48,insider-trading,,"Vp Flannelly Registers 33,452 Of Incyte Corp >INCY",RNS-SEC144,Dow Jones Newswires,"VP Flannelly Registers 33,452 Of Incyte Corp >INCY"
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: 2025 Third Quarter Financial Results,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenue,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.7,earnings,up,Incyte Corp.: Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues: Total revenues were $1.37 billion,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative (SG&A",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.51,products-services,increase,Higher demand for Jakafi and other hematology and oncology marketed products,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,revenues,,Opzelura(R) (ruxolitinib) cream revenue guidance of,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: The Company reiterates its guidance,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Results from the Phase 1 trial,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Ruxolitinib cream,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.52,products-services,,Povorcitinib were presented at the European,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Regulatory submissions for povorcitinib,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Data from the Phase 3 studies evaluating povorcitinib,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Corp.: The Company strengthened its executive leadership team through the appointment of Soni Basi as Executive Vice President,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: The Company announced a strategic partnership with Enable Injections, Inc., to",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $1,365,980 $1,137,871",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakafi net product revenue increased 7% in the third quarter of 2025,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.5,revenues,up,Incyte Corp.: Opzelura net product revenue increased 35% in the third quarter of 2025,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.44,revenues,up,Incyte Corp.: Niktimvo net product revenue increased 27%,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -2-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.46,legal,,Incyte Corp.: Contract dispute settlement,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.39,products-services,,"In May 2025, Incyte and Novartis entered into a settlement agreement",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.7,earnings,up,Incyte is raising its full year 2025 net product revenue guidance to $4.23 - $4.32 billion,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.51,products-services,increase,Higher demand for Jakafi and other hematology and oncology marketed products,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -3-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. FDA",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -4-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi is approved by the U.S. FDA,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -4-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -5-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -5-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 6,330,356 $ 5,444,322",PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -5-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -5-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -5-
INCY,2025-10-28,11:00:05,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Business Wire,Incyte Reports Third Quarter 2025 Financial -6-
INCY,2025-10-28,11:00:07,6CC55E,Incyte Corp.,100,0.61,earnings,positive,3Q EPS $2.11 >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q EPS $2.11 >INCY
INCY,2025-10-28,11:00:07,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Adj EPS $2.26,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Adj EPS $2.26 >INCY
INCY,2025-10-28,11:00:07,6CC55E,Incyte Corp.,100,0.61,earnings,positive,Incyte 3Q Net $424.2M,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Net $424.2M >INCY
INCY,2025-10-28,11:00:07,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte 3Q Rev $1.37B >INCY,NEWS-FLASH,Dow Jones Newswires,Incyte 3Q Rev $1.37B >INCY
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,earnings,,Incyte Corp.: 2025 Third Quarter Financial Results,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.41,revenues,up,"Incyte Corp.: Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Jakafi(R) (ruxolitinib) net product revenue,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.7,earnings,up,Incyte Corp.: Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,investor-relations,,Incyte Corp.: Conference Call,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte Corp.: Total revenues: Total revenues were $1.37 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,equity-actions,,"Incyte Corp.: Selling, general and administrative (SG&A",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.51,products-services,increase,Higher demand for Jakafi and other hematology and oncology marketed products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,revenues,,Opzelura(R) (ruxolitinib) cream revenue guidance of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,earnings,unchanged,Incyte Corp.: The Company reiterates its guidance,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Results from the Phase 1 trial,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: The Phase 3 study evaluating tafasitamab,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.52,products-services,,Incyte Corp.: Ruxolitinib cream,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.52,products-services,,Povorcitinib were presented at the European,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Regulatory submissions for povorcitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.0,products-services,,Incyte Corp.: Data from the Phase 3 studies evaluating povorcitinib,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.53,labor-issues,,Incyte Corp.: The Company strengthened its executive leadership team through the appointment of Soni Basi as Executive Vice President,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,100,0.49,partnerships,,"Incyte Corp.: The Company announced a strategic partnership with Enable Injections, Inc., to",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,-0.68,revenues,down,"Incyte Corp.: Total GAAP revenues $1,365,980 $1,137,871",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Total GAAP operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP net income (loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.41,revenues,up,Incyte Corp.: Jakafi net product revenue increased 7% in the third quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.5,revenues,up,Incyte Corp.: Opzelura net product revenue increased 35% in the third quarter of 2025,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.44,revenues,up,Incyte Corp.: Niktimvo net product revenue increased 27%,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -2-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,equity-actions,,Incyte Corp.: Operating Expenses,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.46,legal,,Incyte Corp.: Contract dispute settlement,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.61,earnings,positive,Incyte Corp.: GAAP (profit,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.39,products-services,,"In May 2025, Incyte and Novartis entered into a settlement agreement",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,earnings,,Incyte Corp.: Operating income,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.7,earnings,up,Incyte is raising its full year 2025 net product revenue guidance to $4.23 - $4.32 billion,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.51,products-services,increase,Higher demand for Jakafi and other hematology and oncology marketed products,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Jakafi net product revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,investor-relations,,Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -3-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.57,products-services,granted,"Inhibitor ruxolitinib, approved by the U.S. FDA",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -4-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.57,products-services,granted,Monjuvi is approved by the U.S. FDA,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -4-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,revenues,,Incyte Corp.: Total revenues,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -5-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Net income (loss),PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -5-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,0.0,assets,,"Incyte Corp.: Total assets $ 6,330,356 $ 5,444,322",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -5-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -5-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,99,-0.65,earnings,negative,Incyte Corp.: Non-GAAP Net Income (Loss,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -5-
INCY,2025-10-28,11:00:10,6CC55E,Incyte Corp.,96,0.62,acquisitions-mergers,,Incyte Corp.: Acquired product rights of,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte Reports Third Quarter 2025 -6-
INCY,2025-10-28,11:04:32,6CC55E,Incyte Corp.,93,0.0,earnings,,"Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September 30, 2025",RNS-SEC8K,Dow Jones Newswires,Incyte Files 8K - Operations And Financial Condition >INCY
INCY,2025-10-28,11:12:19,6CC55E,Incyte Corp.,100,0.72,revenues,up,Incyte Raises 2025 Revenue Guidance,NEWS-FLASH,Dow Jones Newswires,Incyte Raises 2025 Revenue Guidance for Jakafi to $3.05B-$3.075B >INCY
INCY,2025-10-28,12:54:05,6CC55E,Incyte Corp.,100,-0.8,earnings,below-expectations,Incyte Falls After Hiked 2025 Outlook Misses Wall Street,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,12:54:05,6CC55E,Incyte Corp.,100,0.0,earnings,,Factset expected Incyte to earn $1.58 a share,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,12:54:05,6CC55E,Incyte Corp.,100,0.7,earnings,up,Incyte raised its guidance for the year,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,12:54:05,6CC55E,Incyte Corp.,100,0.51,products-services,increase,Higher demand for Jakafi and its other products,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,21:23:36,6CC55E,Incyte Corp.,100,-0.8,earnings,below-expectations,Incyte Falls After Hiked 2025 Outlook Misses Wall Street,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,21:23:36,6CC55E,Incyte Corp.,100,0.0,revenues,,Incyte expects $3.05 billion to $3.075 billion in Jakafi sales this year,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-28,21:23:36,6CC55E,Incyte Corp.,100,0.41,revenues,up,Sales of Jakafi climbed 7% to $791 million,FULL-ARTICLE,Dow Jones Newswires,Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views -- IBD
INCY,2025-10-29,13:16:18,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Overweight by Barclays,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Overweight by Barclays
INCY,2025-10-29,13:16:18,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $101.00/Share From $90.00 by Barclays,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $101.00/Share From $90.00 by Barclays
INCY,2025-10-29,14:24:38,6CC55E,Incyte Corp.,100,0.34,analyst-ratings,neutral,Incyte Is Maintained at Overweight by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Overweight by Wells Fargo
INCY,2025-10-29,14:24:38,6CC55E,Incyte Corp.,100,0.74,price-targets,upgrade,Incyte Price Target Raised to $97.00/Share From $89.00 by Wells Fargo,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $97.00/Share From $89.00 by Wells Fargo
INCY,2025-10-29,15:27:48,6CC55E,Incyte Corp.,100,0.78,price-targets,upgrade,Incyte Price Target Raised to $93.00/Share From $79.00 by Truist Securities,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $93.00/Share From $79.00 by Truist Securities
INCY,2025-10-29,16:58:09,6CC55E,Incyte Corp.,100,0.0,analyst-ratings,neutral,Incyte Is Maintained at Sector Perform by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Is Maintained at Sector Perform by RBC Capital
INCY,2025-10-29,16:58:09,6CC55E,Incyte Corp.,100,0.48,price-targets,upgrade,Incyte Price Target Raised to $84.00/Share From $81.00 by RBC Capital,NEWS-FLASH,Dow Jones Newswires,Incyte Price Target Raised to $84.00/Share From $81.00 by RBC Capital
INCY,2025-10-30,11:30:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina
INCY,2025-10-30,11:30:02,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated MINJUVI(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina
INCY,2025-10-30,11:30:02,6CC55E,Incyte Corp.,100,0.0,products-services,,"Phase 2 study, that evaluated MINJUVI(R) in combination with lenalidomide",PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina
INCY,2025-10-30,11:30:02,6CC55E,Incyte Corp.,100,0.71,products-services,,Monjuvi(R) received accelerated approval by,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina
INCY,2025-10-30,11:30:02,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Monjuvi(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration,PRESS-RELEASE,GlobeNewswire,Knight Therapeutics Announces Approval and Launch of MINJUVI(R) (tafasitamab) in Argentina
INCY,2025-10-30,11:30:20,6CC55E,Incyte Corp.,100,0.57,products-services,granted,Knight Therapeutics Announces Approval and Launch of MINJUVI in Argentina,NEWS-FLASH,Dow Jones Newswires,Knight Therapeutics Announces Approval and Launch of MINJUVI in Argentina
INCY,2025-10-30,12:00:03,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2025-10-30,12:00:03,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am",PRESS-RELEASE,Business Wire,Incyte to Present at Upcoming Investor Conferences
INCY,2025-10-30,12:00:07,6CC55E,Incyte Corp.,100,0.0,marketing,,Incyte to Present at Upcoming Investor Conferences,PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
INCY,2025-10-30,12:00:07,6CC55E,Incyte Corp.,100,0.0,marketing,,"Incyte Corp.: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am",PRESS-RELEASE,Dow Jones Newswires,Press Release: Incyte to Present at Upcoming Investor Conferences
